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Impetigo and pharyngitis are two common suppurative infections in man elicited by 
Streptococcus pyogenes that lead to autoimmune complications in susceptible individuals.  
Although the underlying mechanisms for the onset of post-streptococcal autoimmunity have yet 
to be established, experimental information gained thus far suggests that the resultant pathology 
is a consequence of immunological cross-reactivity between streptococcal antigens, namely the 
anti-phagocytic factor M protein and host proteins, specifically myosin.  Experimental animal 
model systems developed to date have predominantly relied on the immunization of adult 
animals with M protein emulsed in adjuvant.  In the laboratory we have undertaken studies with 
mice to examine the capacity of S. pyogenes as whole organism without adjuvant to elicit 
autoreactive B and T lymphocytes. 
 We have observed that immunizing mice with heat-killed preparations of S. pyogenes as 
neonates, but not adults, induces the production of host cross-reactive serum antibodies akin to 
those documented in cases of post-streptococcal autoimmunity.  Western blot analysis of 
monoclonal antibodies generated from mice immunized with S. pyogenes suggests that 
antibodies induced in neonatal mice preferentially recognize the cardiac isoforms of mouse 
skeletal myosin, whereas, antibodies derived from adult mice primarily recognize determinants 
shared by all isoforms of mouse skeletal myosin. In addition, we have demonstrated the ability of 
neonatal, but not adult, mice to mount a myosin-reactive CD8+ cytotoxic T cell response 
following immunization with S. pyogenes.  Our observations indicate that the response is 
additionally dependent on the genetic background of mice, the route of immunization, and 
requires M protein.   
 In summation, our results suggest that in susceptible individuals exposure to S. pyogenes 
early in life may serve as a priming event and following a subsequent event later in life, possibly 
re-exposure to S. pyogenes, allow the initiation of the pathology associated with post-
streptococcal autoimmunity.  These results contribute to the understanding of the development of 
the mechanisms of post-streptococcal autoimmune complications and may ultimately contribute 
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Introduction.  Streptococcus pyogenes is a group A, beta hemolytic gram-positive cocci that is 
the causative agent of several infectious manifestations in man.  Streptococcal infections are 
typically controlled by a protective antibody response with or without the aid of antibiotics, 
however, a certain small percentage of children worldwide who do not receive proper timely 
antibiotic treatment will develop autoimmune sequelae.  Much research has been devoted to 
understanding the underlying mechanisms that initiate these autoimmune complications and, 
although no clear answers have been found, it is becoming increasingly evident that 
characteristics of the host may play just as important of a role as the infectious organism.  
Because GAS infections are prevalent and may subsequently result in invasive or autoimmune 
complications, the development of an efficacious vaccine is becoming increasingly important.  
Despite the significance of information gained thus far, research into all facets of post-
streptococcal autoimmune scenarios has been hindered by the lack of a complete autoimmune 
animal model system.  This chapter will discuss both historic and current research, as well as, the 
contributions of the research conducted in our laboratory, towards the advancement of the 
understanding of the relationship between host and organism and of the understanding of the 
subsequent autoimmune complications. 
Group A Streptococcus 
Historical Perspective.  Streptococci first came into our acquaintance around the late 1870’s, 
during the time that Louis Pasteur was beginning to develop the germ theory of disease.  
Refusing to accept the currently reigning ideology of diseases being the result of spontaneous 
generation, Pasteur began to focus his attention on puerperal fever, which at that time was a very 
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prevalent cause of maternal and neonatal deaths following childbirth.  Upon examining samples 
acquired from women with puerperal sepsis, he repeatedly encountered chained or paired 
microorganisms. Although it was these microorganisms that Pasteur implicated as the causative 
agent, it was not until 1879 when he introduced this theory at the Academy of Medicine meeting 
streptococci received recognition (reviewed in Stollerman 1975; Horaud et al. 1997).  Two years 
later Billroth and Ehrlich officially identified the organism and named them Streptococcus (rev. 
in Stollerman 1975; Horaud et al. 1997).  Since its introduction Streptococcus has made 
historically significant contributions to the study of genetics and antibacterial chemotherapy.  
Experiments performed in the late 1930’s demonstrated the ability to clear streptococcal 
infections with chemical compounds later identified as sulfonamides and providing the first 
series of antibacterial chemotherapeutic agents (reviewed in Horaud et al. 1997).  About the same 
time, McCarty employed Streptococcus as the experimental agent to demonstrate and define 
bacterial transformation for the first time (reviewed in Horaud et al. 1997).  The focus of more 
recent history of Streptococcus has been primarily towards the relationship with human diseases.  
Probably one of the most celebrated pioneers in streptococcal research is Dr. Rebecca Lancefield.  
Her most notable contributions began in the 1920’s with the definition of streptococcal 
subgroups based on cell wall carbohydrate moieties and later changed the course of streptococcal 
research with the identification of M protein as the major anti-phagocytic factor (Lancefield 
1962).  Other notable investigators include Rammelkamp, Edward Kaplan, James Dale, Edwin 
Beachey, John Zabriskie, Vincent Fischetti and Mclean McCarty.  By expanding on Lancefield’s 
initial work these researchers, among others too numerous to mention, have been able to 
elucidate aspects of streptococcal virulence and the impact of Streptococcus and streptococcal 
related diseases, both primary and sequelae, on the human condition.
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Group A streptococcal infections. S. pyogenes is a human pathogen associated with several 
suppurative infections of the skin and throat, as well as, a number of autoimmune diseases 
including acute rheumatic fever and acute glomuleronephritis.  While the most prevalent 
infections are pharyngitis and impetigo, GAS is associated with several, more invasive infections 
including scarlet fever, streptococcal toxic shock syndrome, cellulitis, erysipelas, necrotizing 
faciitis and gangrene (Stevens 1992; Schlievert et al. 1996).  Pharyngitis, or strep throat as it is 
commonly known, and impetigo are superficial infections that are easily controlled with 
antibiotics, however, these infections may lead to more serious invasive infections such as those 
listed above or to autoimmune complications.  Streptococcal pharyngitis is characterized by a 
sore throat and fever that onsets within 72 hours of initial infection.  With the aid of antibiotics, 
symptoms generally subside within 7 - 10 days and most organisms are cleared, however, in 
untreated cases the organism may be present up to 4 weeks post infection.  This merits concern, 
considering that up to 40% of all cases are mild to asymptomatic and may not warrant treatment, 
thus allowing the spread the organism and creating greater risk of further complications, whether 
invasive or autoimmune (Kehoe 1991; Stevens 1992).  Impetigo is characterized by pustular skin 
lesions most likely found on the extremities and usually is preceded by skin colorization and mild 
trauma to the affected area.  Typically, pharyngeal infections are cleared by a vigorous host 
response that results in lifelong type-specific immunity while impetigo does not.  Additionally, 
streptococcal pharyngitis may appear in any individual over the age of 5 years, while impetigo 
typically reaches peak at two to five years of age. 
 Phage transformed streptococcal organism produce a set of exotoxins and are known to 
induce scarlet fever, a disease characterized by pharyngitis and a rash around the trunk and neck 
that spreads to the extremities.  Most often this infection occurs in children ranging in age from 
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two to ten years.  Other streptococcal invasive infections, necrotizing faciitis, myositis, gangrene, 
are the result of deep tissue infection and exhibit high mortality rates.  These infections usually 
occur in immunocompromised individuals or healthy individuals following a trauma or 
underlying illness.  The most recently identified and potentially most serious invasive GAS 
infection is streptococcal toxic shock syndrome.  Unlike the other invasive infections these 
disease occurs in patients between the ages of 20 and 50 who were otherwise healthy (Scwartz et 
al. 1990).     
 Another potential complication of streptococcal infections is the development of 
autoimmune disorders, which include acute rheumatic fever, acute glomerulonephritis, 
Syndenham’s chorea, psoriasis, and Kawasaki’s disease.  Post-streptococcal autoimmunity 
differs from other cross-reactive antibody associated diseases such as SLE in that, antibodies in 
post-streptococcal sequelae bind directly to the tissue site while in SLE the antibodies form 
immunocomplexes with the autoantigen (DNA) that in turn bind to the tissue site (Chan et al. 
1999; Maddison 1999).   ARF is an autoimmune complication that primarily affects the heart and 
joint tissue and appears in a small percentage of children ranging in age from 5 to 15 years 
approximately three to four weeks following untreated GAS nasopharyngeal infection.  AGN is 
also predominantly a childhood disease, however, it is characterized by renal tissue pathology 
and typically follows impetigo.  Unlike AGN and ARF, psoriasis is an inflammatory skin disease 
that appears to be indiscriminant with age.  These diseases have been shown to follow or be 
exacerbated by a streptococcal infection and will receive more attention later in the review. 
Virulence factors promoting adherence and colonization.  Upon entering the host, the 
organism typically initiates colonization by adhering to host cell epithelium.  S. pyogenes has at 
least eleven potential candidates to carry out this action (Hasty and Courtney 1996); however 
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only five such factors have been well characterized which include lipoteichoic acid (Beachey and 
Simpson 1982; Beachey et al. 1983; Caparon et al. 1991), fibronectin binding protein (Hasty and 
Courtney 1996), M protein (Caparon et al. 1991; Kehoe 1991; Okada et al. 1994), protein F 
(Hasty and Courtney 1996) and the hyaluronic acid capsule (Schrager et al. 1998).  Of course, 
other factors that have not yet been characterized cannot be discounted.  Protein F and fibronectin 
binding protein interact with fibronectin on pharyngeal epithelial cells (Kehoe 1991; Hanski and 
Caparon 1992) and purified preparations of these proteins have been shown to inhibit adhesion of 
GAS to epithelial cells in vitro (Speziale et al. 1984; Kehoe 1991).  Lipoteichoic acid is believed 
to mediate adherence to host epithelium and buccal cells (Simpson and Beachey 1983) through 
the formation of a complex with M protein and binding via its lipid moiety to fibronectin on the 
epithelial cells (Beachey and Simpson 1982). 
 The standard model of adhesion suggests that during the process of its release from the 
cell LTA forms a surface protein-LTA complex where the lipid ends of LTA protrudes outwards 
to permit the binding to fibronectin on the surface of epithelial cells (Beachey et al. 1983).  
However, Caparon et al. (Caparon et al. 1991) have presented evidence indicating that M protein 
does not interact with LTA but instead M protein promotes the formation of aggregates or micro-
colonies.   This suggests that while M protein does not initiate adherence, it directly promotes or 
enhance adherence that ultimately aides in counteracting attachment inhibition mediated by 
secretory IgA (Williams and Gibbons 1972).  While it is generally agreed that M protein itself 
does not play a direct role in adhesion to epithelial cells (Caparon et al. 1991; Okada et al. 1994; 
Hasty and Courtney 1996), certain serotypes of M protein can mediate binding to human 
laryngeal epithelial Hep-2 cells and keratinocytes through CD46 (Okada et al. 1994; Okada et al. 
1995).  However, the significance of this interaction remains in question since Schrager et al. 
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(1998) demonstrated that the hyaluronic acid capsule physically inhibits M protein binding to 
keratinocytes while mediating binding through CD44.  Despite the ambiguity of the roles of the 
various adhesion factors it might be inferred that the availability of such a variety is an indication 
of the organism’s ability to adapt to various host conditions.  Further, instead of dependence on 
one key adhesion factor, each factor may play a minor role, as necessary, in the overall goal of 
adhesion. 
Host immune response to group A streptococcal infections.  Upon bypassing the physical 
barriers and entering the host, the organism may initiate an inflammatory response resulting in 
the influx of the necessary effector cells of the immune system (phagocytes and lymphocytes) 
and serum proteins with effector function, most importantly antibody and complement.  The most 
effective defense against an extracellular organism such as GAS is phagocytosis and the 
activation of the complement system either through the alternative and classical antibody 
mediated pathways.  Phagocytosis can be directed under two mechanisms; first, phagocytic 
macrophages possess receptors for certain bacterial polysaccharides and upon recognition may 
directly mediate phagocytosis, and second, phagocytic activity is greatly enhanced with opsonic 
help of antibodies and complement.   
The complement system is composed of two pathways; antibody mediated classical 
pathway and the less specific alternate pathway (Winkelstein 1981).  Activation of the alternate 
pathway is initiated by the binding of complement factor C3b to the outer surface of the 
organism, while the classical pathway is activated by antibody binding to the pathogen or the 
formation of antigen-antibody complexes.  While the initial events of the two pathways differ 
they eventually overlap with factor C3b.  Involvement of factor C3b leads to the splicing of 
factor C5 into C5a and C5b, where C5a is a major chemotatic agent and C5b will initiate the 
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formation of the membrane attack complex. Activation of the complement cascade will 
ultimately allow for two potential outcomes, lysis or phagocytosis.  First, binding of C3b to the 
organism as an event of either pathway can initiate the formation of the membrane attack 
complex resulting in membrane permeation and subsequent cellular lysis.  Secondly, the bound 
antibody and C3b function as a major opsonin thereby enhancing phagocytic uptake of the 
organism by monocytes, macrophages, or neutrophils.  
The antibody response to GAS plays a pivotal role in controlling GAS infection, not only 
as a means to induce phagocytosis as discussed above but also to hinder attachment to mucosal 
surfaces or neutralize bacterial toxic factors that may have potentially deleterious effect upon the 
host.  Antibody titers against a number of extracellular streptococcal antigens, including the 
group specific carbohydrate, streptolysin O (SLO), DNase B and C5a peptidase have proven 
effective in confirming recent infection.  Typically, the geometric mean titers of anti-SLO in sera 
from children tend to level at the age of three, while the mean titer of anti-DNase B and anti-C5a 
peptidase reach maximum levels around the age of six and nine, respectively (O'Connor et al. 
1991).  Typically, the antibody response to these antigens is dominated by the IgG subclass; 
however, a secretory IgA response to C5a peptidase has been demonstrated (O'Connor et al. 
1991).  The group specific carbohydrate is considered the immunodominant antibody epitope; 
however, the response is primarily mediated by IgM subclass (Emmrich et al. 1985).  Because of 
the central role in pathogenesis of streptococcal diseases, the response to M protein has received 
the most attention.  Antibodies to M protein opsonize streptococci for phagocytosis (Maxted 
1956) and usually provide serotype specific immunity against infection by strains of the same M 
protein serotype (Lancefield 1962; Quinn et al. 1985).  Despite the protective value of these type-
specific antibodies, detection in patient sera following infection is highly variable, with <20% to 
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70% of patients exhibiting detectable levels (Siegel et al. 1961; Quinn et al. 1985).  The site of 
infection also influences the antibody response.  Unlike the throat infection, a very poor serotype-
specific response is generated following skin infection (El Kohly et al. 1980).  This trend has also 
been demonstrated for antibody responses against SLO, while the antibody response against 
DNase B is good regardless of infection site (Kaplan et al. 1970). 
 While the importance of antibodies in GAS infections is well documented, adequate 
information regarding the T lymphocyte response has been lacking.  Historically, T cell help has 
been shown to be a requirement for the antibody response against GAS (Braun et al. 1972), while 
anamnestic cellular responses can be demonstrated in vitro with a patient’s peripheral blood 
lymphocytes.  More recently the CD4+ T cell response against M protein has received the most 
attention in attempts to develop a protective serotype non-specific vaccine.  Research led by 
Good (Pruskakorn et al. 1992; Pruskakorn et al. 1994a; Pruskakorn et al. 1994b) and Kehoe 
(Robinson et al. 1993; Rossiter et al. 1994) have shown that antigen-specific T cell responses 
against M protein are protective in mice, and the immunodominant epitopes have been mapped.  
While the role of the CD4+ T cell population is appreciated in the protective immune response, 
information regarding the role, if any, CD8+ T cells play has been lacking.  Evidence has been 
presented to indicate that GAS may enter host epidermal cells (Hagman et al. 1999), however 
GAS is typically an extracellular organism.  While the ability of an exogenous antigen like GAS 
to enter the class I processing and presentation pathway is not completely understood, several 
mechanisms have received extensive attention elsewhere (Yewdell et al. 1999, Heath and 
Carbone 1999).    Rock et al. (Rock et al. 1993; Kovacsovics-Bankowski and Rock 1995) and 
Harding et al. (Pfeifer et al. 1993; Harding 1996) have shown that extracellular particulate 
antigens, whether protein coated beads or extracellular bacteria, can be processed and presented 
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via class I by activated macrophages in vitro.  This activity has also been demonstrated for 
dendritic cells (Svensson et al. 1997) and B cells (Ke and Kapp 1996).  Cross-priming (Bevan 
1976) is an aspect of class I presentation of exogenous antigen that has received extensive 
attention and yielded the most recent insight regarding potential mechanisms and requirements 
(Bennett et al. 1997, Bennett et al. 1998).  Accordingly, APC may uptake high-dosage antigen or 
apoptotic cells (Kurts et al. 1998) and present the cell bound antigen via class I MHC under 
conditions that require signaling through CD40 by CD4+ T helper cells (Bennett et al. 1997, 
Bennett et al. 1998).  Therefore, while providing means for class I presentation of tissue-
associated antigens for immunological surveillance, this phenomenon may also serve as a means 
for extracellular infectious agents to access this presentation pathway.     
Virulence factors involved in evasion of host immune responses.  Streptococcus pyogenes is 
able to evade phagocytosis with an arsenal of somatic and secreted virulence factors.  The 
hyaluronic acid capsule is considered an important virulence factor, since strains lacking the 
capsule are generally more readily phagocytosed and in turn much less infectious (Husmann et al. 
1997).  The capsule is believed to inhibit phagocytic uptake through steric interactions, physical 
repulsion due to a net negative charge, or other potential mechanisms (Whitnack et al. 1981).  
Being composed of equimolar concentrations of N-acetyl glucosamine and glucuronic acid, 
components ubiquitously found in connective tissue component of the host (Kendall et al. 1937), 
the capsule may potentially provide a protective mask over the organism, diminishing 
recognition for the phagocytic process.  Beyond the physical barrier provided by the capsule, 
other virulence factors, notably M protein and C5a peptidase, are able to directly interfere with 
the host immune response.  M protein is able to prevent non-immune opsonization by binding 
factor H (Horstmann et al. 1988; Horstmann et al. 1992) and more preferably factor H-like 
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protein 1 (FLH-1), the alternative splice product of the factor H gene (Zipfel et al. 1999).  Factor 
H and FLH-1 are important regulators of the complement system that enact their functions by 
splicing C3b and controlling the stability of C3 convertase (Zipfel et al. 1999). This prevention is 
further augmented by C5a peptidase whose primary activity is to selectively cleave a six amino 
acid peptide from the carboxy-terminus of the complement component C5 thereby preventing 
chemotatic signaling necessary for the immune response (Wexler et al. 1985).   
 Although their function remains undetermined, another potential virulence aspect of GAS 
is the family of immunoglobulin-binding proteins (IGPs) (Cleary and Retnoningrum 1994).  This 
family of cell associated proteins includes the M-like protein and a set of other proteins that are 
classified as type IIa or type IIb, where IIa binds human IgG1, IgG2, and IgG4 and IIb binds only 
IgG3 (Cleary and Retnoningrum 1994).  Also, a set of these family members demonstrates IgA 
binding capabilities (Bessen 1994).  While these proteins have been shown to bind 
immunoglobulin and could potentially help to mask the organism from phagocytosis, it has been 
hypothesized that the immunoglobulin-binding proteins function as sensory protein allowing the 
organism to regulate its virulence genes and thus alter the course of infection (Cleary and 
Retnoningrum 1994; Boyle 1995). 
Other virulence factors involved in promoting infection and pathology.  Group A 
streptococcus produces a battery of secreted factors that serve to promote the endurance and 
spread of infection.  While the secreted factors serve to protect the organism, they are also more 
apt to elicit cytopathic effects upon host tissue.  One set of factors serves to facilitate the spread 
of infection by removing physical barriers.  Within this set are the enzymes hyaluronidase 
(Kehoe 1991) and streptokinase (Kehoe 1991; Husmann et al. 1997) and the surface plasmin 




Table 1.  Major virulence factors of Streptococcus pyogenes and their potential role in infection 
and pathogenesis 







N-acetyl glucosamine cell wall 
capsule 
 
GlcNAc is a B cell mitogen 
Persistent Ab titers to 
GlcNAc 
Antibody cross-reactivity 
between GlcNAc and myosin 
Cell Membrane   Induces cross-reactive 





Adherence B and/or T cell mitogen 
Protein F cell wall Adherence  
M protein cell wall Anti-phagocytic 
factor 




Induces host-reactive CTL 
responses in vitro 
M-like protein cell wall Sensory proteins? Bind immunoglobulin and 
other plasma proteins 
Streptolysin O(SLO) 
Streptolysin S (SLS) 
secreted Mediates lysis of  
eucaryotic cells 
SLO has cardiotoxic effects 
SLS suppresses T cells 
Pyrogenic exotoxins  







Suppress antibody response 
Scarlet fever rash 
Hyaluronidase cell surface Tissue invasion Cleaves hyaluronic acid  




The above information was obtained from the following:  Whitnack et al. 1981; Goldstein et al. 
1967; Cunningham and Russell 1983; Hasty and Courtney 1986; Horstmann et al. 1988; Hosein 
et al. 1979; Boyle 1995; Thompson et al. 1970; Hryniewicz et al. 1978, Bohach et al. 1989; 
Kehoe 1991; Wexler 1985 et al. 1985. 
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connective tissue component, thereby permitting tissue penetration (Kehoe 1991).  GAS removes 
fibrin clots either directly with streptokinase or indirectly with plasmin-binding proteins that bind 
plasmin, the key fibrinolytic enzyme (Lottenberg et al. 1987).  This binding not only allows 
plasmin to remain enzymatically active but also prevents it from regulation by its inhibitor, α-2 
plasma inhibitor (Lottenberg et al. 1987).   
 Other secreted factors include streptolysin O (SLO) (Thompson et al. 1970, Halbert et al. 
1961), streptolysin S (SLS) (Hryniewicz et al. 1978), and the pyrogenic exotoxins (SPE A, B, C).  
SLO is capable of lysing a wide range of eucaryotic cells, most notably cardiocytes and 
hepatocytes, by binding to the cell membrane to form a ring structure that allows high molecular 
weight cytoplasmic proteins to leak out (Thompson et al. 1970).  SLO is very antigenic and anti-
SLO antibody titers are a useful diagnostic indicator for recent GAS infection.  Because it is 
cardiotoxic and highly immunogenic, a potential model for rheumatic fever suggests that SLO is 
carried to the cardiac tissue by circulating immune complexes of SLO and antibody however, 
supporting in situ data has been lacking (Halbert et al. 1961).  SLS is a non-antigenic 
extracellular product that has been shown to be lytic for eucaryotic cells, including both red and 
white blood cells (Hryniewicz et al. 1978).  SLS has been shown to lyse both the cell membranes 
and granules of phagocytes that lead to local tissue damage and a local inflammatory response.   
Other well-characterized secreted virulence factors are the pyrogenic exotoxins, SPE A, B, and 
C.  Based on their shared biological activities these proteins belong to a family of pyrogenic 
toxin superantigens (Bohach et al. 1989).  SPE A and SPE C are encoded by a bacteriophage and 
expression of the SPE A gene has been shown to be associated with strains that can cause severe 
invasive infections (Schlievert et al. 1996).  The primary effect of these exotoxins is to elicit 
fever however, they have been shown to cause a wide array of problems: inducing the 
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characteristic rash of scarlet fever, myocardial and hepatic necrosis, decrease in antibody 
synthesis, and acting as a superantigen for T cells (Marrack and Kappler 1990; Schlievert et al. 
1996). 
Streptococcal M protein and the M protein family.  Of all the virulence factors produced by S. 
pyogenes, M protein is considered most important.  This is not only by virtue of its anti-
phagocytic properties but also due to its structural and antigenic diversity (Manjula and Fischetti 
1980; Phillips et al. 1981; Manjula et al. 1985), its ability to induce a protective antibody 
response (Lancefield 1962; Quinn et al. 1985; Pruskakorn et al. 1992) and its potential to elicit 
host cross-reactive immune responses (Kingston and Glynn 1971; Krisher and Cunningham 
1985; Dale and Beachey 1987; Huber and Cunningham 1996).  Because of these properties M 
protein has garnered much attention from the research community as a vaccine candidate for 
GAS infections and to understand the role the protein has in post-streptococcal autoimmune 
sequelae. 
M protein is a dimeric alpha helical coiled-coil protein that extends approximately 60 nm from 
the surface of the organism (Phillips et al. 1981).  The protein is able to maintain this coiled-coil 
conformation due to a seven residue periodicity of non-polar amino acids found throughout the 
molecule, with the notable exception of the wall and membrane-spanning region and the short 
random sequence at the extreme amino terminus (Manjula and Fischetti 1980; Manjula et al. 
1985). Within this periodicity the first and fourth residues are hydrophobic in nature forming the 
core residues of the coil, the fifth is typically a basic residue, and an acidic residue can be usually 
be found in the last position (Manjula and Fischetti 1980; Manjula et al. 1985). While the 
periodicity is conserved, M protein does contain residual interruptions, especially of the 


























































Figure 1.  Schematic representation of M6 protein 




allowing flexibility (Phillips et al. 1981; Fischetti 1989).  Based on these amino acid 
irregularities within the heptad repeat, the central portion of the protein can be divided into three 
subregions which correlate with the A, B and C sequence repeat regions (Fischetti 1989). 
 The N-terminal region of M protein contains a significantly higher net negative charge 
than the C-terminal region (Fischetti 1989), which may hinder contact between GAS and 
phagocytes due to electrostatic repulsion since phagocytes have a net negative surface charge 
(Lichtman and Weed 1970; Manjula et al. 1985).  The negative charge of the outer surface may 
also be a factor in the protective antibody response against M protein since it has been 
demonstrated that opsonic antibodies against M protein are more basic that non-opsonic  
antibodies thereby eliminating the net negative charge upon binding (Fischetti 1983; Fischetti 
1989). 
 Despite the relatively conserved coiled-coil structural conformation, M protein is able to 
maintain antigenic diversity.  M protein contains three regions of tandem repeats designated as A, 
B and C, where the A and B region are found in the amino terminal portion and the C region is 
within the more conserved carboxy region (Hollingshead et al. 1986; Fischetti 1989). Due to 
naturally occurring insertional or deletional recombination events the number and size of repeats 
within these regions may vary between the various M proteins, even among different strains or 
isolates of the same serotype (Fischetti et al. 1985).  Sequence analysis of the various M genes 
indicates that the exposed amino terminus is the highly variable and the carboxy terminus is more 
conserved among the different serotypes (Fischetti et al. 1985).  It is the extensive variability of 
the amino terminus for which serological typing is conferred, and so far over 100 distinct M 
protein serotypes have been identified.  Epidemiological studies have indicated that 
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 the serotype of the M protein is an important factor in the incidence of GAS infections and 
sequelae (Berrios et al. 1986; Stollerman 1991; Johnson et al. 1992).  GAS serotypes that are 
associated with nasopharyngeal infections do not typically cause skin infections and the reverse 
typically holds true as well, although there are certain serotypes that can infect both areas.  
Furthermore, with a few exceptions, GAS serotypes that are associated with rheumatic fever 
typically cause nasopharyngeal infections while serotypes that cause skin infections are 
associated with glomerulonephritis (Veasy and Hill 1997).  Detailed antibody reactivity studies 
indicate that antigenic differences exist within the conserved carboxy region as well, suggesting 
that most M protein serotypes may be placed in one of two major classes of M protein (Bessen et 
al. 1989; O'Toole et al. 1992).  Nearly all serotypes of GAS that have been associated with ARF 
have been shown to express class I M protein (Bessen et al. 1989).  Therefore, GAS serotypes 
associated with rheumatic fever express M proteins that are antigenically distinct from the other 
non-rheumatic serotypes. 
 M protein is a member of the M protein family, which includes structurally related M-like 
proteins (Boyle 1995).  The family is a large group of fibrous alpha-helical surface proteins that 
share similar carboxy terminal halves, including the repeats of the C region and two non-adjacent 
domains of the cell wall and membrane spanning portion, while maintaining high variability 
within the amino-terminal halves (Bessen and Fischetti 1990; Nilson et al. 1995).  Both M 
protein and M-like protein bind one or more of several different plasma proteins including 
immunoglobulin, fibrinogen, plasminogen, albumin, and complement components and β2-
microglobulin, however, only M protein exhibits anti-phagocytic activity (Cedervall et al. 1995).  
Many GAS may express more than one protein from this family (Cedervall et al. 1995), however, 
with the exception of M protein, their overall role in bacterial pathogenesis has not been 
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completely understood.  It has been observed that GAS isolates exhibiting IgA binding activity 
are much more likely to be found in wound and deep tissue infections than in nasopharyngeal 
sites (Bessen and Fischetti 1990; Bessen 1994).  Also, binding of the various plasma proteins has 
been shown to stabilize the dimer structure of the M-like proteins at physiological temperatures 
(Nilson et al. 1995).   
 The most important aspect of M protein is the ability to inhibit non-immune opsonization 
either by binding the complement control protein factor H, as already described above, or binding 
plasma fibrinogen (Bessen and Fischetti 1990; Dale et al. 1996).  It has been suggested that the 
interaction with plasma fibrinogen masks C3b binding sites on the streptococcal surface, thereby 
preventing activation of the alternative complement pathway and subsequent phagocytosis by 
neutrophils (Dale et al. 1996).  Also, fibrinogen has been shown to interact with the amino-
terminus of M protein (Ryc et al. 1989) and prevent antibody binding to that particular area, 
which is especially advantageous considering the immunodominant antibody epitope of M 
protein is located within the B repeat region of the amino terminus (Fischetti and Windels 1988).  
Despite the effective protective mechanism of binding to either fibrinogen or factor H, M protein 
cannot prevent subsequent immune opsonization.  Opsonic antibodies are directed against the 10 
or so amino acids of the extreme amino terminus, an area not bound by fibrinogen (Fischetti and 
Windels 1988).  However, GAS may still maintain a slight advantage because the production of 
opsonic antibodies is not only delayed but also made in much lower titers as compared to non-
opsonic antibodies (Jones and Fischetti 1988).  Furthermore, the protective antibody response to 
GAS is serotype specific and cannot protect the host against infection from other serotypes. 
 Immunity to GAS is highly dependent on the production of opsonic antibodies against M 
protein; therefore, M protein has become a potential vaccine candidate for GAS.  In addition to 
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the problem of serotype specificity of the opsonic antibody response as mentioned above, M 
protein contains epitopes that have the potential to elicit deleterious autoimmune responses as 
will be discussed later in the review.  Extensive work contributed by groups led by either Good 
(Pruskakorn et al. 1992; Pruskakorn et al. 1994a; Pruskakorn et al. 1994b) or Kehoe (Robinson et 
al. 1993; Rossiter et al. 1994; Delvig et al. 1997), have delved into the problem of identifying a 
M protein peptide that will elicit a serotype non-specific opsonic antibody response along with a 
strong helper T cell response to promote memory.  CD4 T cell epitopes have been mapped 
throughout the length of select M protein serotypes; however, in order to avoid serotype specific 
responses efforts have been focused primarily on the conserved carboxy region (Robinson et al. 
1993; Rossiter et al. 1994).  Good et al. (Pruskakorn et al. 1994b) have described one particular 
epitope derived from the conserved region of M5 that is capable of inducing bactericidial 
antibodies as well as a helper T cell response to multiple GAS serotypes, however the antibody 
response was less effective in killing than serotype specific antibodies.  In addition, human CD4+ 
T cell lines specific for this peptide also demonstrated proliferative responses to mammalian 
myosin (Pruskakorn et al. 1994a).   
 
Acute Rheumatic Fever and Other Post-streptococcal Autoimmune 
Sequelae 
 
History and epidemiology. For over three hundred years ARF has been under the scrutiny of the 
medical establishment, however, complete appreciation of the disease pathology did not come 
until within the last century.  During the early period Guillaume de Baillou distinguished ARF 
from other causes of rheumatism and Thomas Syndenham described the acute chorea that bears 
his name, however neither one connected these symptoms to a disease of the heart (reviewed in 
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Stollerman 1975; Read and Zabriskie 1977a).  Although the first definitive descriptions of 
cardiac lesions of acute rheumatic fever were being published as early as the early eighteenth 
century, it took over one hundred years before cardiac involvement in rheumatic fever was 
appreciated.  It was at this time that William Wells, the man credited for the first description of 
the subcutaneous nodules in cases of rheumatic fever, presented a clinical study detailing heart 
pathology of a series of true cases of rheumatic fever (Stollerman 1975; Read and Zabriskie 
1977a).  This was followed by the eloquent studies of Jean-Baptiste Bouillaud, the ‘Father of 
rheumatic heart disease’ who in 1836 gave the first detailed auscultation methods for diagnosing 
acute rheumatic fever (Stollerman 1975; Read and Zabriskie 1977a).  While several 
manifestations of rheumatic fever were being described separately during this time, it was Walter 
Cheadle who in 1889 comprehensively described, for the first time, all the symptoms of ARF as a 
syndrome and his definition has not deviated much even to this day (Read and Zabriskie 1977a).  
His classification of the symptoms into phase correlates with major and minor Jones’ criteria still 
used today for diagnosis (Dajani 1992). 
 The symptoms of rheumatic fever, glomerulonephritis and psoriasis have been known to 
man for several hundred years.  Clinicians knew that outbreaks of rheumatic fever and 
glomerulonephritis almost invariably followed epidemics of scarlet fever, however, confirmation 
of the diseases being linked to an infectious entity did not come until the early part of this 
century.  While the relationship of antecedent sore throat and rheumatic fever was first being 
described in 1880 by Fowler, it was not appreciated until 1907, when Bela Schick developed the 
concept of rheumatic fever being a complication of a bacteria infection (Stollerman 1975; Read 
and Zabriskie 1977a).  Schick also drafted the concept of the latent period between the initial 
infection and the sequelae, which was corroborated about the same time by Poyton and Payne
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 and yet again by Coombs in 1924 (Veasy and Hill 1997).  These studies were soon followed by 
four important studies that provided final evidence supporting the relationship between group A 
streptococcus pharyngitis and ARF.  During the early 1930’s Rebecca Lancefield defined 
subgroups of streptococci based on the cell wall carbohydrate and identified the GAS as the most 
important human pathogen (Lancefield 1962).  Also in the 1930’s, two independent 
epidemiological studies, conducted by Coburn (1935) in the United States, and Collis (1932) in 
England, confirmed the relationship between streptococcal pharyngitis and the development of 
ARF.  The final evidence came from studies conducted by a group led by Rammelkamp, which 
demonstrated that rheumatic fever could be prevented by treating streptococcal pharyngitis with 
penicillin (rev. in Stollerman 1975).  Correlation between streptococcal throat and skin infections 
and glomerulonephritis soon followed in 1929 and 1940, respectively.  Although psoriasis does 
not epidemiological correlate to scarlet fever as does ARF and AGN, the relationship with 
antecedent streptococcal sore throat and development of psoriasis was confirmed in 1916.     
 Probably one of the most interesting aspects of ARF is its changing nature.  Once one of 
the major causes of death in children in this country, it has now become an occasional outbreak, 
while still remaining a serious threat to children in more under-developed countries (Gordis 
1985).  During the beginning of this century ARF was the leading cause of death for adolescents 
and heart disease for individuals under the age of forty in the United States (Homer and Shulman 
1991).  At this time, ARF had a reported annual incidence of 100 to 200 cases out of 100,000 
population and a death rate of 25 to 30 per 100,000 population that seriously outnumbered deaths 
related to other infectious diseases including polio, measles, and diphtheria (Homer and Shulman 
1991).  However, by the 1940’s the incidence had declined to about 50 per 100,000 population 
and continued a steady decline to an incidence rate of 0.5 per 100, 000 by the early 1980’s 
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 (Gordis 1985; Griffiths and Gersony 1990).  This steep decline led some in the medical 
establishment to predict the eventual disappearance of the disease in the United States; however, 
in recent years ARF has had an unexpected resurgence.  Isolated outbreaks have been reported in 
Utah (Veasy et al. 1987), Ohio (Congeni et al. 1987), Pennsylvania (Wald et al. 1987), New York 
(Giardina and Heaton 1988; Griffiths and Gersony 1990), and Tennessee (Westlake et al. 1990).  
West Virginia also had an increased incidence rate in recent years (Hoffman et al. 1997).   
 AGN appears to be following a similar epidemiological path as ARF, in that by the 
1950’s the incidence had declined considerably in the United States and Europe, but it continues 
to be a major childhood threat in less developed countries (Ayoub and Chun 1990).  Like ARF, 
AGN is predominantly a childhood disease, where 60% of all cases occur in the 2 to 12 year age 
range and less than 5% occurring in children under 2 years of age (Richards 1991).  Typically, 
AGN occurs in the presence of a nephritogenic strain of GAS with an overall attack rate of 15% 
regardless of infection site (Stetson et al. 1955), however, nephritogenic strain of M49 serotype 
has been shown to give a 25% and 5% risk of AGN development following skin or throat 
infection, respectively (Anthony et al. 1969).  Psoriasis, on the other hand, does not demonstrate 
such age discrimination and affects about 2% of the Western population. 
 Predicting the manner of these diseases has proven difficult due to the interplay of several 
important epidemiological factors, both environmental and host related.  In the past, the major 
environmental factor has been socioeconomic status, where ARF has been a disease associated 
with crowded, impoverished urban areas and in many under-developed countries this trend still 
holds true.  The incidence decline witnessed during the past fifty years in the United States has 
been widely attributed to better living standards, whether better nutrition, hygiene or housing 
(Land and Bisno 1983; Gordis 1985).  While socioeconomic conditions are important they alone
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cannot explain the changes in the United States.  Recent outbreaks have occurred in mostly 
middle-class suburbanian and rural areas instead of the predicted urban areas (Wald et al. 1987; 
Westlake et al. 1990; Veasy and Hill 1997).  The decline in ARF incidence may also be 
attributed to the introduction and widespread use of antibiotics.  Penicillin has been shown to be 
important in preventing onset and recurrences of ARF as well as decrease the morbidity.  
However, the incidence of ARF began decreasing before widespread use of penicillin and about 
one-third of ARF cases follow mild or asymptomatic pharyngitis that receive no medical 
attention.  
Clinical aspects of ARF and other post-streptococcal autoimmune complications.  The 
clinical presentation of ARF primarily involves three major organs systems; the heart, joints and 
nervous system and diagnosis is usually made predominately on the basis of Jones’ criteria 
(Dajani 1992).  Systemic manifestations may include one or more of the following; polyarthritis, 
carditis and chorea, and usually occur simultaneously with skin manifestations that include 
erythema marginatum and subcutaneous nodules. The polyarthritis of ARF is the most common 
but least specific symptom involving the larger joints and is characteristically asymmetric and 
migratory in nature.  Syndemham’s chorea is the result of an inflammation of the central nervous 
system specifically involving the basal ganglia and caudate nuclei (Ayoub and Chun 1990).  It is 
a delayed manifestation appearing up to 3 months after the onset of ARF in about 20% of ARF 
patients and in some cases may be the only manifestations (Ayoub and Chun 1990). 
 Rheumatic carditis associated with ARF is a pancarditis affecting the endocardium, 
myocardium, and pericardium at varying degrees, however the hallmark of rheumatic carditis is 
valvulitis where the inflammation leads to mitral valve insufficiency and potentially valve 
stenosis.  Another hallmark characteristic of ARF is the granulomatous lesions known as 
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Aschoff’s nodules or bodies that were first described in 1904 by Ludwig Aschoff and can be 
found in interstitium of myocardium, atrial endocardium and heart valves.  While these lesions 
are considered one of the major indicators of ARF, doubt still remains about their composition 
and, more important, their role in the disease process.  Histological analysis reveals that 
Aschoff’s bodies are predominately derived from injured heart muscle cells trying to undergo 
regeneration, otherwise known as Anitschkow cells (Wagner 1960).  It has been inferred that 
these Anitschkow cells are responsible for the scarring of heart tissue associated with ARF 
(Stehbens and Zuccollo 1999).  Established Aschoff’s lesions are not directly stained with typical 
lymphocyte and macrophage reagents, however the damage could be the result of inflammatory 
cytokines produced during multiple phases of infiltration of macrophages followed by T and B 
lymphocyte infiltration (Kemeny et al. 1989; Fraser et al. 1997).  In regard to their role in the 
disease process, Aschoff himself argued that the cardiac failure associated with this disease is 
due to weakness resulting from changes in the myocardium more so than by valvular lesions 
(Stollerman 1975).  Furthermore, the persistence of Aschoff bodies in the asymptomatic patient 
with clinically inactive rheumatic heart disease may actually represent a low-grade chronic 
inflammatory process that has little to do with the functional state of the myocardium (Stehbens 
and Zuccollo 1999).  
 Other autoimmune complications of streptococcal infection that have received much 
attention from the research community include acute glomerulonephritis and psoriasis.   Psoriasis 
is an inflammatory skin disease characterized by lesions that are sharply demarcated reddish 
plaques of various size and cover with scaling.  These symptoms are due to reversible 
keratinocyte hyperproliferation giving rise to the increased epidermal turnover or scaling 
(England et al. 1997; Prinz 1997).  In greater than 10% of patients these symptoms are also 
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accompanied by joint involvement which may lead to severe arthritis.  AGN is characterized by 
renal tissue involvement and glomerular injury is evidenced by the sudden appearance of 
hematuria and proteinura that is often accompanied with edema (Richards 1991).  Hematuria in 
varying degrees is present in all patients with up to 90% exhibiting proteinura (Zarconi and 
Smith 1988; Richards 1991).  Typically, 60 - 70 percent of these patients display hypertension 
and edema.  Renal biopsies of patients demonstrate diffuse proliferation of endothelial and 
mesangial cells accompanied by polymorphonuclear cell infiltrate (Zarconi and Smith 1988).  
Other microscopic finds include diffuse antibody and complement deposits, which are believed 
to be the cause of the symptoms and pathology. 
Role of humoral immune response in pathology of post-streptococcal acute rheumatic 
fever.   Although the underlying mechanisms of pathology have yet to be truly understood, ARF 
has long been considered an autoimmune event.  This suspicion has been based upon several 
factors, including the latent period between initial infection and the onset of ARF, the ability to 
prevent such an event with effective penicillin treatment, and most importantly, the exaggerated 
antibody responses exhibited by ARF patients.  One of the earliest and most sustaining theories 
suggested that susceptibility to the disease might be due to immune hyperresponsiveness (rev. 
Ayoub 1991).  This theory eventually became contested when Cavelti described heart-reactive 
antibodies for the first time, putting forth the idea that autoimmune mechanisms may be involved 
in the pathogenesis of ARF (Cavelti 1945). 
 Early evidence suggesting that antibodies may play a role in pathology was presented first 
by Kaplan, who confirmed the presence of heart reactive serum antibodies in ARF patients and 
also found diffuse antibody and complement deposits throughout the myocardium that was 
localized primarily at edges of cardiac myofibers (Kaplan 1960; Kaplan et al. 1964b).  Kaplan 
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then followed up this work by demonstrating for the first time that antibodies raised against GAS 
cross-react with cardiac tissue (Kaplan 1963; Kaplan and Suchy 1964a).  About the same time, 
Goldstein et al. (1967) demonstrated that antibodies to GAS cell wall polysaccharide GlcNAc 
cross-react with heart valve glycoproteins and Zabriskie and Freimer (Zabriskie and Freimer 
1966) described an antibody cross-reaction between GAS membranes and myocardial 
sarcolemma.  Seven years later Beachey and Stollerman (Beachey and Stollerman 1973) 
demonstrated that M protein was capable of absorbing heart-reactive antibodies from human 
sera.  Since then, it has been repeatedly shown that ARF patients typically exhibit high titers of 
anti-streptococcal antibodies in their sera against M protein and GlcNAc that cross-react with 
cardiac myosin (van de Rijn et al. 1977; Cunningham and Russell 1983; Cunningham et al. 
1989).  Antibody cross-reaction has also been implicated in other aspects of ARF, including 
chorea.  A study of a group of patients with chorea found that almost half of the patients 
exhibited antibodies reactive with the cytoplasm of neurons in the subthalamic and caudate 
nuclei (Husby et al. 1976). 
 Although these antibodies have been extensively described and antibody deposits have 
been consistently found in histological sections (Kaplan 1960; Kaplan et al. 1964b; Kemeny et al. 
1989), their role on the course of the disease remains largely unknown. The anti-streptococcal 
carbohydrate antibodies are typically of the IgM isotype and have been shown to be capable of 
mediating complement lysis in vitro (Prehm et al. 1995).  Research conducted by the laboratories 
of Ayoub (Dudding and Ayoub 1968; Shulman et al. 1974a) and Eichbaum (1995), observed that 
ARF patients with heart problems have persistently high titers of anti-streptococcal antibody 
compared to controls and ARF patients without cardiac problems suggesting ARF patients have 
an exaggerated humoral immune response.  Observations have been made in ARF patients that a
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 sustained rise in the anti-streptococcal antibody titer that cross-reacts with cardiac tissue has 
been shown to precede an attack of ARF (Kaplan and Frengley 1969).  Furthermore, sufficient 
evidence has been presented to show that streptococcal infections are capable of inducing cross-
reactive antibody responses in both humans and laboratory animals (Zabriskie and Freimer 1966; 
van de Rijn et al. 1977; Cunningham et al. 1988).  However, it is difficult to assign a primary role 
for the cross-reactive antibodies since evidence that can ascribe pathogenic potential to such 
antibodies is lacking (Neu et al. 1993) and because normal healthy individuals exhibit low levels 
of self-reactive natural antibodies in their sera without any resultant complications (Klinman et 
al. 1988).   
 Also, it may be postulated that these antibodies are secondary to the disease process, 
being the result of antigen release due to organ specific inflammation and damage and not due so 
much to direct cross-reactivity (Neu et al. 1993).  Patients who have sustained cardiac injury or 
surgery exhibit myosin reactive antibodies in their sera, however these antibodies do not cross-
react with GAS determinants (Kennedy and Das 1976).  Likewise, antibodies raised against 
bovine heart valve homogenates were not cross-reactive to GAS polysaccharide (Kasp-
Grochowska et al. 1972a).  Upon histological staining of human heart and kidney tissue with this 
bovine heart antisera and anti-streptococcal sera they found that the bovine heart sera reacted to 
connective tissue and basement membrane while the anti-streptococcal sera reacted to cellular 
components of both myocytes and fibroblasts in the heart and the glomerular tufts of the kidney 
(Kasp-Grochowska et al. 1972b).  Demonstration of this cross-reactivity leads to another 
interesting facet of the autoimmune response; a bacterial carbohydrate is capable of eliciting 
antibodies that can cross-react with protein determinants.  Cunningham et al. (1983; 1984; 1986; 
1992) have developed an extensive panel of murine and human monoclonal antibodies that cross-
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react with GAS group specific carbohydrate (GlcNAc) and mammalian proteins including 
myosin and keratin.  In addition, they have shown that this cross-reaction cannot be inhibited 
with the removal of carbohydrate from the proteins with n-acetyl-muraminidase treatment 
(Shikhman and Cunningham 1994).  Harris et al. (1997) demonstrated that monoclonal 
antibodies against GAS polysaccharide were capable of isolating cross-reactive peptides from a 
panel of phage display libraries.   Since the peptides binding to these antibodies appeared to be 
specific they suggested that distinct mechanisms exist for carbohydrate and peptide recognition 
and that cross-reactive peptides may be found for most anti-carbohydrate antibodies (Harris et al. 
1997).   
Involvement of cellular immune response in pathology of post-streptococcal autoimmune 
diseases.  The group led by Zabriskie (Read et al. 1974) was among the first to note a 
relationship between cell-mediated immune responses to streptococcal antigens and attacks of 
ARF in humans.  Histological sectioning and staining of biopsied cardiac tissue reveals that 
pathology is primarily due to lymphocytic infiltrates (Raizada et al. 1983; Kemeny et al. 1994) 
however, the question remains as to how and why these cells are recruited. In both active and 
chronic cases of ARF, these infiltrates are found to be mostly macrophages and T lymphocytes of 
which the CD4+ population outnumbers the CD8+ population 4:1 (Kemeny et al. 1994).  
Phenotypic and cytokine profiles of peripheral blood lymphocytes (PBL) of ARF patients 
compared to controls indicate that ARF patients exhibit hyperimmune responses where there is a 
sustained increase in the number and percentage of CD4+ T cells and B cells but a decrease in the 
percentage of CD8+ T cells (Lueker et al. 1975; Williams et al. 1982; Cairns 1988; Bhatia et al. 
1989; Alarcon-Riquelme et al. 1990; Morris et al. 1993a; Morris et al. 1993b).   
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Several studies have suggested that during the acute phase of disease, the numbers and 
percentages of CD4+ T cells were increased, returning to normal during convalescence while the 
CD8+ T cells were decreased during the acute phase and increased during recovery (Cairns 1988; 
Alarcon-Riquelme et al. 1990; Bhatnagar et al. 1999).  This increased percentage in peripheral 
CD4+ lymphocytes has been shown to correlate with the increased percentage of peripheral 
CD25+ (IL-2R) cells (Morris et al. 1993a; Morris et al. 1993b).  Furthermore, the increases in 
both CD4+ and CD25+ cells correlate to the increased production of IL-2 in ARF patients (Narin 
et al. 1995).  In addition to increased IL-2 levels (Morris et al. 1993b; Narin et al. 1995), acute 
phase patients exhibit increased levels of inflammatory cytokines, including IL-1 (Morris et al. 
1993b; Narin et al. 1995), IL-6, IL-8 (Kutukculer and Narin 1995; Yegin et al. 1997), and TNF-α 
(Miller et al. 1989; Yegin et al. 1997).  The results of these studies have led to the proposal 
suggesting that the pathological outcome of ARF is a CD4+ lymphocyte-driven hyperimmune 
response with convalescence mediated by CD8+ lymphocytes down-regulating the deviant 
immune responses (Cairns 1988; Alarcon-Riquelme et al. 1990; Bhatnagar et al. 1999).  
However, extensive studies with experimental autoimmune myocarditis indicate that CD4+ T 
cells are necessary to initiate the response but CD8+ T cells mediate the pathological outcome 
and recovery (Rose et al. 1990; Neu et al. 1993; Smith and Allen 1993). 
 In addition to an overzealous immune response, several reports have indicated that ARF 
patients exhibit cross-reactive autoimmune cellular responses.  el-Demellawy et al. (1997) 
demonstrated that PBL from ARF patients recognize a 50 kDa and 54 kDa protein of myocardial 
extracts and that pre-culturing with GAS extracts may intensify the proliferative response.   
Cloning of lymphocyte infiltrates has yielded conflicting results.  Guilherme et al. (1995) have 
been able to isolate clones that cross-reacted with M protein and myosin however; Yoshinaga et 
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al. (1995) could not.  Cloning of PBL from active and chronic cases of ARF has given no clearer 
answer either.  The T cell lines produced by Pruksakorn et al. (1994a) that cross-reacted between 
M protein and myosin were isolated from healthy individuals.  While this study may not confirm 
the presence of cross-reactive lymphocytes, it does indicate that precursor myosin reactive T cells 
can exist in the periphery.   Furthermore, the T cell lines developed from ARF patients in the 
Yoshinaga study reacted only with lysates of streptococcal strains associated with ARF but not 
strains associated with nephritis or non-pathogenic streptococci (Yoshinaga et al. 1995).  While 
the T cell data may not provide conclusive support for a cross-reactive immune response, it at 
least underscores the notion that these patients exhibit hyperimmune responsiveness.     
 While ample evidence has been provided indicating a role for the T lymphocyte 
compartment in rheumatic fever, the question of tissue-specific recruitment remains.  Fibroblasts 
of biopsied tissue from ARF patients, but not normal controls or patients of other potentially fatal 
cardiac diseases, were shown to have aberrant increases in MHC class II molecule expression, 
and therefore have the potential to act as antigen present cells (Amoils et al. 1986).  In support of 
this data, histological analysis by Raizada et al. (1983) demonstrated that CD4+ T infiltrates were 
closely positioned to cardiac fibroblasts and collagen fibrils.  Studies conducted with the myosin-
induced myocarditis murine model indicate the resident APC in the normal myocardium express 
MHC class II and can present myosin to primed T cells in vitro (Smith and Allen 1992; 
Donermeyer et al. 1995).  In addition, myosin immunization activates endothelial ICAM-1 
expression which upregulates expression of class II MHC and Class I MHC on cardiac interstitial 
cells and myofibers, respectively (Pummerer et al. 1991; Pummerer et al. 1996).   
Kotb (1998) has suggested that T cell responses initiated against microbial antigens and 
superantigens can generate high levels of inflammatory cytokines that ultimately lead to 
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localized tissue destruction and subsequent release of self-antigen that allows for the expansion 
of autoreactive T cells.  S. pyogenes produces several superantigens, including pyrogenic 
exotoxins (SPE), LTA, and M protein.   In vitro and in vivo studies have demonstrated that 
streptococcal proteins, especially the M protein, can induce the differentiation of human and 
rabbit cytotoxic T lymphocytes with the capacity to kill myocardial cells and cell lines (Dale et 
al. 1981; Dale and Beachey 1987; Kotb et al. 1989).  Certain serotypes of M protein that have 
been associated with ARF have been shown to have superantigenic effects on particular subsets 
of human lymphocytes (Tomai et al. 1990; Tomai et al. 1991; Tomai et al. 1992; Watanabe-
Ohnishi et al. 1994), however, this has not been correlated to Vβ gene usage in ARF patients 
(Abbott et al. 1996). 
Role of the immune response in other post-streptococcal autoimmune sequelae. Due to 
pathological manifestations and histological findings psoriasis has been suspected to be an 
autoimmune disorder, in that, extensive granulocytic and T lymphocytic infiltrates, as well as 
antibody deposits, can be found throughout the dermis and epidermis (Bjerke et al. 1978; Baker 
et al. 1984a).  Lesional eruptions coincide with an influx of activated macrophages and CD4+ T 
cells while disease resolution is associated with the influx of CD8+ T cells (Bjerke et al. 1978; 
Baker et al. 1984a; Baker and Fry 1992).  Infiltrating T cells have been observed in close 
proximity to class II MHC-bearing dendritic cells (Baker et al. 1984b).  Psoriatic pathology has 
been induced in uninvolved psoriatic skin transplants on SCID mice following injection of 
activated mononuclear cells (Gottlieb et al. 1996).  Further, immunoregulatory agents 
cyclosporin A and anti-CD4 antibody clinically alleviate symptoms (Griffiths et al. 1986; Morel 
et al. 1992).  Studies have demonstrated the capacity of psoriatic T cells to be mitogenic to 
keratinocytes in vitro (Prinz et al. 1994; Bata-Csorgo et al. 1995) and T cell stimulating 
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cytokines IL-2 and IFN-γ exacerbate skin lesions in vivo (Lee et al. 1988; Fierlbeck and Rassner 
1990).  T cells isolated from lesions also produce TNF-β, IL-3, and IL-5 (Vollmer et al. 1994), 
however it is IFN-γ that is believed to play the central role (Baker et al. 1988; Scheynius et al. 
1992; Prinz et al. 1994).  IFN-γ along with TNF-α and β, induce ICAM-1 and MHC II 
expression on keratinocytes witnessed in vivo (Vollmer et al. 1994).  
 The relationship between GAS throat infections and psoriasis has long been established; 
only recently has direct supporting evidence emerged.  Psoriatic patients have been shown to 
exhibit circulating autoreactive antibody (Perez-Lorenzo et al. 1998), especially to keratins 
(Shikhman and Cunningham 1994; Sigmundsdottir et al. 1997; Valdimarrson et al. 1997) but, as 
with ARF, no direct association with pathology can be demonstrated.   Circulating T cells from 
psoriatic patients demonstrate the ability to respond to streptococcal M protein peptides that 
share sequence homology to keratin (McFadden et al. 1991; Sigmundsdottir et al. 1997).  T cell 
lines derived from psoriatic lesions display specific responses to streptococcal antigens (Baker et 
al. 1993).  While direct cross-reactivity has been demonstrated, others have postulated a role for 
streptococcal superantigens including M protein and SPE (Leung et al. 1995a; Leung et al. 
1995b; Valdimarrson et al. 1997). 
 Unlike ARF and psoriasis, cell mediated immunity is lacking in AGN (Rajajee et al. 
1984). Therefore, the resultant pathology of AGN is believed to be due to an elevated antibody 
response resulting in antibody and complement deposition and the subsequent inflammatory 
response.  The mechanisms under investigation include antibody-antigen complexes that build up 
in the target tissue (Nordstrand et al. 1996), direct antibody cross-reactivity (Lange 1995), and 
streptococcal antigen deposition (Holm 1988; Nordstrand et al. 1998).  Dillon et al. (1974) were 
among the first to provide supporting evidence when they reported that patients with AGN 
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demonstrate elevated antibody titers to DNase B but not SLO as compared to controls and that 
following skin infections the anti-DNase B titers rose more often and persisted longer than the 
anti-SLO titers.  More recently, Mori et al. (1997) found that IgG titers against M12 C region but 
not the AB region were higher in AGN patients and persisted after the SLO and streptokinase 
titers returned to normal. 
 In addition to the elevated antibody response witnessed in AGN patients, it is believed 
that antibody cross-reactivity may play a role as well.  Markowitz and Lange were the first to 
observe immunologic cross-reactivity between the streptococcal glycoprotein and the glomerular 
basement membrane (Markowitz and Lange 1964).  Several groups have since demonstrated in a 
variety of in vitro systems the cross-reactivity between anti-streptococcal antibodies and kidney 
basement membrane (Fitzsimons et al. 1987; Kraus and Beachey 1988; Kraus et al. 1990).  
Antibody cross-reactivity and corresponding pathology have also been demonstrated in vivo with 
laboratory animals (Fitzsimons and Lange 1991; Lange 1995).  Histological findings indicate that 
although IgM and IgG are present, C3 arrives first and is the major immune deposit found in the 
kidney (Nordstrand et al. 1996).  A possible explanation may be that the localization of 
streptokinase to glomeruli causes subsequent deposition of complement as an effect of the ability 
of streptokinase to convert plasminogen to plasmin (Holm 1988; Nordstrand et al. 1998).  
Immune complexes are believed to have a role in the later stage of disease since C3 deposition is 
followed by IgG deposition in humans (Sorger 1986). 
Potential role of streptococcal M protein in autoimmunity.  Epidemiological studies indicate 
the association of particular streptococcal serotypes with systemic infection and sequelae (Berrios 
et al. 1986; Johnson et al. 1992). Several groups have demonstrated the ability of M protein to 
induce antibodies that cross-react with various host coil-coiled proteins (Hosein et al.
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 1979; Dale and Beachy 1985a; Dale and Beachy 1985b; Cunningham et al. 1988; Kraus et al. 
1990; Vashishtha and Fischetti 1993).  The alpha helical coiled-coil feature of M protein is not a 
common conformation for most bacterial surface proteins; however, the conformation is 
prevalent among mammalian proteins.  Research conducted by laboratory of Fischetti (Manjula 
and Fischetti 1980; Manjula et al. 1985) have shown that M protein, especially those serotypes 
associated with autoimmune sequelae, shares extensive amino acid sequence and 
physicochemical similarities with coiled-coil mammalian proteins, notably myosin heavy chain, 
tropomyosin, and type I keratins.  Furthermore, the coiled-coil in the B region is characteristically 
more similar to mammalian coiled-coil proteins, especially myosin (Manjula and Fischetti 1986) 
and the B region contains the immunodominant antibody epitopes (Fischetti and Windels 1988).  
These examples of shared homology, especially in regions of immunodominancy, provide an 
explanation for the ability of M protein to induce a host-crossreactive antibody response.  
Independent studies by Dale and Beachey et al. (1985a; 1985b; Kraus et al. 1990), Cunningham 
et al. (1988; 1992), and Fischetti et al. (Vashishtha and Fischetti 1993) have demonstrated in 
experimental animals the ability of M protein to elicit antibodies that cross-react with 
mammalian coiled-coil proteins; notably myosin, tropomyosin, keratin and actin.   
 Experimental evidence indicating a role for M protein in inducing a host cross-reactive 
cellular response has been conflicting (Robinson et al. 1993; Pruskakorn et al. 1994a; Guilherme 
et al. 1995; Yoshinaga et al. 1995; Huber and Cunningham 1996).  In vitro and in vivo studies 
have shown that M protein has the potential to induce cytotoxic T cell responses that have the 
capacity to kill myocardial cells (Friedman et al. 1971; Yang et al. 1977; Dale and Beachey 1987; 
Kotb et al. 1989; el-Demellawy et al. 1997).  Dale and Beachey et al. (1987; Kotb et al. 1989) 
have demonstrated this for human lymphocytes, and Yang et al. (1977) and Friedman et al. 
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(1971) were able to actively immunize laboratory animals with GAS and demonstrate lytic 
activity to heart cultures.  However, several groups that have been able to demonstrate the 
antigenicity of M protein have not been able to induce such cross-reactive responses (Robinson et 
al. 1993; Pruskakorn et al. 1994a).  
 Peptic extracts of M protein from rheumatogenic strains of GAS (M5, M6, M18, M19, 
and M24) have been shown to have superantigenic potential for human cord blood T cells and 
peripheral blood lymphocytes (Dale et al. 1981; Dale and Beachey 1987; Tomai et al. 1991; 
Watanabe-Ohnishi et al. 1994).  Work initiated by Dale et al. (1981; 1987) and carried on by 
Kotb et al. (Tomai et al. 1991; Tomai et al. 1992; Watanabe-Ohnishi et al. 1994) demonstrated 
that peptic extracts of M protein (pepM) from rheumatogenic strains of GAS (M5, M6, M18, 
M19, and M24) are all superantigens for human T cells with all sharing a specificity for Vβ4, 
however, each serotype has its own unique set of Vβ specificity which is also distinct from those 
reported for streptococcal pyrogenic exotoxins.  Furthermore, phenotypic analysis of psoriatic 
lesional T cells indicates an increase in Vβ2 expressing T cells (Lewis et al. 1993), as well as, 
Vβ1, 8, 12 (Abe et al. 1991; Lewis et al. 1993).  This led to the hypothesis that the 
superantigenicity of M protein may play a role in the pathogenesis of post-streptococcal 
autoimmune diseases (Tomai et al. 1990; Watanabi-Ohnishi et al. 1995).  The superantigenic 
ability of M protein has been questioned as other groups have been unable to repeat this response 
with recombinant protein (Degnan et al. 1997) or have demonstrated the superantigenicity is due 
to exotoxin contamination (Fleischer et al. 1992).  Furthermore, while patients with invasive 
GAS infections have abnormalities in the Vβ repertoire of peripheral blood T cells consistent 
with superantigen stimulation by streptococcal proteins (Watanabi-Ohnishi et al. 1995), namely 
the exotoxins, a study of the Vβ repertoire of ARF patients did not show any such abnormalities 
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(Abbott et al. 1996).  While indicating that superantigen responses are not a primary mechanism 
of autoimmune sequelae, it does not rule out the possibility that superantigens may exacerbate 
existing autoimmune responses. 
Influence of host genetic factors on susceptibility to ARF and other post-streptococcal 
autoimmune disorders.  It has been long suspected that genetic or heredity factors play a very 
important role in the susceptibility to rheumatic fever.  Although this theory first came into 
existence in the late eighteenth century when Sir Arthur Newsholme conducted the first 
epidemiological study of rheumatic fever, tangible scientific evidence has not been forthcoming.  
Evidence exists for the genetic control of the immune response to GAS (Greenberg et al. 1980; 
Greenberg et al. 1981).  Greenberg et al. found that the immune response to streptococcal 
antigens is controlled by two HLA-linked genes (Greenberg et al. 1981) and is inherited in an 
autosomal dominant manner (Greenberg et al. 1980).  In addition, Hafez et al. discovered a 
relationship between HLA expression and the immune response to carbohydrates where a 
recessive trait exists for hyper-responsiveness to carbohydrates (Hafez et al. 1990).  Several 
groups have attempted to correlate susceptibility to post-streptococcal autoimmune disorders to 
genetic factors, particularly race and HLA antigen expression, for over twenty years and although 
correlations have been made they are not without contradictions.  In fact, the pioneering 
immunogenetic study conducted in 1973 by Falk et al. (1973), which reported a reduced 
frequency in HLA-A3 in ARF patients, was contradicted two years later by Caughey et al. (1975) 
who saw an increased frequency of HLA-A3, as well as HLA-A8, in RF patients.  Another class I 
HLA antigen that has received attention is HLA-B5.  Greenberg et al. (1975) were the first to 
note that lymphocytes from HLA-B5 individuals were more responsive in vitro to streptococcal 
antigens than their non-HLA-B5 bearing counterparts.  Furthermore, an association has been 
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made between the presence of elevated immune complex levels and the presence of HLA-B5 in 
RF patients (Yoshinoya and Pope 1980).  Yet, the frequency of HLA-B5 was found to be reduced 
in RF families (Read et al. 1977b).  Similar studies conducted with psoriatic patients indicate that 
HLA-Cw6, B13, and Bw57 appear to confer susceptibility (Christophers 1996).   
 The difficulties in demonstrating susceptibility linkage to HLA class I genes have also 
been encountered by several groups who undertook studies beginning in the 1980s that delved 
into the linkage to HLA class II genes.  Most likely the greatest challenge has been due to 
population diversity and ethnicity.  Association with HLA-DR4 was reported in Caucasians 
populations in the U.S. (Anastasiou-Nana et al. 1986; Ayoub et al. 1986) and Saudia Arabia 
(Rajapakse et al. 1987).  HLA-DR1 was found associated with black populations in South Africa 
(Maharaj et al. 1987) whereas HLA-DR2 was implicated in susceptibility in RF in black 
Americans (Ayoub et al. 1986).  In Brazilian patients of mixed background (Guilherme et al. 
1991) HLA-DR7 and DR53 were found in higher frequencies.  Interestingly, psoriasis a 
predominantly a Caucasian disease, seems to have an association with HLA-DR7 as well 
(Christophers 1996).  This data may be interpreted as indicating that the real susceptibility gene 
for RF is not represented by any of these markers but instead by another genes present in HLA 
complex that could display various linkage patterns with HLA-DR and DQ (Gerbase-DeLima et 
al. 1994).  Another potential explanation is that the HLA genes do not play a significant role in 
dictating susceptibility (Ertug 1993).  Either way more substantiated scientific evidence is 
necessary. 
 Another potential indicator for susceptibility to ARF is the expression of a B cell 
alloantigen recognized by the D8/17 monoclonal antibody, an antibody produced in mice against 
B cells from ARF patients (Patarroyo et al. 1979; Zabriskie et al. 1985; Gibofsky et al. 1991; 
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Kemeny et al. 1994).  Originally, Patarroyo et al. (1979) developed the alloantisera using B cells 
from RF patients and noted the existence of a surface marker on peripheral blood mononuclear 
cells stimulated with pokeweed mitogen defined by the alloantisera 883 and that this antisera 
reacted to over 75% of RF patients from the United States and Columbia.  When the supply of 
alloantisera was exhausted, Zabriskie et al. repeated the immunization strategy and developed 
D8/17 (Zabriskie et al. 1985).  Subsequent analysis found that this D8/17 reacts with an antigen 
on a large proportion of B cells from ARF or RHD patients from differing ethnic backgrounds at 
various frequencies (Gibofsky et al. 1991; Ganguly et al. 1992) and that it is not an HLA antigen 
(Kemeny et al. 1994).  Patients with certain neurological disorders, including Syndenhams 
chorea, Tourette’s and subgroups of obsessive-compulsive disorder, have been shown to express 
higher levels of the alloantigen (Swedom et al. 1997; Hollander et al. 1999).  In addition, this 
antibody has been shown to recognize helical coiled-coil structures (Gibofsky et al. 1991), 
cardiac, skeletal, and smooth muscle, epithelia and hepatocytes, and more specifically, to M6 M 
protein, vimentin and myosin (Kemeny et al. 1994).   
  
Overview of our studies 
Introduction. Unlike most autoimmune diseases the precipitating event for ARF, streptococcal 
pharyngitis, is known.  Extensive examination of patients and in vitro experimentation have 
given credence to the theory that ARF is an autoimmune sequelae.  But despite the  
overwhelming evidence indicating that group A streptococcus can induce cross-reactive 
autoimmune responses, the underlying mechanisms of rheumatic fever remain elusive.  One of 
the greatest challenges facing researchers studying this phenomenon is reconciling the data 
demonstrating the ability of streptococcal antigens to consistently induce cross-reactive immune 
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responses in vitro with the reality that this disease affects only a certain small percentage of the 
population and not all of these patients consistently exhibit abnormal cross-reactive immune 
responses.  Modern medicine has been able to dampen the threat of autoimmune complications 
with the advent of prophylatic penicillin treatment, however the ability to predict and ultimately 
prevent and treat the acute autoimmune illness still remains an elusive goal.  Identification of 
susceptible individuals has proven difficult with no clear genetic marker in sight creating a 
greater need for prevention.  Extensive research has been applied to the development of a GAS 
vaccine with the predominance of research targeted towards the major immunodominant antigen 
M protein.  Despite the promise of inducing protective immunity with such a vaccine, M protein 
has been shown to induce host cross-reactive immune responses that may ultimately prove 
detrimental to the individual.  The ability to confirm the circumstantial evidence obtained thus 
far against M protein would be greatly improved with the development of a post-streptococcal 
autoimmune animal model.   
Based on our observation that neonatal mice immunized with S. pyogenes exhibit life-
long host cross-reactive antibody responses reminiscent of ARF patients, we have decided to take 
advantage of this immunization strategy and develop a mouse model for post-streptococcal 
autoimmune diseases.  Research outlined in the following chapters will include work devoted to 
characterizing the antibody and T lymphocytic immune responses following neonatal 
immunization with S. pyogenes in an attempt to determine the extent to which GAS may induce 
immune responses to mammalian proteins, namely muscle myosin.  The data presented within 
the subsequent chapters focuses primarily on the antibody and CTL responses elicited following 
immunization with heat-killed S. pyogenes.  Due to unforeseen problems within our system, 
mostly the mitogenicity of streptococcal M protein, we were unable to evaluate autoreactive
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 CD4+ T cell responses.   In the future methodical approaches will be undertaken to identify 
antigen-specific CD4+ cells.    
Capacity of the neonatal immune system.  Although we have been able to elicit host cross-
reactive immune responses in our neonatally challenged mice, controversy exists regarding the 
extent to which neonates are capable of mounting a productive immune response following 
antigenic exposure.  Over forty years ago Medawar and colleagues provided the first 
experimental evidence suggesting that the neonatal immune system is uniquely susceptible to 
tolerance induction (Billingham et al. 1953), an understanding which has provided an excellent 
explanation and time-frame for the development of self tolerance.  Since this observation, two 
major hypotheses have emerged attempting to explain the mechanisms of this phenomenon.  The 
first hypothesis suggests that experimental neonatal tolerance occurs by negative selection much 
in the same manner as natural negative selection occurs (Morrissey et al. 1983), while the second 
suggests that neonatal tolerance is due to the generation of a T cell response biased towards a 
predominantly suppressive Th2 response (Singh et al. 1996; Adkins and Du 1998).  However, 
recent evidence has been put forth to contradict these hypotheses by suggesting that under the 
proper conditions neonates are capable of eliciting a normal protective Th1-type immune 
response comparable to the more immunologically mature adult animal. 
 Adkins et al. (1994) and Singh et al. (1996) demonstrated that neonatal antigen exposure 
of soluble protein or peptide in complete Fruends adjuvant, respectively; can induce a primary T 
cell response that is split between a Th1 and Th2 response but becomes biased towards a Th2 
response upon secondary challenge, as determined by antibody and cytokine profiles.  Forsthuber 
et al. (1996) demonstrated that immunizing neonatal mice with protein in incomplete Fruends’ 
adjuvant can induce a Th1 type response that may be recalled when the animal is an adult, 
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provided that the booster contains complete Freunds’ adjuvant.   In contrast, Pertmer and 
Robinson (1999), while able to induce similar Th1 immune responses with a DNA vaccine of 
influenza hemagglutinin, were unable to induce antibody responses to the protein until two 
weeks of age.  In regard to eliciting protective CTL responses, Sarzotti et al. (1996) and Siegrist 
et al. (1998) demonstrated the ability of neonatal mice to mount a protective CTL response using 
two distinct viral models.  Furthermore, Pilarski et al. (1977) found that mice have detectable 
anti-allogenic CTL responses within three days of birth. 
 While it has been repeatedly demonstrated that neonatal mice have a tendency to elicit a 
deviant (Th2) immune response upon antigenic challenge, questions still remain as to the cause.  
An obvious explanation would be the immunological immaturity of the neonatal immune system.  
In support of this argument, murine T cells have TCR with limited N region addition that 
restricts the diversity of the TCR during the neonatal period (Feeney 1991).  However, neonatal T 
cells have been shown to express receptors for cytokines and costimulatory molecules in similar 
amounts as the adult animal (Adkins et al. 1994).  Furthermore, neonatally thymectomized mice 
produce a Th1 response upon challenge with soluble protein, suggesting that T cells have fully 
mature capacity as early as day one of life (Adkins and Du 1998).  Other potential explanations 
include deficiencies in production of key cytokines (Adkins et al. 1994; Adkins and Du 1998; 
Arulanandam et al. 1999) or antigen processing and presentation (Levin and Gershon 1989; 
Ridge et al. 1996).  Typically neonatal mice produce larger amounts of IL-4, a Th2 cytokine, as 
compared to adult mice (Singh et al. 1996; Adkins and Du 1998).  Adkins et al. (1994; 1998) 
found neonatal mice compared to adult mice, exhibit a more rapid kinetics and produce higher 
levels of cytokines, namely IL-2, IL-4 and INF-γ and that in vitro IL-6 enhances the ability of 
neonatal T cells to respond to secondary stimuli.  Arulanandam et al. (1999) 
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demonstrated that upon antigenic challenge neonatal mice have decreased IL-12 production 
compared to adult animals, and the addition of IL-12 in the immunization to neonatal mice will 
enhance the Th1 response.  Deficiencies exist for neonatal antigen processing and presentation as 
well.   Levin and Gershon (1989) found that neonatal spleen cells exhibit inadequate antigen 
processing and presentation of soluble antigen in vitro.  Interestingly, the deficiencies of neonatal 
spleen cell antigen presentation cannot be ascribed to suppressive cells or factors since neonatal 
cells actually produce ample amounts of soluble proliferative factors (Levin and Gershon 1989).  
This observation has led Levin and Gershon (1989) to suggest that the problem lies somewhere 
in the initial stages of this event.  However, Morris et al. (1992) demonstrated that neonatal 
splenic B cells are capable of binding, internalizing, and degrading radiolabeled antigen.  While 
neonatal B cells may express nearly adult levels of MHC class II and necessary costimulatory 
molecules, and the neonatal lymph node environment may support T and B cell collaboration, 
neonatal B cells are unable to differentiate or induce IL-2 production in T cells (Morris et al. 
1992; Astori et al. 1998).   Additionally, neonatal dendritic cells demonstrate a limited ability to 
induce either adult or cord blood T cells to proliferate in response to T cell mitogens PHA and 
Con A.  However, this may be overcome with increased doses of mitogen or cell number (Petty 
and Hunt 1998).   Yet, neonatal dendritic cells may maintain some degree of functionality 
compared to spleen APC since Ridge et al. (1996) found that dendritic cells were capable of 
eliciting immune responses in neonatal mice; whereas, a mixed spleen population induced 
tolerance.  
Characterization of myosin cross-reactive monoclonal antibodies.   The cross-reactivity 
between streptococcal antigens and mammalian myosin has long been established (Cunningham 
et al. 1984, Dale and Beachey 1985a, Manjula et al. 1985).  The first chapter discusses work 
 
 42 
conducted in the laboratory characterizing the myosin cross-reactive antibody response in 
BALB/c mice as a result of neonatal S. pyogenes immunization.  Monoclonal antibodies were 
produced from mice immunized as adults or neonates with streptococcal strain D471 (serotype 
M6), its M- variant UAB152, and J17A4 (non-typable).  This immunization scheme allowed for 
examination of the cross-reactive antibody response induced in mice as a function of age and M 
protein.  In ELISA analysis, these monoclonal antibodies demonstrated cross-reactivity to several 
mammalian antigens, including keratin, DNA and commercially prepared rabbit myosin.  These 
results are in agreement with similar work conducted by Cunningham et al (1984; 1986; 
Shikhman and Cunningham 1994); and our study takes such analysis a step further. 
 Extensive Western blotting analysis was undertaken to determine the reactivity against 
mouse myosin isolated from both cardiac and skeletal sources.  We found that antibodies derived 
from mice immunized as neonates with S. pyogenes preferentially recognized the cardiac 
isoforms of myosin, whereas, antibodies derived from adult immunized mice display no such 
discrimination of the skeletal myosin isoforms.  This suggests that exposure to GAS at a young 
age may selectively induce a cross-reactive antibody response to the cardiac isoforms of myosin 
and could therefore play a potential role in the cardiac pathology associated with acute rheumatic 
fever without the destruction of other muscles in the body.  
Neonatal immunization with S. pyogenes induces myosin-reactive cytolytic T cell responses 
in BALB/c mice.   Once we ascertained the extent to which S. pyogenes could induce an auto-
reactive antibody response, experiments were undertaken to determine if immunization with S. 
pyogenes could induce a T cell response against myosin as well.   BALB/c were immunized as 
adults or neonates with S. pyogenes strain D471, its M- variant UAB152, recombinant M6 M 
protein, or the control antigen cytochrome c.  BALB/c mice immunized as adults with D471 
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mounted a poor CTL response against streptococcal M protein and no CTL response against 
mammalian myosin; whereas, mice immunized with the same vaccine within three days of birth 
and boosted at 5 - 6 weeks of age mounted a measurable CTL responses against both 
streptococcal M protein and mammalian muscle myosin that was inhibitable by the addition of 
anti-CD8 antibodies in the assay.  The CTL response against myosin, but not M protein, appeared 
to be dependent upon the age of initial exposure to the vaccine D471, in that the response against 
myosin was detected only in mice primed up to 22 days of birth but not after.  Our results suggest 
that immunization with a rheumatogenic strain of S. pyogenes can induce age dependent myosin-
reactive CTL responses providing further evidence to the competence of this immunization 
strategy as a suitable mouse model system for studying childhood post-streptococcal autoimmune 
complications. 
Role of streptococcal M protein and its C-terminal conserved region in inducing myosin-
reactive CTL responses in neonatal mice.  Experiments discussed in chapter three were 
designed to determine if the induction of a myosin-reactive CTL response is exclusive to 
rheumatogenic serotypes of S. pyogenes (D471).  Additionally, we wanted to determine if the 
more conserved carboxy terminal region is responsible for eliciting the myosin-reactive CTL 
response. These experiments were designed around the findings by Bessen et al. (Bessen et al. 
1989; O'Toole et al. 1992) suggesting that most M protein serotypes may be placed in one of two 
major classes of M protein and that nearly all serotypes of GAS that have been associated with 
ARF have been shown to express class I M protein.  Also, this portion of M protein is under 
consideration as a vaccine candidate (Robinson et al. 1993; Pruskakorn et al. 1994a; Pruskakorn 
et al. 1994b).   
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For the first set of experiments neonatal BALB/c mice were immunized with non-
rheumatogenic streptococcal strains of GAS that included B737 (M49), H3 (M12) and J17A4.  
To address the role of the c-terminal region, mice were immunized with recombinant protein 
consisting of the carboxy terminal region of MP (C6), the variable amino-terminal region of M 
protein (AB6) or D471 treated with pepsin to cleave away the variable amino terminus of M 
protein (D471*).   
 We found that all strains of GAS tested were capable of eliciting a myosin-reactive CTL 
response. Only J17A4 elicited a myosin-reactive CTL response comparable to that elicited by 
D471.  In addition, only these two strains elicited responses that preferentially recognized mouse 
neonatal cardiac myosin. This myosin-reactive cytolytic response was seen in conjunction with a 
response against the carboxy-terminal conserved region of M protein and mice primed with C6 or 
D471* elicited a response to myosin, whereas, mice treated with AB6 did not. These results 
suggest that the carboxy terminal region of M protein contains an epitope that is capable of 
inducing a myosin-reactive CTL response in BALB/c mice. 
Induction of the myosin-reactive CTL responses in mice with heat-killed S. pyogenes:  The 
role of age, haplotype, route of immunization and presence of B lymphocytes.  To complete 
the BALB/c studies we demonstrated the obligate role of M protein in the induction of a CTL 
response against myosin following neonatal immunization with heat-killed S. pyogenes.  
Specifically, we demonstrate that the M protein must be cell bound because immunization with a 
combination of an M protein streptococcal mutant and recombinant protein does not allow for the 
development of a myosin-reactive CTL response.   Also, in chapter four we undertook a 
preliminary study to determine what role, if any, genetic factors play in the develop of myosin-
reactive CTL response we have measured following neonatal S. pyogenes exposure, mice of the 
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same MHC haplotype as BALB/c (DBA/2J) or of differing haplotypes, C57Bl/6 and CBA/J.  Our 
results suggested that mice of the H-2d background (BALB/c and DBA/2J), as well as, mice of 
the H-2b background (C57Bl/6) are capable of eliciting myosin-reactive CTL responses following 
neonatal exposure with D471, whereas CBA/2J (H-2k) were incapable.  Although not conclusive, 
these results suggest that genetic factors can potentially play a role in determining the ability of 
the host to develop potentially deleterious auto-reactive CTL responses following exposure to S. 
pyogenes.  The final set of experiments undertaken and presented in chapter four were performed 
to determine what effect the route of immunization and the presence of B lymphocytes has on the 
ability of mice to elicit a myosin-reactive response following neonatal S. pyogenes exposure.  
Experiments were performed with BALB/c and C57Bl/6 wild type and immunoglobulin heavy 
chain knock-out (Igh-/-) mice.  The results suggest that intranasal immunization alone does not 
elicit an immune response to M protein or myosin, either locally or systemically, regardless of 
the age of immunization.  However, if the mice are immunized as neonates intranasally with S. 
pyogenes vaccine and boosted intraperitoneally with recombinant M protein a CTL response is 
generated against both M protein and myosin suggesting that intranasal exposure during the 
neonatal period can prime a systemic autoimmune response.  Assays conducted with C57Bl/6 
Igh-/- mice indicate that the lack of the B cell compartment has no direct effect upon the 
development of a CTL response against either M protein or myosin following neonatal 
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Antibodies recognizing mammalian cardiac myosin are a hallmark of acute rheumatic 
fever, an autoimmune complication of pharyngitis caused by the group A streptococcus.   
Previous reports demonstrate that antibodies reactive toward mammalian myosin can be induced 
in adult mice following systemic immunization with membrane fractions of GAS or purified 
streptococcal M protein, albeit with no pathological consequences.  Here, we show that 
antibodies capable of binding mammalian myosin are induced and persist for several months in 
sera of BALB/c mice immunized within one week of birth with heat killed GAS.  We have 
constructed representative hybridomas to permit characterization and comparison of myosin-
reactive antibodies induced following immunization of neonatal versus adult mice.  Employing 
western blot analyses we demonstrate that most of the myosin-reactive antibodies induced in 
neonatal mice cross-react with the group-specific determinant N-acetylglucosamine and 
recognize primarily the cardiac isoforms of mouse myosin.  In contrast, antibodies derived from 
adult mice immunized with GAS and boosted with recombinant M protein or mouse myosin 
recognize determinant(s) shared by most isoforms of mouse skeletal myosin.  These findings 
reveal that different classes of myosin-reactive antibodies can be induced by antigens associated 
with the group A streptococcus depending on the age at exposure.  We propose that antibodies 
recognizing cardiac myosin induced by the group A streptococcus early in ontogeny are likely to 





Streptococcus pyogenes, a β-hemolytic group A streptococcus, is a causative agent of 
several suppurative skin and mucosal infections in humans.  In a small percentage of children, 
streptococcal pharyngitis may be followed within 3 to 4 weeks by acute rheumatic fever, a 
disease characterized by fever, polyarthritis and/or carditis (1, 2).  In a significant number of 
patients, mitral valve involvement occurs and is characterized by stenosis and/or regurgitation of 
valve, which can be fatal (1 - 3).  Biopsy and autopsy may reveal thickening and calcification of 
the mitral valve leaflets and shortening of the supporting papillary muscles (3, 4).  Frequently, 
granulomatous lesions called 'Aschcoff nodules' are found within the mitral valve and the 
pericardium (2, 4).  Additionally, antibody deposits may be found within the valve leaflets and 
the myocardium (1, 2).  Individuals presenting with ARF display elevated titers of anti-
streptococcal antibodies; some of these cross-react with cardiac myosin (5). ARF, when not fatal, 
resolves itself but can recur with recurring streptococcal pharyngitis.  Therefore, the treatment for 
ARF is geared towards preventing the recurrence of streptococcal pharyngitis, thereby preventing 
the recurrence of ARF.  Long-term penicillin prophylaxis is prescribed for ARF patients and is 
very effective (2, 6).  Timely intervention of streptococcal pharyngitis in children with penicillin 
treatment has also effectively reduced the incidence of ARF in developed nations (7). Due to the 
reduced incidence of ARF and the lack of suitable animal model systems, the mechanism of ARF 
and the mechanism of penicillin intervention remain a mystery. 
In both humans and mice the protective antibody response against GAS is directed 
primarily against the group specific carbohydrate N-acetyl-β-D-glucosamine and the anti-
phagocytic virulence factor, M protein (8 - 10). The induction of heart-cross-reactive antibodies 
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in ARF is thought to involve antigen mimicry by the pathogen in susceptible individuals (1, 2, 
11, 12). Antibodies cross-reactive with mammalian myosin can be induced in laboratory mice 
following immunization with preparations of streptococcal membranes as well as purified M 
protein (13), arguing in favor of a direct role of the pathogen in the induction of a cross-reactive 
humoral immune response. 
Mammalian myosins can be divided into three distinct families, the skeletal muscle 
myosins, the smooth muscle myosins and the non-muscle myosins.  Each family consists of 
distinct isoforms of heavy and light chains, encoded by distinct genes (14). Each muscle 
expresses one or more isoforms of the appropriate family of myosins (14 - 17); the expression of 
distinct isoforms in a given muscle may also change as a function of age (16, 17).  The various 
isoforms of myosin display high degree of conservation across species at the amino acid as well 
as at the nucleotide level (14).  Antibodies against streptococcal antigens such as M protein have 
been shown to cross-react with the skeletal muscle myosins and not the smooth or non-muscle 
myosins.  Studies employing synthetic peptides both of M protein and human cardiac myosin 
have been instrumental in localizing the cross-reactive epitopes shared by these two proteins (18, 
19).  The putative myosin epitope mapped in these studies LRRDLD is shared by heavy chains of 
all isoforms of the skeletal muscle myosins.  It is not clear how antibodies recognizing this 
epitope would induce pathological damage of joints and the heart and spare other skeletal 
muscles of the body.  Furthermore, in the adult inbred mouse model, myosin-reactive antibodies 
induced by M protein do not lead to pathology similar to that observed in ARF.  Therefore, their 
relevance to pathogenesis of ARF remains unclear. 
Here we demonstrate that antibodies against mammalian skeletal myosin can be induced 
by heat-killed GAS in the absence of any adjuvant in neonatal but not adult mice.  We have 
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developed panels of monoclonal antibodies reactive toward mouse myosin from BALB/c mice 
immunized as neonates with GAS and from adult mice immunized with GAS and boosted with 
M protein or myosin.  The current study presents a comparison of the monoclonal antibodies 
within these panels with respect to their ability to distinguish between distinct isoforms of 
autologous myosin.  We find that antibodies induced by GAS in neonatal mice bind primarily to 
cardiac specific isoforms of mouse skeletal myosin while those induced in adult mice recognize 
an epitope shared by most isoforms of skeletal myosin.  These results suggest that antibodies 
induced by GAS early in life are distinct from the myosin-reactive antibodies described 
heretofore.  Their potential role in the pathogenesis of ARF is discussed. 
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MATERIALS AND METHODS 
 
Mice and immunizations:  BALB/c mice were purchased from Jackson Laboratories, Bar 
Harbor, ME and bred at the WVU-OLAR. Newborn mice were immunized intraperitoneally with 
107 heat-killed GAS of the appropriate strain in 50µl volume.  Adult mice were immunized 
intraperitoneally with 108 bacteria of appropriate strain or 50 µg of recombinant M6 protein or 
myosin extracted from gastrocnemius muscle of BALB/c mice. 
Bacteria:  GAS strain J17A4 was obtained from ATCC, strain D471 was a gift of Dr. Susan 
Hollingshead, UAB, Birmingham AL.  Both strains were grown in Todd-Hewitt broth, heat-
killed by incubation at 60°C for 1.5 hours, washed extensively with 0.85% saline, resuspended in 
0.85% saline.  The cell concentration was estimated by measuring absorbance at 600 nm.  Heat-
killed J17A4 was treated with pepsin at pH 2 for 30 minutes at 37°C as described (20) to cleave 
surface proteins and thereby expose the group A carbohydrate.  The preparation was neutralized 
by the addition of NaOH, washed with and resuspended in 0.85% saline.  Bacteria were stored 
frozen at -20°C in aliquots of 109/ml. 
Antigens:  N-acetyl-β-D-glucosamine coupled to BSA (GlcNAc-BSA) was a gift of Dr. 
Madeleine Cunningham, University of Oklahoma Health Science Center, Oklahoma City, 
Oklahoma.  Rabbit muscle myosins (whole myosin, MyHC, MLC, HMM and LMM) were 
purchased from Sigma chemical company (St. Louis, MO).  Recombinant M6 protein was 
prepared as follows: Plasmid TR06 containing codons 1 to 412 of the emm6 mature peptide 
cloned in pET20b(+) was a gift from Dr. Susan Hollingshead.  This plasmid was expressed in E. 
coli strain BL21:DE3 (pLysS).  The M6 protein was induced with 1mM IPTG (Sigma Chemical 
Company) for 1.5 hrs.  Periplasmic extracts were prepared by washing cells with one-half 
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volume of TSE (150 mM Tris, 20% Sucrose, 1mM EDTA) followed by a 20 minute osmotic 
shock with one-tenth volume 5mM MgSO4 followed by centrifugation at 10,000 g.  The M6 
protein was purified from the periplasmic extract by affinity chromatography employing Ni-
NTA-Sepharose (Qiagen).  The protein was checked by SDS-PAGE for purity and stored frozen 
at -20°C.  Myosin extracts from muscles of BALB/c mice were prepared essentially as described 
(21).  Briefly, hind limb muscles, diaphragm and hearts were dissected from BALB/c mice of 
appropriate ages.  All hind limb muscles were pooled in the case of embryonic, newborn or 7 day 
old mice. Adult hearts were separated into atria and ventricles.  Muscles were minced on ice in 
four volumes/wt of cold extraction buffer (0.3 M NaCl, 0.1 M NaH2PO4, 0.05 M Na2HPO4, 10 
mM EDTA and 1.4 mM β-mercaptoethanol).  Following a 30-minute incubation on ice, cellular 
debris was removed by centrifugation at 13,000 g for 30 min at 4oC.  Supernatants were then 
diluted with an equal volume of a storage solution (40 mM sodium pyrophosphate, 50% glycerol) 
and stored at -20oC.  Protein concentrations were determined employing a kit (DC Protein Assay, 
Bio-Rad). 
Monoclonal antibodies: Splenocytes harvested from experimental mice were fused with 
P3.X63.Ag8.653 mouse myeloma by standard procedures (22).  Hybridoma supernatants were 
screened for binding to BSA, GlcNAc-BSA, M6 protein and rabbit whole myosin by ELISA. All 
supernatants reacting strongly with BSA were eliminated from further analysis.  Selected 
hybridoma wells were subcloned by limiting dilution.  Subclones were screened by ELISA.  
Positive clones were expanded by bulk culture in RPMI 1640 (Life Technologies) supplemented 
with 10% FCS (Hyclone laboratories) and 2x10-5 M β-mercaptoethanol.  All selected clones 
described here expressed IgM heavy chains and κ light chains.  Hybridoma clones A4.840, BF-
F3, BA-G5, F1.652, N2.261, N3.36, and SC-71 were obtained from ATCC.  These were cultured 
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as above for collection of supernatants.  All supernatants were stored frozen at -20°C until use.  
Antibodies NOQ7.4D and hsm-V were purchased from Sigma Chemical Co. 
ELISA Analysis: Protein was adsorbed onto 96 well assay plates (Costar) at 1 µg/ml protein in 
0.1 M borate saline (overnight at 4oC or 3 hrs at 37oC).  Wells were blocked with 1% BSA in 
PBS for 1 hour at room temp and following a wash with PBS, undiluted hybridoma supernatants 
or serial dilutions of serum samples were added to the wells (overnight at 4oC or 37oC 3 hrs).  
Plates were washed and goat anti-mouse IgM or goat anti-mouse IgG antibody conjugated with 
alkaline-phosphatase (Southern Biotechnology Associates) was added. Phosphatase substrate was 
added after washing plates (Sigma 105, Sigma Chemical Co.) and following the development of 
color, absorbance at 405 nm was recorded employing a microplate reader (Bio-Rad, model 
3550).  The binding of monoclonal antibodies to cardiac MyHC was performed as follows: 
Polystyrene plates were coated with antibodies NOQ7.4D or N2.261 (both IgG1 isotype).  After 
blocking with 1% BSA in PBS, extracts from embryonic of adult hearts was added and incubated 
at 4 C overnight.  Plates were washed, hybridoma supernatants were added and incubated for 3 
hrs at 37 C.  After washing, binding was detected by the addition of goat anti-mouse IgM 
conjugated to alkaline phosphatase followed by phosphatase substrate. 
SDS-PAGE and Western Blot analyses: Muscle extracts (0.2 µg - 2 µg/lane) were resolved by 
one of two SDS-PAGE systems.  The first consisted of resolving gel containing 5% acrylamide 
(C = 5%); 30% glycerol and a stacking gel containing 4% acrylamide; 30% glycerol (23). 
Electrophoresis of this assembly was conducted at 4oC at 8 mA for 3.5 hours and 10 mA for an 
additional 5 hours using a 25 mM tris, 192 mM glycine, 0.1% SDS running buffer.  The other 
system consisted of resolving gel containing 8% acrylamide (C = 2%) and 30% glycerol and a 
stacking gel of 4% acrylamide and 30% glycerol (24).  Preparation and execution these gels were 
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carried out as previously described, with the exception that EDTA was omitted from the stacking 
gel.  In both systems, 2-mercaptoethanol was added to the running buffer of the upper reservoir at 
a final concentration of 10 mM.  Electrophoresis was conducted in a Mini-PROTEAN II 
electrophoresis system  (Bio-Rad).  Following electrophoresis gels were either silver stained 
(Bio-Rad Silver Stain Plus Kit) or transferred to PVDF membranes (Bio-Rad) under semi-dry 
transfer conditions (Bio-Rad Trans-Blot SD Transfer Cell) at 50 mA per gel for one hour.  The 
transfer was facilitated by one of two buffer systems; 10 mM CAPS (Sigma Chemical Company) 
with 5% methanol for 5%/30% gels and 10 mM CAPS, 0.05% DTT, 1% methanol for 8%/30% 
gels).  Membranes were blocked with 5% non-fat milk in PBS at 4oC overnight.  Following a 
wash in phosphate buffered saline (PBS), membranes were incubated with undiluted hybridoma 
tissue culture supernatants for one hour at room temperature followed by a 1 hour incubation 
with biotinylated anti-isotype antibody (Southern Biotechnology Associates, Birmingham AL) 
and then a 30 min incubation with streptavidin-HRP (Southern Biotechnology Associates).  
Membranes were washed extensively with 0.1% tween 20 in PBS after each incubation.  
Reactions were visualized by incubating membranes with ECL chemoluminescent reagents 
(Amersham) for 1 minute followed by multiple exposures to x-ray film (Fuji) ranging from 1 to 
15 minutes.  
RESULTS 
Induction of anti-myosin antibodies in BALB/c mice  
BALB/c mice were immunized with heat killed GAS at different ages.  We chose two 
strains for our study; D471 expresses M protein of the M6 serotype, which has been associated 
with rheumatic fever in humans (i.e. rheumatogenic strain), and J17A4, a non-rheumatogenic  
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strain of an unknown M-type. We chose this strain to test whether M protein from rheumatogenic 
strains of GAS was necessary for the elicitation of anti-myosin antibodies in mice.  The heat-
killed preparation of J17A4 was further treated with pepsin at acid pH, as described in materials 
and methods, to cleave surface exposed proteins and to maximally expose the group A 
carbohydrate.  Preparations of GAS treated in this manner have been shown to induce 
autoreactive antibodies in mice (25).  The treated preparation is known to yield a stronger anti-
GlcNAc antibody response in neonatal as well as adult BALB/c mice than the untreated one (M. 
Elliott, unpublished observations).  
We gave 2-day-old mice 2∗ 107 heat-killed organisms and 6-week-old adult mice 2∗ 108 
organisms by the intraperitoneal route.  Neonatally immunized mice were bled at 14 days of age 
and then at intervals of 10 weeks.  Some mice immunized as neonates were boosted at 8 weeks 
of age, bled at 10 weeks and every 10 weeks thereafter.  Adult mice were immunized at six 
weeks of age, given a booster 14 days following the primary immunization, bled at 10 weeks of 
age and at intervals of 10 weeks thereafter.  One group of adult mice was immunized with 50g 
of purified recombinant M6 protein at 6 weeks of age and boosted at 8 weeks of age.  Data 
shown in figure 1 represent a comparison of the levels of antibodies of the IgM subclass against 
three distinct antigens in the variously immunized mice as well as unimmunized control mice at 
2, 10, 20, 30, 40, 50, 60 and 70 weeks of age.  Data are shown for serum dilution of 5,000 for N-
acetylglucosamine (fig 1a), 2,500 for myosin (fig 1b) and serum dilution of 500 for M protein 
(fig 1c). 
In adult mice immunized with D471 or J17A4, high titers of antibodies of the IgM 
subclass against N-acetylglucosamine (GlcNAc) were induced within 2 weeks of immunization 
(fig1a).  The titers dropped as a function of age to slightly above baseline and remained at this 
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level through the remainder of the experiment.  Levels of anti-myosin antibodies were only 
slightly above those in unimmunized mice (fig 1b) and did not rise over the period of the 
experiment. Levels of antibodies against M6 protein were increased two weeks after the second 
immunization but were much lower in comparison to those induced by purified recombinant M6 
protein (fig 1c). 
In adult mice immunized and boosted with purified M6 protein, response to M6 protein 
was the highest at 10 weeks of age; dropping to background levels within 30 weeks and 
remaining low throughout the course of the experiment.  Antibodies against GlcNAc as well as 
myosin were elevated slightly above background in this group of mice and maintained at that 
level throughout the experiment (fig 1a and 1b).  The significance of the latter response is not 
clear at this point. 
In mice immunized within one week of birth with either D471 or J17A4 and boosted at 6 
weeks of age with the same preparation, levels of antibodies against all three antigens were 
elevated at 10 weeks of age (fig 1 a, b and c).  However, in both these groups, antibody levels 
dropped to a plateau above the baseline and remained there throughout the course of the 
experiment.  In mice immunized within one week of birth with D471 or J17A4, levels of 
antibodies against GlcNAc increased slowly as a function of age (fig 1a); and continued to rise 
throughout the remainder of the experiment.  Similarly, levels of antibodies against myosin were 
increased steadily in parallel (fig 1b).  Levels of anti-GlcNAc as well as anti-myosin antibodies 
in these mice between 30 and 60 weeks were significantly higher than in all other groups. This is 
reminiscent of antibodies observed in ARF patients (1, 26, 27).  The levels of antibodies against 
M6 protein were very low in these two groups of mice throughout the course of the experiment 
(fig 1c).  Thus, a subclass of antibodies against GlcNAc preferentially induced in neonatal mice 
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by both strains of GAS was related to anti-myosin antibodies observed in their sera.  
Interestingly, high titers against the respective antigens were not observed in mice immunized as 
neonates and boosted as adults with heat-killed GAS. 
Finally, IgG antibodies against all three antigens were also present in sera of mice 
immunized with heat-killed GAS within one week of birth and in mice immunized with M6 
protein at 6 weeks of age (results not shown).  To explore the basis for the anomalous anti-
myosin response following immunization with GAS, we established panels of representative 
monoclonal antibodies. 
Analysis of monoclonal anti-myosin antibodies from BALB/c mice immunized with GAS by 
ELISA: 
We chose 6 different groups of mice for construction of hybridomas (Table 1). Mice 
immunized with either J17A4 or D471 at 2 days of age were sacrificed at the age of 60 weeks for 
hybridoma construction (groups 1 and 2).  Another group of 2 mice immunized with D471 at 2 
days of age was boosted at 8 weeks of age and sacrificed at 10 weeks (group 3).  We also 
generated hybridomas from adult BALB/c mice immunized with D471 and boosted with either 
D471 (group 4), purified recombinant M6 protein (group 5) or mouse myosin (group 6).   
Following an ELISA based screen, a total of 22 myosin-reactive monoclonal antibodies were 
recovered, all of which were of the IgM isotype.  We were able to recover only one IgG antibody  
that was specific for M6 protein.  Group 4 yielded several anti-GlcNAc antibodies and one anti-
M6 protein antibody confirming the serological data that GAS fails to induce myosin-reactive 
antibodies in adult mice.  We excluded this group from further analyses. 
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 Previous studies have shown that myosin-reactive antibodies induced by streptococcal 
antigens recognize the coiled tail region of the skeletal myosin heavy chains (13, 18, 19).  We 
tested the 22 myosin-reactive antibodies for binding to isolated rabbit myosin heavy chains and 
light chains as well as purified heavy meromyosin (the head region of myosin) and the light 
meromyosin (the tail region).  Table 2 summarizes the findings. Several things are of note: 
firstly, all of the antibodies in groups 1,2 and 3 reacted strongly with GlcNAc; as expected, 
antibodies from groups 5 and 6 displayed comparatively weaker binding to this antigen, if at all.  
Furthermore, while hexoseaminidase treatment of plate-bound antigens eliminated reactivity of 
all antibodies with GlcNAc-BSA, it did not alter binding to the myosin components (results not 
shown).  Secondly, all of the anti-myosin antibodies reacted with MyHC; five antibodies (groups 
1, 2 and 3) additionally reacted with MLC.  Thirdly, all antibodies reacted with LMM.  Antibody 
1M12 also reacted with HMM.  Five antibodies (group 1 and group 2) displayed weak reactivity 
toward M6 protein whereas; antibodies induced in adult mice following boosters with M6 protein 
bound M6 very well.  Additionally, two antibodies from group 6 also bound M6.  Thus, many of 
the antibodies described here reacted with GlcNAc, M protein and myosin.  Examples of anti-
GlcNAc antibodies reacting with both M protein and MyHC have been previously described 
(28); reactivity with MLC is a novel finding.  None of the antibodies bound to laminin, vimentin, 
troponin or tropomyosin; all of the antibodies from groups 1 and 2 and two each from groups 3, 5 
and 6 bound to keratin (results not shown).  These binding assays were unable to identify major 
differences between antibodies induced in neonatal versus adult mice.  Therefore, we decided to 
probe western blots of mouse skeletal myosins resolved to separate distinct isoforms, with our 
panels of antibodies. 
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Resolution and identification of distinct mouse skeletal myosin isoforms: 
 Eight distinct isoforms of mammalian skeletal myosin heavy chains (MyHC, Mr = 
220Kda) encoded by distinct genes have been described; these are (I) embryonic, (ii) neonatal, 
(iii) type IIa, (iv) type IIx/IId, (v) type IIb, (vi) type I (also known as cardiac β, (vii) cardiac α and 
(viii) ocular (14).  Antibodies against distinct human and rat MyHC have been established and 
used extensively in studies addressing the developmental regulation of myosin gene expression 
using western blot as well as immunofluorescent techniques (17,29-31).  Since no such 
information about the mouse MyHC isoform expression was available, we decided to use the 
available antibodies and conduct these analyses at the outset. 
We prepared crude myosin extracts from a variety of different muscles, from mice of 
different ages.  The preparations were subjected to electrophoresis on polyacrylamide gels 
containing glycerol to permit resolution of myosin isoforms on the basis of net charge.  The 
myosin isoforms in each sample were identified on the basis of migratory pattern by comparison 
with a previous study (32) in combination with western blot analysis using pre-characterized 
antibodies raised against human or rat myosins.  Ten distinct myosin extracts representing 
distinct muscles of fetal to adult BALB/c mice were chosen for this study to identify and 
distinguish seven of the eight skeletal MyHC isoforms.   
The top panel in figure 2a shows a silver stained SDS-PAGE (8% acrylamide, 30% 
glycerol) depicting six of these extracts.  The embryonic isoform of skeletal myosin was present 
in an extract prepared from hind limbs muscles of fetal (18-day embryonic) mice (lane 1) and 
from hind limb muscles of newborn (12-24 hour old) mice (lane 2).  Bands corresponding to this 
isoform were detected by antibody F1.652 (17, 29). 
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The neonatal MyHC isoform was present in extracts from hind limb muscles of fetal mice 
(lane 1), newborn mice (lane 2) and 7-day-old mice (lane 3) as well as in the diaphragm of 7-day-
old mice (lane 4).  Bands corresponding to the NN isoform were detected by antibody N3-36 that 
has been shown to bind the NN, IIa, IIb and IIx/IId MyHC isoforms of human and rat origin (29, 
30). Antibody SC-71 also recognized bands corresponding to this isoform in extracts of newborn 
and 7-day-old hind limbs; although SC-71 was shown to be specific for the type IIa isoform of rat 
myosin in previous studies (31).  Additionally, SC-71 showed very strong reactivity toward a 
band co-migrating with the NN isoform within the embryonic hind limb extract.  The type IIa 
isoform of mouse myosin was found to be most abundant in an extract of the soleus muscle (lane 
5) and was detected by antibody SC-71 (fig 2d).  SC-71 also detected this isoform in extract of 
hind limb muscles from 7-day-old mice (lane 3). 
The type IIb myosin isoform was present only in the extract prepared from the 
gastrocnemius muscle of adult (6 week old) mice and was detected by antibody BF-F3 raised 
against and shown to be specific for the rat IIb myosin (31). 
The type IIx/IId isoform was detected in an extract from the gastrocnemius of adult mice 
(lane 6) and was detected by antibody N3.36.  Antibody N3.36 also detected a band 
corresponding to this isoform in an extract from the diaphragm of 7-day-old mice (lane 4). 
The type I isoform was present in extracts of fetal hind limbs, diaphragm and the soleus 
muscle (lanes 1, 4 and 5).  This isoform was detected by antibody A4.840 that also recognizes the 
corresponding isoform of human and rat origin (16, 17, 30). 
The EMB, type IIa and type I isoforms were additionally detected by antibody N2.261 
which has been shown to recognize the type I/cardiac β as well as the type IIa isoforms of human 
and rat origin (16, 17).  Of note is the weak reaction with a slow migrating band in the diaphragm 
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extract (lane 4), On the basis of non-reactivity of N2.261 with the extract from the gastrocnemius 
muscle (lane 6), we adjudged this band to be type IIa MyHC.  Overloading of the diaphragm 
extract permitted the detection of this isoform by antibody SC-71, thereby confirming its 
presence in this extract (results not shown). 
Three extracts prepared from hearts of BALB/c mice were resolved by SDS-PAGE (5% 
polyacrylamide, 30% glycerol.  The abundance and migratory patterns of the two isoforms (α and 
β) of cardiac myosin were displayed by silver staining of gel and are shown in the top panel of 
figure 2b.  The cardiac β isoform, which is expressed in heart ventricles, predominates in the 
fetal mouse heart extract (lane 1), the α and the β isoforms are present at about equimolar 
concentrations in the hearts of newborn mice (lane 2) and the β isoform is absent in heart 
ventricles of adult mice (lane 3).  The cardiac β isoform was detected by antibody A4.840 
described above.  The antibody BA-G5 specific for the rat cardiac α isoform (31) was unable to 
detect the corresponding isoform in our extracts (results not shown).  However, both the cardiac 
α and β isoforms were detected by N2.261.  Thus the determinant recognized by the N2.261 
antibody appears to be present on the EMB, type IIa, type I/cardiac β as well as cardiac α 
isoforms of mouse myosin. 
These analyses prepared us for the correct interpretation of binding patterns displayed by 
the panel of monoclonal antibodies generated within our laboratory.  They also revealed novel 
antigenic differences between myosin isoforms of human, rat and mouse origin. 
Antibodies recovered from mice primed with GAS as neonates recognize cardiac myosin specific 
determinants:  
 All of the monoclonal antibodies described in Table 2 were screened by western blot 
analysis employing the myosin extracts described above.  All of the antibodies reacted with 
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myosin bands if the extracts were resolved on a 5% acrylamide gel and transferred to the PVDF 
membrane in the presence of DTT, but failed to react if the extracts were resolved with 8% 
acrylamide and transferred without DTT.  The EMB and the NN isoforms of MyHC within the 
embryonic extract and the IIx/IId and the IIb isoforms within the gastrocnemius extract migrated 
very close together on 5% acrylamide gels and transferred as a single band.  Since the embryonic 
extract contained large amounts of the EMB isoform, the reactivity with the EMB isoform was 
scored negative if the intensity of reaction with the band in lane 1at a position corresponding to 
the EMB isoform was weaker than that in lane 2.  Detection of reactivity toward the IIb MyHC 
isoform was facilitated by the inclusion of an extract from gastrocnemius of 2-week-old mice.  
This extract contained primarily the NN and the IIb MyHC isoforms which formed a doublet on 
blots prepared from the 5% acrylamide SDS-PAGE (results not shown); the faster migrating 
band was identified as the IIb isoform by antibody BF-F3 described above.  Panels in figure 3 
represent results obtained with SDS-PAGE containing 5% acrylamide, 30% glycerol and 
transferred in the presence of DTT. 
Antibodies BA1-23, FD3-6-1 (group 1) and 1G19, 1L23, 1M12 and 1N24 (group 2) were 
derived from mice that were immunized with heat-killed GAS within the first week of life and 
did not receive any additional immunizations.  As shown in figure 3, antibodies BA1-23, FD3-6-
1 and 1L23 all detected the type I isoform of mouse myosin in the soleus muscle extract and 
showed weak reactivity toward type IIa isoform (lane 5 in corresponding panels).  Binding to the 
type IIa isoform was not faithfully reproduced in subsequent repeats of the experiment.  Antibody 
1G19 recognized both type I and type IIa myosins.  Antibody 1M12 detected bands in lanes 3, 5 
and 6 but not in lane 4.  It also recognized the IIb isoform in western blots of 8% acrylamide gels.  
It was adjudged that this antibody reacted with type I (weak reaction) as well as types IIa and IIb 
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myosin.  Antibody 1N24 recognized the NN as well as types I, IIa, IIb and IIx/IId MyHC 
isoforms resolved on both 5% and 8% acrylamide gels.  Thus, all six myosin-reactive antibodies 
from these two groups recognized the type I/cardiac β isoform of mouse myosin, three 
recognized only this isoform. 
Antibody 11E18 (group 3) recognized the NN, type I, and type IIa isoforms while 
antibodies 11L6, 11L24 additionally recognized type IIx/IId isoform.  Antibodies 11N24 and 
11AA23 detected the NN and type I, IIa, IIb and IIx/IId isoforms.  
Antibodies derived from mice immunized at six weeks of age with D471 and boosted 
with either M6 protein (group 5) or mouse hind limb myosin (group 6) were tested next.  
Antibodies 14A23, 14L7 and 14H15 derived from group 5 reacted with all isoforms of myosin 
MyHC except the EMB, but also consistently gave a high background (results not shown).  
Antibodies 14I23 and 14J16 failed to detect myosin by western blot.  All seven antibodies 
derived from group 6 displayed strong reactivity toward all isoforms of mouse myosin except the 
embryonic isoform and are represented here by a blot probed with antibody 15E23. 
Western blot analysis of heart muscle extracts revealed that all of the antibodies described 
above with the exception of 11E18, 11L6 and 11L24 recognized both α and β isoforms of 
cardiac MyHC.  Antibody 11E18 (group 3) recognized only the β isoform of cardiac MyHC; 
Figure 4 shows a sampling of these western blots with at least one example from each of the five 
experimental groups that included myosin-reactive monoclonal antibodies.  Reactivity toward 
cardiac myosins was additionally tested in an indirect ELISA as described in materials and 
methods.  Antibodies 11L6 and 11L24 were able to recognize MyHC from all three extracts of 
BALB/c hearts in this assay (results not shown).  It is possible that the epitope(s) recognized by 
these antibodies were lost upon dissociation of MLC from MyHC in SDS-PAGE. 
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As summarized in Table 3, analyses presented above identified six distinct reactivity 
patterns of anti-MyHC antibodies induced in BALB/c mice.  Anti-myosin antibodies recovered 
from mice exposed to the J17A4 strain of GAS as neonates (group 1) showed the narrowest 
pattern of reactivity, primarily binding the cardiac MyHC.  One antibody with specificity for the 
cardiac MyHC was also recovered from mice immunized as neonates with the D471 strain of 
GAS.  Two other antibodies from group 2 recognized additional MyHC isoforms and the fourth 
one recognized all but the EMB isoforms.   The reactivity of one antibody from group 3 was 
restricted to the type I / cardiac, IIa and NN MyHC isoforms.  The remainder recognized all 
MyHC isoforms with the exception of the EMB, by western blot and/or ELISA.  Finally, 
antibodies from groups 5 and 6 recognized all but the EMB MyHC isoform.   
Finally, western blot analyses of MLC resolved on 12% SDS-PAGE with all antibodies 
failed (results not shown).  Our findings demonstrate that anti-myosin antibodies resulting from 
immunization of BALB/c mice with GAS can distinguish between distinct isoforms of skeletal 





We have described previously that immunization of neonatal mice with heat-killed S. 
pneumoniae induced the production of a class of anti-phosphorylcholine antibodies distinct from 
those produced in adult mice and which were non-protective and possibly autoreactive (39).  We 
decided to explore whether antigens from other pathogenic bacteria could induce autoreactive 
and potentially pathogenic antibodies in neonatal mice.  We chose GAS for two reasons: the 
antibody response in humans and mice against the group-specific determinant GlcNAc has been 
characterized (8, 9), and the etiologic relationship between GAS and diseases such as ARF is 
established (1, 2).  A large number of prior studies demonstrate that myosin-cross-reactive 
antibodies are induced by GAS in ARF patients and in laboratory mice (11 - 13, 18, 19).  
However, their role in the pathogenesis of ARF remains unclear. 
The current study reveals that anti-myosin antibodies are induced and persist in BALB/c 
mice that have been exposed to heat-killed GAS as neonates.  These antibodies react strongly 
with GlcNAc but show weak reactivity toward the M6 protein.  While the presence of an emm 
gene in J17A4 has been documented (34), whether a functional M protein is expressed by this 
strain is unknown.  Nevertheless, small amounts of surface proteins may be retained within the 
J17A4 preparation treated with pepsin.  We have recently observed that a variant of D471 with 
an insertional inactivation in the emm6 gene is capable of inducing the production and 
persistence of anti-myosin serum antibodies in neonatal BALB/c mice.  Thus, the presence of an 
M protein is not essential for the induction of myosin-reactive antibodies.  Furthermore, we 
failed to observe any strain-specific differences in the serum antibody responses in BALB/c mice 
(this study) and in DBA/2J and C57Bl/6J mice (M. Elliott, unpublished observations). The
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 reasons for failure to boost the autoreactive response induced by GAS in neonates by second 
immunization with GAS at 8 weeks of age are unclear.  This appears to be a BALB/c strain-
related characteristic since in DBA/2J and C57Bl/6J mice, a booster of D471 in mice neonatally 
primed with D471 leads to a prompt increase in GlcNAc- and myosin-reactive antibodies (M. 
Elliott, unpublished observations). 
We have also demonstrated that heat-killed GAS was unable to induce anti-myosin 
antibodies in adult mice without additional boosters with purified M protein or myosin. 
Furthermore, monoclonal antibodies recovered following boosters with mouse myosin or the M6 
protein, react with all isoforms of skeletal MyHC except the EMB isoform.  In contrast, 
antibodies induced following immunization with GAS in neonatal mice show restricted 
reactivity, binding cardiac MyHC in preference to other isoforms of skeletal myosin heavy 
chains.  The basis for binding of some of these antibodies to MLC remains unclear.   
Since the cardiac myosin extracts employed in our studies were prepared from whole 
hearts, we expected contamination by smooth muscle myosins from blood vessels associated 
with the heart.  Additional protein bands were found in the same molecular weight range as the 
cardiac skeletal myosins upon SDS-PAGE.  However, we failed to detect any of these bands in 
western blots with the antibodies described here and with hsm-V, an antibody specific for human 
smooth muscle myosin (35).  Therefore, we could not determine whether the antibodies 
described in this study could recognize smooth muscle myosins.  
Upon histological examination of mice from groups 1 and 2 we failed to observe any 
abnormalities of the heart, joints or kidney.  All mice within these two groups progressively 
developed alopecia of the whole body.  Due to lack of evidence in favor of an immunologic 
mechanism, the alopecia was adjudged 'idiopathic'.  Mice in all other groups maintained perfectly
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 normal hair well beyond 70 weeks of age.  Histological analyses were also conducted on groups 
of mice immunized with GAS within the first week of life and sacrificed at various times 
thereafter to detect signs of pathology that might have been overlooked in the absence of overt 
symptoms, albeit with negative results. 
We have additionally observed that all but one of the antibodies from groups 1 and 2 and 
none from groups 3, 5 or 6 bind to hyaluronic acid and/or heparin sulfate by ELISA. 
Additionally, BALB/c as well as DBA/2J and C57Bl/6 mice immunized with GAS within one 
week of birth, but not as adults, carry persistent antibodies that bind hyaluronic acid and heparin 
sulfate (M. Elliott, unpublished observations).  Both of these are acidic glycosaminoglycans 
found in the mammalian extracellular matrices.  Hyaluronic acid commonly occurs at the surface 
of certain cells, in the serum and as a backbone in complex proteoglycans (36).  Hyaluronic acid 
is also found on mitral valve leaflets, within the pericardium of the heart (37) where it probably 
functions as a lubricant.  We propose that these antibodies may be multireactive like the 
monoclonals described here.  They may bind hyaluronic acid coating the mitral valve, cardiac 
myocytes and resident fibroblasts.  They may also gain entry into cardiac myocytes, bind to the 
myosins and compromise myocyte function.  The lack of these symptoms in our model system 
suggests that mere presence of autoantibodies is not sufficient to cause pathology.  Hyaluronic 
acid may also be responsible for the chronic stimulation of autoreactive antibodies in ARF sera 
and in our mouse model system. 
In the current study, we immunized mice by the systemic route; attempts to detect 
significant amounts of autoantibodies following intranasal immunization have repeatedly failed.  
Additionally, in similar studies, we have observed that systemic immunization of neonatal, but 
not adult, mice with heat-killed GAS expressing the M protein led to the induction of myosin-
 
 68 
reactive CD8+ CTL (Cunningham and Elliott, submitted for publication) as well as CD4+ cells 
(Elliott and Cunningham, unpublished observations).  Despite the identification of functionally 
active autoreactive T cells, no pathology was detected in these studies. 
Systemic autoimmune diseases such as SLE are thought to be primarily the result of 
autoantibodies (38).  The pathological insult is primarily through deposition of immune 
complexes in basement membranes, cytokine imbalances may also contribute to the disease.  
Antibodies capable of binding acidic glycosaminoglycans are also detected in SLE (39); their 
role in the disease process is unknown.  Recent studies have utilized gene targeting in 
combination with genetic animal models of SLE and autoimmune diabetes to establish that B 
cells are required for initiation of the disease (40 - 42).   In most other autoimmune diseases, the 
presence of autoantibodies is thought to reflect the release of sequestered autoantigen following 
tissue or organ damage and therefore, secondary to the disease process.  In contrast, in ARF, 
myosin- and glycosaminoglycan- reactive antibodies appear to be induced by the pathogen and 
therefore are likely to be involved in the initial stages of the disease.  Since convalescent patients 
and individuals on long-term penicillin prophylaxis continue to carry autoantibodies in their sera 
(5), their relevance to disease in later stages remains unclear.  ARF remains one of the few 
diseases where a cause-effect relationship between a pathogen and pathogenesis is firmly 
established. Understanding the mechanism of ARF pathogenesis might lead to new insights into 
the mechanisms of other autoimmune diseases of man. 
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In summary, we have begun to identify various components of the immune system with 
potential for pathogenesis and which are stimulated by GAS in neonatal but not adult mice.  
Despite the lack of pathology, the similarities with ARF make this model system suitable for 
dissecting the mechanisms of post-streptococcal autoimmune diseases.  Since autoimmune 
diseases are thought to involve multiple events, identification of the pathogenic mechanisms in 



























Figure 1: Antibody responses in BALB/c mice immunized with heat-killed GAS.  Mice were 
immunized as described in materials and methods.  Data represent geometric means of 
absorbance values (Y-axis) corresponding to serum dilutions of 1:5000 (panel a), 1:2500 (panel 
b) and 1:500 (panel c) plotted against age of mice (in weeks) for each experimental group, with 
eight mice per group.  Eight groups (based on the immunizing antigen and age at immunization) 
are as follows: unimmunized control (open diamonds), D471 at 6 and 8 weeks (filled circles), 
J17A4 at 6 and 8 weeks (filled squares), M6 protein at 6 and 8 weeks (open triangles), D471 at 2 
and 8 weeks (filled triangles), J17A4 at 2 and 8 weeks (filled diamonds), D471 at 2 weeks only 
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     Table 1: Summary of hybridomas obtained following distinct immunization strategies 
numbers of monoclonal 
antibodies reactive towardc 








GlcNAc M6 Myosind 
1 2 d J17A4 none 60 wk > 100 2 2 
2 2 d D471 none 60 wk > 100 4 4 
3 2 d D471 D471 10 wk > 100 0 5 
4 6 wk D471 D471 10 wk > 100 1 0 
5 6 wk D471 M6 10 wk 21 6 5 
6 6 wk D471 Myosin 10 wk 32 2 6 
 
a Heat-killed GAS of appropriate strain (J17A4 or D471) was injected by intraperitoneal route 
at 1 - 2∗ 107 to 2 day old mice and at 1∗ 108 to 6 wk old mice. 
b heat-killed GAS was injected at 108 per mouse; recombinant M6 protein mouse myosin 
(prepared from the gastrocnemius muscle of adult mice) was injected at 100 µg per mouse. 
c
 as determined by ELISA.  Scoring based on absorbance at 405nm > 0.5 units above 
background. 
d whole myosin from rabbit hind limbs (Sigma Chemicals) 
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Table 2: Binding of myosin components by monoclonal antibodies induced by GAS 
 
Groupa  mAb Binding of antibodies in ELISAb to 
  GAS antigens   Myosin componentsc 
  GlcNAc M6 MyHC MLC HMM LMM 
BA1-23 +++++ + +++++ +++ -- ++++ 1 
FD3-6-1 +++++ + ++++ +++ -- ++++ 
1G19 +++++ + +++ -- -- +++ 
1L23 +++++ + +++ +++ ++ +++ 
1M12 +++++ + ++++ +++ -- +++++ 
2 
1N24 +++++ -- +++++ -- -- ++++ 
11E18 ++++ -- ++++ +++ -- ++++ 
11L6 +++ -- ++++ -- -- ++++ 
11L24 +++ -- ++++ -- -- ++++ 
11N24 +++ -- ++++ -- -- ++++ 
3 
11AA23 +++ -- +++++ -- -- +++++ 
14A23 ++ + +++ -- -- ++++ 
14L7 -- ++ +++ -- -- ++++ 
14H15 + ++++ +++ -- -- ++++ 
14I23 ++ +++ +++ -- -- ++++ 
5 
14J16 ++ +++ +++ -- -- +++ 
15A11 +++ +++ +++++ -- -- ++++ 
15E23 +++ ++ +++++  -- ++++ 
15F19 ++ -- +++++ -- -- ++++ 
15K6 + -- ++++ -- -- ++++ 
15K20 + -- ++++ -- -- ++++ 
6 
15L12 ++++ -- +++++ -- -- ++++ 
 
a Groups as per Table 1, column 1 
b  absorbance values (at 405 nm) are represented as follows: 0.25-0.5 = +; 0.5-1.0 = ++; 1.0-1.5 
= +++; 1.5-2.0 = ++++; >2.0 = +++++.  
c MyHC = myosin heavy chains, MLC = myosin light chains, HMM = heavy meromyosin, 





































Figure 2: Western blot analysis of mouse MyHC with antibodies raised against human and rat 
MyHC.  Myosin extracts were prepared, electrophoresed and transferred to PVDF membranes as 
described in materials and methods.  Tissue source of myosin in lanes is as follows: figure 1a 18-
day-embryonic hindlimb (lane 1), 1 day hindlimb (lane 2), 7-day hindlimb (lane 3), 7-day 
diaphragm (lane 4), 3 week soleus (lane 5) and 5 wk gastrocnemius (lane 6).  Figure 1b: 18-day 
embryonic heart (lane 1), 1 day heart (lane 2), and 5 week heart ventricle (lane 3).  Each panel is 
probed with the antibody noted.  
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Figure 3: Western Blot analysis of MyHC isoforms from hind limbs and diaphragm with mouse 
monoclonal antibodies induced by GAS.  Myosin extracts were prepared, electrophoresed and 
transferred to PVDF membranes as described in materials and methods.  Tissue source of myosin 
in lanes is as follows: 18-day-embryonic hindlimb (lane 1), 1 day hindlimb (lane 2), 7-day 
hindlimb (lane 3), 7-day diaphragm (lane 4), 3 week soleus (lane 5) and 5 wk gastrocnemius 
















































Figure 4: Western blot analysis of mouse cardiac MyHC with mouse monoclonal antibodies 
induced by GAS.  Muscle myosin extracts were prepared, electrophoresed and transferred to 
PVDF membranes as described in material and methods.  Tissue source of myosin in lanes is as 
follows:  18-day embryonic heart (lane 1), 1 day heart (lane 2), and 5 week heart ventricle (lane 
3).  Each panel is probed with the antibody noted. 



















TABLE 3: Patterns for cross-recognition of endogenous MyHC by antibodies against GAS  
Pattern # of 
repeats 
groupa Mouse myosin heavy chain isoform recognizedb 
   α β / I IIa IIb IIx/IId Neo Emb 
1 3 1, 2 + + +/-     
2 1 2 + +/- +     
3 1 2 + + + +    
4 1 3  + +   +  
5 2 3 +c +c + + + +  
6 11 2,3,5,6 + + + + + +  
a Groups as per Table 1, column 1 
b based on detection by western blots as shown in figs 3 and 4 and indirect ELISA (for cardiac 
myosins). 
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Induction of myosin-reactive CTL in mice following immunization with heat-
killed Streptococcus pyogenes  
 
 








 Cardiac myosin is one of the hypothetical target autoantigens associated with acute 
rheumatic fever; an autoimmune disease induced by the group A streptococcus.  We have 
investigated the capacity of group A streptococcus to induce a cytotoxic T lymphocyte response 
against myosin in laboratory mice.  Immunization of adult mice with heat-killed Streptococcus 
pyogenes strain D471 (D471) induced a CTL response directed against streptococcal M protein 
but not against myosin.  In contrast, in newborn mice a CTL response against M protein as well 
as myosin was induced following intraperitoneal immunization with D471 or purified 
recombinant M protein, but not with a variant of D471 lacking the M protein.  The capacity of 
D471 to prime myosin-reactive CTL was lost in mice three weeks of age and older.  Myosin-
reactive memory CTL primed in neonatal mice by D471 could be restimulated several weeks 
later not only by D471 and myosin but also by purified recombinant M protein.  CD8+ 
splenocytes enriched from neonatal mice immunized with D471 and cultured in the presence of 
recombinant M protein lysed target cells pulsed with tryptic digest of M protein or myosin.  Our 
observations establish the capacity of group A streptococcus to cross-prime and expand CTL 
reactive against myosin in BALB/c mice and reveal that age at primary exposure plays a critical 




 Streptococcus pyogenes, a β-hemolytic group A streptococcus, causes infections of the 
skin and the nasopharynx in humans (1).  In addition, non-suppurative complications occur as 
sequelae to streptococcal infections in some individuals (2, 3).  Acute rheumatic fever (ARF) and 
acute glomerulonephritis (AGN) represent some of the more serious complications as they 
involve damage to heart and renal tissues, respectively.  The major manifestations of ARF 
include arthritis and carditis, the latter being mainly pericarditis, sometimes in combination 
Aschcoff bodies and fibrotic stenosis of the mitral valve (4).  In biopsy and autopsy specimen 
from affected hearts in ARF, infiltrates consisting primarily of T lymphocytes have been noted 
(5, 6).  The presence of both CD4 and CD8 bearing T cells along with some B cells has been 
documented (6).  Detailed phenotypic and functional analyses of lymphocytes in these infiltrates 
have failed to elucidate their role in disease pathology.  Additionally, sera from ARF patients 
have been shown to contain antibodies directed against cardiac antigens (7-9). 
 Studies utilizing lymphocytes isolated from ARF patients as well as attempts to develop 
animal model systems for ARF have revealed the capacity of the group A streptococcus to induce 
abnormal immune responses in mammalian hosts (10-12).  Cross-reactions between 
streptococcal antigens, the M protein in particular, and human cardiac antigens such as myosin 
have been established at the level of antibody and CD4 T cell epitopes (13-15).  Based on these 
studies and numerous other reports, it is widely accepted that the autoimmune sequelae to 
streptococcal infections result at least in part from elicitation of immune response against host 
antigens by S. pyogenes during the course of an infection.  Pepsin extracts of M protein from at 
least 3 distinct serotypes of Streptococcus pyogenes have been shown to act as superantigens for  
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T lymphocytes expressing specific Vβ genes from normal human peripheral blood (16, 17).  It 
has been proposed that superantigen driven stimulation of T cells may further contribute to 
disease pathogenesis associated with ARF and related manifestations. 
 Additional attempts at understanding the mechanism of ARF have been directed at 
identifying cytotoxic lymphocytes capable of destroying cardiac myocytes in ARF patients.  
Lymphocytes isolated from valvular tissue from ARF cases have been shown to lyse cultured 
cardiac cells (18).  Furthermore, peripheral blood lymphocytes from normal humans cultured 
with pepsin extracts of M protein have been shown to acquire a capacity for lysis of cultured 
myocardial cells in vitro (19).   
 Studies addressing the possible induction of cytotoxic T lymphocytes against host 
antigens following exposure to group A streptococcus have not been documented to date.  Since 
S. pyogenes is an extracellular pathogen, CTL response against streptococcal antigens most likely 
do not constitute a major mechanism of defense against this organism in human hosts.  
Nevertheless, the presence of CD8 bearing cells in cardiac biopsy specimen from ARF patients 
warrants their evaluation as potential mediators of target organ damage.  In the current report we 
demonstrate that myosin-reactive CTL are elicited by a rheumatogenic strain of Streptococcus 
pyogenes in neonatal but not in adult mice.  Furthermore, neonatal exposure to heat-killed S. 
pyogenes induces memory for myosin-reactive CTL that can be reactivated by either S. pyogenes 
or purified recombinant M protein later in life.  We then discuss why despite their presence, we 




MATERIAL AND METHODS 
Mice:  BALB/c mice were purchased from Jackson Laboratory, Bar Harbor, ME and bred at 
WVU animal facility. 
Antigens:   
Streptococcus pyogenes strains D471 (serotype M6) and UAB152 (a derivative of D471 
containing insertional inactivation of the emm6 gene) were grown from single colonies in 2 liters 
of Todd-Hewitt broth without aeration in the presence of 7.5% CO2 until growth ceased.  The 
cultures were pasteurized by incubation in a 5°C water bath for 1.5 hours at which point cells 
were centrifuged, washed 5 times with 500ml of 0.85% saline and resuspended in 0.85% saline.  
The cells were frozen at –20º C in 5ml aliquots after adjusting the cell density to OD600 of 2.0/ml 
(2∗ 108 bacteria/ml).  Both strains were a gift from Dr. Hollingshead (UAB).   
Plasmid TR06 was gift of Dr. Hollingshead.  This plasmid contains residues 1 to 413 of the 
mature M6 protein cloned into the NcoI and XhoI sites of pET20b+ (Novagen).  The recombinant 
M6 protein with a carboxy-terminal His-6 tag was expressed in BL21:(DE3), pLysS by induction 
with Iptg for 1 hr and was purified from periplasmic extracts by adsorption to Ni-NTA-sepharose 
(Qiagen).   
Gastrocnemius muscles pooled from hindlimbs of 5 week old mice were placed in four volumes 
by weight of 0.3 M NaCl, 0.1 M NaH2PO4, 0.05 M Na2HPO4, 10 mM EDTA, 1.4 mM 2-
mercaptoethanol (20), minced fine and incubated on ice for 30 minutes with periodic mixing.  
Samples were centrifuged at 13,000 g for 30 minutes; supernatants were diluted 5 fold in storage 
buffer (40 mM Na4P2O7, 50% glycerol) and stored at –20º C.  Rabbit myosin and bovine 
cytochrome c were purchased from Sigma Chemical Co., St. Louis, MO.
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Immunizations:  Mice were immunized with 107 heat-killed S. pyogenes per gram of body weight 
or soluble antigens M protein, myosin or bovine cytochrome c at the doses specified in the results 
section.  The volumes were maintained at 50-100 µl (neonatal) or 200 µl (adult) per mouse by the 
intraperitoneal route or in 5 µl (neonatal) or 20 µl (adult) per mouse divided equally between two 
nostrils. 
Analysis of CTL responses: 
Preparation of antigen peptides: M protein, rabbit myosin, mouse muscle extract and bovine 
cytochrome c were adjusted to a final concentration of 1 mg/ml in sterile Dulbecco’s phosphate 
buffered saline, to which, trypsin (Sigma chemical Co., St. Louis, MO) was added at 10 µg/mg 
protein.  Proteolysis was carried out for 20 hours at 37º C and digested samples were stored at - 
20º C. 
Cell cultures:  Single cell suspension of splenocytes were washed extensively with incomplete 
RPMI following red blood cell lysis with 0.15 M NH4Cl lysing buffer.  Cell counts and viability 
were monitored via trypan blue exclusion.  The spleen cells were in a buffer (5mM EDTA-
DPBS) containing pre-determined dilutions of biotinylated anti-CD45R (RA3-6B2) and anti-
CD4 (a mix of GK1.5 and RM4-4, Pharmingen) monoclonal antibodies.  Following a 20 minute 
incubation on ice cells were washed and incubated with streptavidin-labeled magnetic beads 
(Miltenyi Biotec) for 15 minutes on ice.  The stained cells were then passed through a MACS 
CS+ depletion column (Miltenyi Biotec) for separation as described by the manufacturers and 
non-bound cells were collected for assay and culture.  Efficiency of enrichment was monitored 
by flow cytometric analysis employing a FACScan (BDIS, San Jose CA).  Typically, cells used 
for assay and culturing contained <2% CD4+, <5% B220+ cells and >65% CD8+ cells.  Non-
bound cells were placed in culture with three to five times the number of irradiated adult spleen
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 cells and tryptic digests of recombinant M protein or bovine cytochrome c for a period of five 
days and washed with serum-free RPMI1640 before subsequent functional assay. 
Cytolytic assay:  Spleens from experimental mice were processed into single cell suspensions in 
serum-free RPMI1640, washed once and resuspended in phenol red-free RPMI with 5% fetal calf 
serum.  Cultured cells were washed once in RPMI1640 prior to functional assay.  P815 cells (H-
2d expressing mastocytoma cell line) (21) were incubated with tryptic peptides of appropriate 
antigen for 30 - 60 minutes in serum-free, phenol red-free RPMI1640 at a concentration of 
2∗ 105/ml.  Effector cells (splenocytes) were plated with the P815 cells loaded with peptides at 
various ratios in phenol-red free RPMI in 96-well microtiter plates for each antigen tested.  
Controls included target cells alone, appropriate serial dilutions of effector cells, target cells 
lysed with 1% Triton X-100 and media alone.  The assay plates were incubated at 37º C for 
approximately 5 hours in the presence of 7.5 % CO2. Subsequently, the plates were centrifuged 
for 2 minutes at 500 rpm and 50µl of the supernatants were transferred to a new assay plate.  An 
equal amount Promega Cytox96 assay substrate (oxidized to a colored product in the presence of 
LDH) was added to all wells.  The absorbance was read at 490 nm following a 30 minutes 
incubation employing a multiscan (Biorad).  Absorbance was proportional to the amount of LDH 
release by lysed cells and therefore to the amount of target cell lysis.  Absorbance values for all 
experimental and control sets (run in triplicates) were averaged and the antigen-specific lysis was 
calculated as percent of maximum lysis as follows:   
Abs [effector + target]  - Abs [effectors (spontaneous)] - Abs [target (spontaneous)]  
 Abs [targets (maximum lysis)] - Abs [targets (spontaneous)]  
 
Inhibition of CTL activity:  Monoclonal antibodies against mouse CD4 (RL172) and CD8 
(3.155) were harvested from hybridoma (ATCC) tissue culture supernatants by precipitation with
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 (NH4)2SO4 and extensive dialysis against phosphate buffered saline, sterilized by filtration. 
Antibodies were titrated by staining of BALB/c spleen cells in an indirect  immunofluorescence 
assay and flow cytometric analysis.  Appropriate dilutions of antibodies were added to effector 
splenocytes prior to mixing with antigen-pulsed P815 cells.  The remainder of assay and analysis 
was conducted as described above. 
All statistical analyses were performed by calculating the p value by ANOVA and the standard 
error using Microsoft Excel Analysis Toolpak.  Lytic units were calculated as previously 
described (22). 
RESULTS 
CTL response in adult BALB/c mice immunized with Streptococcus pyogenes: 
 Our initial experiments were designed to determine whether streptococcal M protein and 
mammalian myosin could elicit a CTL response in laboratory mice.  To this end we utilized 
purified recombinant M protein representing a rheumatogenic strain of S. pyogenes (serotype M6, 
strain D471) and a crude extract of myosin obtained from the hind limbs of BALB/c mice as 
immmunogens.  Tryptic digests prepared from the affinity-purified recombinant M protein and a 
commercially available preparation of purified rabbit hind limb myosin were then used as assay 
antigens.  Bovine cytochrome c has been shown to induce CTL responses in mice when 
administered by the intraperitoneal route.  Therefore we used this antigen as a control for our 
studies.  Adult BALB/c mice were administered 100µg of M protein, myosin or bovine 
cytochrome c by the intraperitoneal route, and boosted by the same route 12 days later.  Five to 7 
days following the second immunization, splenocytes were harvested and assayed as described.  
As shown in figure 1a immunization of adult BALB/c mice with purified recombinant M protein
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 induced specific lysis of P815 (H-2d) cells loaded with tryptic peptides of M protein but not 
cytochrome c or myosin.  Similarly, immunization with mouse myosin or bovine cytochrome c 
induced lysis of P815 cells in an antigen-specific manner (fig 1b and c).  Data shown translate 
into average lytic units (per 107 effector cells) giving 20% antigen-specific lysis of 10.2, 7.3 and 
8.9 for antigens M protein, myosin and cytochrome c, respectively.  Lysis of EL4 (H-2b) or 
CBA.D1 (H-2k) cells similarly pulsed with the three tryptic digests was negligible (results not 
shown).  Thus, adult BALB/c mice display the capacity to present as well as recognize 
streptococcal M protein and autologous myosin in the context of class I (H-2d) MyHC.  
Furthermore, CTL response against mouse myosin in BALB/c mice can be readily measured 
employing peptides of rabbit myosin.  These results further established that the CTL responses 
against the streptococcal M protein and mouse myosin could be easily induced and detected 
employing a simple non-radioactive assay. 
 We next sought to determine whether administration of heat-killed Streptococcus 
pyogenes organisms could induce a CTL response against M protein and against myosin which 
has been shown to share T-cell epitopes with M protein (14, 15).  Adult BALB/c mice (H-2d) 
were administered heat-killed whole-cell preparation of S. pyogenes strain D471 (D471) by 
intraperitoneal route. Splenocytes harvested 7 days following two intraperitoneal immunizations 
with 2∗ 108 D471 given 12 days apart were harvested and assayed as described in materials and 
methods.  As shown in fig 1d, the assay detected lysis of a small but significant proportion of 
target P815 cells loaded with tryptic peptides of recombinant M protein at the highest effector to 
target cell ratio.  Lysis of target cells loaded with tryptic peptides of bovine cytochrome c or 
rabbit myosin was minimal even at the highest E:T ratio.  Antigen-specific lysis of target cells 
loaded with M protein was inhibited in the presence of anti-CD8 antibodies but not anti-CD4
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 antibodies confirming that lysis was induced primarily by CD8-bearing cells (fig 1e).  In adult 
BALB/c mice immunized four times with heat-killed D471 over a 4-month period, the CTL 
response against M protein was significantly above that against the control antigen cytochrome c 
(fig 1f). However, hyperimmunization with D471 failed to elicit a CTL response against myosin, 
suggesting that repeated exposure to killed pathogen was not sufficient to induce an immune 
response against the autoantigen myosin.  Thus, our results clearly demonstrate that the 
streptococcal M protein, either soluble or cell-associated, is not capable of inducing a myosin-
reactive CTL response in adult BALB/c mice. 
Myosin-reactive CTL in neonatal BALB/c mice immunized with Streptococcus pyogenes: 
 The lymphocyte repertoire in mouse and man changes dramatically as a function of age 
with respect to antigen specificity (23, 24).  It is also known that perturbations of the immune 
system in neonatal stages of development can have long-lasting effects (25, 26).  While the 
mechanism of pathogenesis in most autoimmune diseases remain unclear, it is recognized that 
the initiating events may occur long before the disease symptoms are manifest.  We therefore 
proceeded to test whether S. pyogenes might stimulate myosin-reactive CTL cells in neonatal 
mice. 
 Newborn BALB/c mice were immunized by the intraperitoneal route with heat-killed 
Streptococcus pyogenes or purified recombinant M protein within one week of birth and 
sacrificed seven days following immunization for analysis of antigen-specific CTL.  As shown in 
figure 2a, in mice immunized with D471, we detected a CTL response against M protein.  
Interestingly, we also detected a CTL response against myosin.  These results indicate that 
Streptococcus pyogenes can indeed induce the priming of autoreactive and potentially harmful
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 CTL in laboratory mice.  They further establish that age at exposure to S. pyogenes is critical in 
the capacity to mount an autoreactive CTL response. 
 In mice immunized within one week of birth with 5 µg of recombinant M protein, a 
strong CTL response against M protein was noted (fig 2b).  The percent M protein-specific lysis 
in this group of mice for each of the E:T ratios tested was comparable to or better than that 
observed in mice immunized with heat-killed D471 (note difference in x-axis scale, 2a versus 
2b).  However, while the percent myosin-specific lysis of target cells by splenocytes from this 
group of mice was clearly above background, it was not comparable to that observed in mice 
immunized with D471.  Two explanations for this observation are considered.  Firstly, it is 
possible that the myosin-reactive CTL are induced by some other streptococcal antigen and that 
the M protein alone is not sufficient to induce maximal CTL response against myosin.  
Alternately, uptake and processing of the streptococcus by host macrophages may result in the 
processing and presentation of unique M protein CTL epitopes that may not be optimally 
generated following extracellular degradation of soluble M protein.  Such epitopes may be 
critical in the elicitation of myosin-reactive CTL. 
 To investigate whether group A streptococcus might induce myosin-reactive CTL in the 
absence of M protein, we utilized strain UAB152, a variant of D471 derived by insertional 
inactivation of the emm6 gene.  CTL responses against M protein as well as myosin were absent 
in mice immunized within one week of birth with a heat-killed preparation of strain UAB152 (fig 
2c).  While these findings do not exclude the role of other streptococcal antigens in the induction 
of a CTL response against myosin, the obligate role of M protein is underscored. 
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Kinetics of myosin-reactive CTL in neonatal BALB/c mice 
 This next set of studies was conducted to compare the kinetics of elicitation of CTL 
reactive toward M protein and myosin following immunization with D471 in order to gain 
insight into the relationship between the two antigens.  We immunized newborn BALB/c mice 
within 3 days of birth with D471.  They were sacrificed on different days to assay the CTL 
responses against M protein and myosin.  Four days following immunization with D471, the lytic 
response of splenocytes against P815 cells pulsed with tryptic digests of the M protein or myosin 
was indistinguishable from non-specific lysis of target cells loaded with cytochrome c (fig 3a and 
3f).  M protein-specific lysis was significantly above background on days 7, 10 and 13 following 
immunization (fig 3b, c, d, respectively), with peak response on day 7 (Fig 3b).  By day 18 the 
capacity for M protein-specific lysis had dropped to background levels (fig 3e).  On day 7 of the 
response, anti-CD8 and anti-CD4 antibodies produced about 70-80% and 10-15% inhibition of 
antigen-specific lysis of target cells respectively (fig 3b).  On days 10 and 13, 90% or greater of 
the lytic response was inhibited in the presence of anti-CD8 antibody (fig 3c and 3d).  These 
findings establish that M protein-specific lysis is induced primarily by CD8-bearing cells 
following exposure of newborn BALB/c mice to heat-killed Streptococcus pyogenes by the 
systemic route.  The kinetics of the response indicates that the antigen (M protein) is rapidly 
eliminated. 
 Interestingly, capacity for lysis of myosin pulsed target cells was also observed in the 
same group of mice as above with kinetics identical to that of M protein specific CTL (fig 3f-j).  
Lytic indices for myosin-specific lysis for all the E:T ratios on days 7, 10 and 13 of the response 
were comparable to those for M protein-specific lysis.  (Day 7 - 12.3:10.9, Day 10 - 5.4; 4.6, Day 
13 - 5: 4.2)  Furthermore, the extent of inhibition of antigen-specific lysis achieved in the
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 presence of anti-CD8 or anti-CD4 antibodies on days 7, 10 and 13 is identical for both antigens. 
These observations suggest the existence of shared CTL epitope(s) between the two antigens. 
 
Capacity of D471 to prime a CTL response against myosin is lost at weaning: 
 Having established that administration of heat-killed Streptococcus pyogenes to neonatal 
mice is required for the generation of myosin-reactive CTL in BALB/c mice, we chose to define 
the age limits to which this capacity might be restricted.  Groups of mice were primed with D471 
at 107 heat-killed organisms per gram of body weight on days 10, 20 or 30 after birth and boosted 
at 6 to 7 weeks of age with 2∗ 108 D471.  They were sacrificed 7 days later for analysis of the 
immune response.  As shown in Figure 4, no significant differences were noted in the CTL 
response against M protein in mice primed with D471 on days 10, 22 (weaning age) or 30 (fig 
4a-c).  In contrast, CTL response against myosin was highest in mice primed on day 10 (fig 4a) 
and this was equivalent to that seen in mice primed within three days of life (compare with fig 
5a).  In mice primed on day 22, the myosin-specific CTL response was weaker, (lytic index = 
3.4) yet significantly above than that in mice primed with D471 on day 30 (fig 4b).  In the latter 
group the myosin-specific lytic response at all E:T ratios was indistinguishable from non-specific 
lysis (fig 4c).  Thus, priming for an optimum CTL response against myosin was best achieved by 
immunizing with D471 within the first 10 days of life.  The capacity to elicit myosin-reactive 
CTL declined with increasing age and was lost in mice 30 days of age or older.  These findings 
demonstrate the significance of host age in the capacity of the group A streptococcus to 
successfully initiate a CTL response against myosin. 
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Myosin-reactive memory CTL can be reactivated with soluble M protein and vice versa 
 In further attempts to explore the relationship between the streptococcal M protein and 
mammalian myosin, we examined the secondary CTL response in BALB/c mice primed during 
the first week of life with 107 heat-killed D471.  As shown in figure 5a, in mice primed with 
D471, the CTL response against the M protein as well as against myosin was reactivated 
following an intraperitoneal booster with 108 heat-killed D471 given at 4 months of age.  An 
equivalent dose of the variant strain UAB152 lacking the M protein failed to reactivate CTL 
against both the M protein and myosin (fig 5b).  These results confirm the requirement for M 
protein in the stimulation of myosin-reactive CTL.  The absence of a CTL response against 
myosin in this group of mice (fig 5b) and in a group boosted with 100µg of the control antigen 
bovine cytochrome c (results not shown) suggests the absence of chronic stimulation of specific 
CTL by endogenous myosin.   
 Interestingly, a booster of 100 µg of purified recombinant M protein in mice primed with 
D471 reactivated not only the M protein-reactive CTL as expected, but also myosin-reactive CTL 
(fig 5c).  The lytic indices for myosin-specific lysis in experiments shown in fig 5a and 5b are 5.5 
and 1.0 respectively.  Additionally, immunization with 100µg of mouse muscle extract induced a 
CTL response against myosin as well as M protein (fig 5d).  These findings strongly support the 
idea that cross-priming between M protein and myosin results from existence of cross-reactive 




M protein-reactive CTLs elicited in neonatal mice cross-react with myosin 
Our results thus far suggest that the myosin-reactive CTL response elicited in neonatal 
mice may be due to antigen cross-reaction to streptococcal M protein.  In order to rule out the 
possible involvement of endogenous myosin in our experiment, we conducted the following 
experiment.  CD8+ splenocytes were enriched from adult and neonatal mice immunized with 
D471 by magnetic sorting as described in material and methods.  The enriched cells were assayed 
directly for lysis of antigen labeled target cells or were restimulated in vitro with enzymatic 
digests of recombinant M protein or cytochrome c for five days.  As shown, CD8+ spleen cells 
from mice immunized as adults with D471 were capable of lysing P815 cells labeled with tryptic 
digests of M protein but not myosin or cytochrome c (fig 6a).  A comparison with figure 1d 
shows and 8 – 10 fold enrichment of M protein reactive CTL.  The CTL response measured 
against both M protein and myosin in cultured cells were inhibited by addition of anti-CD8 but 
not anti-CD4 to the assay (data not shown).  CD8+ splenocytes obtained from unimmunized age 
matched control mice and cultured with either recombinant M protein or cytochrome c failed to 
lyse P815 pulsed with tryptic digests of recombinant M protein, myosin or cytochrome c (results 
not shown).   
 Culture of CD8+ splenocytes from adult mice immunized with D471 in the presence of M 
protein selectively enriched the specific CD8+ cells and maintained them functionally active (fig 
6b) whereas, culture with digest of cytochrome c led to a loss of CTL activity against M protein 
(fig 6c).  This finding suggests that presence of antigen, in this case M protein, was necessary to 
maintain functional activity in vitro. 
 CD8+ spleen cells from neonatal mice immunized with D471 were capable of lysing P815 
cells labeled with either tryptic digests of M protein or myosin but not cytochrome c (fig 6d).  
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Following culture with M protein for 5 days, the CTL response against both M protein and 
myosin was maintained (fig 6e) whereas, culture in the presence of tryptic digests of cytochrome  
c led to a loss of response against M protein as well as myosin (fig 6f).  The logical interpretation 
of these results is that the myosin-reactive CTL response following neonatal exposure to D471 
results from cross-reaction of CTL against M protein. 
 
DISCUSSION 
 It is becoming increasingly evident that T cells are potential mediators of the pathology 
witnessed in rheumatic fever.  Due to the shared structural characteristics and epitopes (27, 28), it 
has been hypothesized that T cells elicited against streptococcal M protein cross-react with the 
host protein myosin.  Patients with ARF demonstrate lymphocytic infiltrates in cardiac tissue (5, 
6), however, there are conflicting reports of their ability to cross-react with streptococcal 
preparations and cardiac proteins.  Guilherme et al. (10) reported that T cell clones isolated from 
cardiac valve samples of rheumatic fever patients demonstrated cross-reactivity between type 5 
M protein and heart tissue protein extracts.  Yet, Yoshinaga et al. (12) were unable to 
demonstrate such cross-reactivity with their T cell lines isolated from cardiac tissue of RF 
patients. el-Demellawy et al. (18) has demonstrated that PBL from ARF patients recognize a 50 
kDa and 54 kDa protein of myocardial extracts and that the proliferative response may be 
intensified by pre-culturing cells with GAS extracts.  Cloning of PBL from active and chronic 
cases of ARF has yielded conflicting results as well.  The T cell lines of both CD4+ and CD8+ 
phenotypes produced by Pruskakorn et al. (14) that cross-reacted between M protein and myosin 
were isolated from healthy individuals.  Further study of human lymphocytes have shown that 
peptic preparations of certain serotypes of M protein have a mitogenic effect on a particular 
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subset of naive human lymphocytes (16, 29) and this stimulation has the potential to invoke 
cytotoxic activity against cultured human heart cells (19, 30).  These studies have allowed for 
thehypothesis that the superantigenic ability of M protein is able to augment the immune 
response against streptococcal antigens and, therefore, the cross-reactive immune response to 
host antigens, if one is primed.  However, despite these promising studies, having cross-reactive 
T cells may not be sufficient to cause disease, in that, M protein-reactive and myosin cross-
reactive T cells were isolated from normal human subjects with no history of ARF (14). 
 In depth evaluation of such a hypothesis is hindered by the lack of a good animal model 
system. While it has been possible to induce viral mediated autoimmune diseases, such as 
experimental allergic encephalomyelitis and Coxsackie B3 myocarditis, in laboratory animals 
(31, 32), immunization of adult animals with Streptococcus pyogenes or components thereof 
usually does not induce autoreactive T cells (15).  Hyperimmunization of guinea pigs or rabbits 
with Group A streptococcal preparations has been shown to induce the elicitation of cytotoxic 
responses against cardiac cells (30, 33, 34).  Cromartie et al. (34) demonstrated the ability to 
induce cardiac lesions in mice reminiscent of ARF, however in this case an inflammatory 
response to antigen deposited in the tissue was adjudged responsible for the pathology.  
 Based on our previous observation that immunizing neonatal, but not adult, mice with 
whole heat-killed S. pyogenes strain D471 induces the production of antibodies against the group 
specific determinant and that cross-react with myosin, we undertook this study to determine the 
extent this immunization strategy could elicit a T cell response.  Specifically, we wanted to 
determine if immunization of neonatal mice with D471 could elicit CTL responses against the 
suspect host antigen, myosin, and if so, determine the capacity of M protein in the induction of 
such a response. CD8+ T cells have been shown to play an important role in the pathogenesis of 
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several tissues targeted autoimmune diseases (35, 36).  Our model includes an extracellular 
organism and therefore, the induction of a CTL response may not be as evident.  Harding et al. 
(37, 38) and Rock et al. (39) have demonstrated the ability of extracellular antigens to be 
presented via class I MHC.  In addition, S. pyogenes has been shown to be capable of binding 
and entering and residing in host epithelium in patients with recurrent tonsillitis and in carriers 
(40).  As such, S. pyogenes may spend some time as a viable intracellular pathogen and elicit a 
CTL response.  Since we have employed heat-killed vaccine in our studies, our findings suggest 
that other mechanisms may also be involved in the generation of a CTL response against this 
organism.   
 Based on studies conducted to date, we know very little about the capacity of neonates to 
respond to various antigens.  Studies in the area have employed the trial and error approach using 
distinct antigens.  Of note are recent studies that have attempted to identify conditions conducive 
to the generation of optimal immune responses, in neonates.  Utilizing the hen egg lysozyme 
(HEL) model for neonatal tolerance induction (25, 40), neonates were shown capable of eliciting 
an antigen-specific proliferative Th cell response.  In addition, Sarzotti et al. (42) and Siegrist et 
al. (43) demonstrated the ability of neonatal mice to mount a protective CTL response using two 
distinct viral models.  Furthermore, Pilarski et al. found that mice have detectable anti-allogenic 
CTL responses within three days of birth (44).  Our data clearly shows that neonatal mice can 
mount CTL responses against bacterial antigens.  
 Results shown in figure 2 demonstrate the ability of mice neonatally treated with whole 
heat-killed S. pyogenes to elicit a CTL response against both M protein and myosin. The 
specificity of this response was confirmed by the lack of response against the unrelated control 
antigen cytochrome c.  Examination of the kinetics of this response (fig 3) reveals that both the 
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M protein and myosin CTL responses peak at seven days following exposure to antigen and 
diminish after eighteen days.  This super-imposable kinetics of the responses against two distinct 
antigens suggests the presence of cross-reactive determinants shared by the two proteins.  If the 
CTL response against myosin was induced by an indirect mechanism, one would expect the 
kinetics of this response to be distinct from that of M protein specific CTL.  The capacity of M 
protein to maintain and enrich for the myosin reactive CTL in vitro further supports the existence 
of a shared CTL epitope.  We intend to investigate the molecular basis for this cross-reactivity 
using synthetic peptides.  
Another key finding in this study is the age dependence of the ability to mount a myosin-
reactive response following exposure to S. pyogenes.  First, adult mice are quite capable of 
mounting a CTL response against myosin when immunized with purified rabbit myosin, yet 
immunization with S. pyogenes or M protein does not lead to the elicitation of myosin-reactive 
CTL in adult mice.  Second, as shown in figure 4, the level of measurable lytic response against 
M protein was maintained despite the age of immunization, however, the level of the lytic 
response against myosin decreased steadily with the age of the mouse.  A possible explanation 
for this is that the population of dual reactive CD8+ T cells prevailing early during ontogeny is 
replaced by M protein specific cells as a function of age.  The myosin-reactive CD8+ cells may be 
deleted, anergized or merely outnumbered by those specific for M protein.  This finding is 
reminiscent of earlier reports that demonstrate the ontogenic development of dominant idiotypes 
associated with bacterial polysaccharide antigens (45 - 47) and the loss of certain TCR Vβ upon 
negative selection by endogenous viruses (48, 49).  Thus a growing body of evidence suggests 
that autoreactive lymphocytes may be most easily activated during early life before the immune 
system is fully mature.  Together, these findings help shape the theories about how autoimmune 
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diseases develop.  It is now believed that most autoimmune diseases originate in early life and 
are manifest as pathological conditions much later. 
We have demonstrated here that in mice immunized with S. pyogenes early in life the 
myosin-reactive CTL remain as memory cells fully capable of a response when restimulated by 
either M protein or myosin much later in life.  Interestingly, the myosin-reactive CTL pose no 
harm to the host suggesting that in this model system endogenous myosin is not released and that 
the epitopes recognized by these CTL are not presented by the host during their lifetime.  Peak 
incidence of ARF is known to occur between the ages of five and fifteen, a time when the 
immune system is thought to be mature.  Perhaps additional events, which may include re-
exposure to S. pyogenes, are necessary to precipitate the pathology of sequelae such as ARF.  Our 
model system has thus permitted identification of potentially harmful CTL that can be induced by 
S. pyogenes prior to the manifestation of the autoimmune sequelae.  Being able to detect such 
harmful lymphocytes before autoimmune diseases become debilitating would greatly benefit the 























Figure 1. Analysis of cytolytic T cell responses induced in adult primed BALB/c mice.  Groups 
of six to eight mice were immunized at least twice intraperitoneally (i.p.) with either 200 µg of 
either recombinant M protein type 6 (a), crude mouse skeletal myosin extract (b) or bovine 
cytochrome c (c), or 2∗ 108 heat-killed D471 either twice (d, e) or four times (f) as outlined in 
material and methods. Within 7 - 10 days following the last immunization spleen cells were 
harvested and assayed for cytolytic responses against P815 target cells labeled with tryptic 
digests of either recombinant M protein type 6 (MP) (!), cytochrome c (Cyt c) (") or 
commercially prepared rabbit myosin (MY) (!) starting at a 200:1 effector to target cell ratio. 
Assays in figure 1e demonstrate the lose of M protein specific lysis in the presence of anti-CD4 
(#) or anti-CD8 (!) monoclonal antibodies.  Percent lysis is represented on the y-axis and the 













































































Figure 2.  Analysis of myosin-specific CTL responses in BALB/c mice challenged as neonates 
with heat-killed S. pyogenes.  Neonatal mice in groups of four were immunized i.p. within 7 days 
post partum with 2∗ 107 heat-killed D471 or UAB152 (a and c, respectively) or with 5 µg of 
recombinant MP (b).  Spleen cells were harvested and assayed for antigen specific CTL 
responses against MP (!), Cyt c ("), or MY (!).  The y-axis represents percent lysis and the 
effector to target cell ratio is represented on the x-axis.  Each point is the geometric mean for that 




























































Figure 3.  Kinetics of the myosin-specific CTL response elicited in BALB/c mice primed as 
neonates with heat-killed D471.  Groups of four mice were immunized i.p. within 48 hours of 
birth with 2∗ 107 heat-killed D471 and spleen cells were harvested at various timepoints including 
day 4 (a, f), day 7 (b, g), day 10 (c, h), day 13 (d, i), and day 18 (e, j) following immunization.  
Assays were conducted with E:T ratios starting at 100:1 to measure the MP (!) (a – e) and MY 
(!) (f – j) specific CTL responses, as well as, to determine if the responses could be inhibited by 

















































































Figure 4. The role of age in the induction of a myosin specific CTL response.  Groups of 5 mice 
were immunized with 2∗ 107 heat-killed D471 at either day 10, day 22 or day 30 post partum. 
CTL assays were performed on spleens cells for antigen specific responses against MP (!), or 
MY (!).  Lytic responses to target cells loaded with tryptic digest of the irrelevant control 





























































Figure 5.  Requirement of M protein during neonatal exposure of S. pyogenes for the induction 
of a myosin-specific CTL response.  Groups of 3 - 5 mice were initially immunized i.p. within 7 
days of birth with 2∗ 107 heat-killed D471 and boosted as adults with either an immunogenic dose 
of either D471 (a), UAB152 (b), mouse myosin extract (d) or recombinant M protein (c). Within 
7 days of the last immunization spleen cells were harvested and assayed for CTL responses 
















































































Figure 6:  CTL activity of CD8+ enriched splenocytes before and after culturing with 
recombinant streptococcal M protein.  Mice were immunized as adults (a - c) with 100 µg of M6 
or within three days of birth with 2∗ 107 heat-killed D471 (d - f).  Splenocytes were harvested and 
enriched for CD8+ cells as outlined in material and methods.  Enriched cells were either assayed 
directly (a, d) against MP (!), MY (!) or Cyt c (") or placed into culture with tryptic digests of 
M6 (b, e) or Cyt c (c, f) for five days before being assayed against the same antigens.  Percent 
specific lysis is represented on the y-axis and the effector to target cell ratio on the x-axis.  y-axis 
error bars represent standard error and the n value indicates the number of experimental groups 
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Myosin-reactive CTL are induced in neonatal mice by the C-terminal 




















 Previously, we have shown that neonatal, but not adult, BALB/c mice primed with heat-
killed Streptococcus pyogenes strain D471 (serotype M6) develop a cytotoxic T cell response to 
both streptococcal M protein type 6 (MP) and mammalian myosin.  To determine if the 
elicitation of a myosin-reactive CTL response is exclusive to rheumatogenic serotypes of S. 
pyogenes, neonatal BALB/c mice were immunized with non-rheumatogenic streptococcal strains 
B737 (M49), H3 (M12) and J17A4 (M-type unknown).  Mice immunized with J17A4 mounted a 
myosin-reactive CTL response comparable to that elicited by D471, and mice treated with B737 
or H3 mounted a weaker myosin-reactive cytolytic response than that elicited by D471 and 
J17A4.  Screening for cytolytic responses against myosin purified from hearts and two hindlimb 
muscles suggested that myosin-reactive CTL induced by D471 and J17A4, but not B737 and H3, 
are primarily mediated against neonatal cardiac myosin.  This myosin-reactive cytolytic response 
was seen in conjunction with a response against the carboxy-terminal conserved region of M 
protein.  Furthermore, mice primed with recombinant protein consisting of the carboxy terminal 
region of MP or D471 treated with pepsin to cleave away the variable amino terminus of M 
protein elicited a response to myosin, whereas, mice treated with the variable amino-terminal 
region of M protein did not. Taken together, these results suggest that carboxy terminal region of 
M protein, which is under consideration as a vaccine candidate, contains an epitope that is 





 Group A streptococcus is a common human pathogen that primarily causes skin and 
nasopharyngeal infections (1).  One of the potential consequences of an untreated streptococcal 
pharyngeal infection is acute rheumatic fever (ARF), an autoimmune manifestation that primarily 
targets the joints and heart (4 - 6).  While it is widely accepted that ARF is the result of an 
immune response evoked by GAS (4 – 6, 13 -15), the exact mechanism by which the infection 
triggers disease in a susceptible host remains unclear.  Virulence factors expressed by GAS are 
known to share epitopes with mammalian proteins and it has been suggested that this molecular 
mimicry has the potential to elicit auto-reactive responses that may initiate tissue destruction (7 - 
13).  Such virulence factor is the anti-phagocytic factor M protein, an alpha helical coiled-coil 
surface protein of which exists more than 80 different serotypes based upon the antigentically 
variable amino terminal region (2, 3).  Antigenic determinants within the carboxy terminal  C 
repeat region allow most M protein serotypes to fall into one of two major classes of M protein.  
At the molecular level, specific amino acids marking key residues within the C repeat region 
distinguish class I M protein from class II (42).  Nearly all serotypes of GAS that have been 
associated with ARF have been shown to express class I M protein (42).  
  In vitro and in vivo studies have shown that M protein has the potential to induce 
cytotoxic T cell responses that have the capacity to kill myocardial cells (16 - 18).  Furthermore, 
extensive in vitro studies suggest that ARF patients can harbor lymphocytes that exhibit cross-
reactive responses to both M protein and cardiac proteins (19 - 21).  M protein serotypes that 
have been associated with ARF, especially M5, have been shown to act as superantigens to 
human T cells displaying particular Vβ gene elements (24 - 26), however, this has been disputed  
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(22, 23) and numbers of T cells expressing these Vβ are not elevated in patients with RHD (27).  
Furthermore, peptides from the conserved region of M5 have been shown to induce human T 
cells to cross-react with cardiac proteins (2, 29, 30).  In attempts to design an effective safe 
vaccine for GAS, Good et al. and Robinson et al. have used M5 peptides to map the major CD4 
T cell epitopes of M protein, especially the conserved carboxy terminal region (29 - 31).  While 
they have been able to identify immunogenicity of M5 peptides that fail to induce myosin-
reactive T cell responses in adult mice, these peptides have not been tested in neonatal mice.  Our 
previous studies and this one indicate that myosin-specific T cell responses are easily induced in 
neonatal mice (28). 
 Since the peak incidence of ARF and AGN in humans is in children of school age and 
preschool age, respectively, the focus of our research has been to identify abnormal immune 
responses induced by S. pyogenes in neonatal inbred mice and characterize the basis for these 
responses at a molecular level.  We have previously observed that neonatal, but not adult mice 
immunized with heat-killed D471 (M6 serotype), develop cytotoxic T cell responses against 
mammalian myosin and that M protein is required for the induction of this response (28).  Also, 
these neonatally treated mice develop myosin cross-reactive antibodies that recognize the cardiac 
specific isoforms of myosin (37).  We have undertaken the current study to determine if the CTL 
response elicited by S. pyogenes could distinguish endogenous (mouse) isoforms of cardiac 
myosin from skeletal isoforms and to determine which region of M protein was responsible for 
the induction of this myosin-reactive CTL response.  We report that S. pyogenes can elicit a CTL 
response in neonatal mice that preferentially recognizes the cardiac isoforms of mouse myosin.  
In addition, our results indicate that it is the conserved carboxy-terminal region of M protein is 
capable of inducing a CTL response to myosin, however, in both neonatal and adult mice.  These 
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results are important in light of the fact that the carboxy-terminal of M protein it is currently 
being considered as a candidate for a GAS vaccine (29 - 33).  
 
MATERIAL AND METHODS 
Mice:   
BALB/c mice were purchased from Jackson Laboratories and bred in our animal facilities. 
 
Immunization with heat-killed S. pyogenes:   
S. pyogenes strains D471 (serotype M6), UAB152 (chapter2), H3 (M12), J17A4 (non-typable) 
and B737 (M49) (ATCC) were grown overnight in Todd-Hewitt broth and heat-killed with 
incubation at 65° C for 1 hour.  They were then washed five times in 0.85% saline adjusted to a 
density of 109 - 1010/ml and stored at -20° C.  To prepare D471*, heat-killed culture was adjusted 
to pH 2.0 with HCl and treated pepsin for 1 hour at 37° C, neutralized with NaOH, and washed 
and resuspended in 0.85% saline (32).  Neonatal mice were immunized by intraperitoneal route 
(i.p.) with either 5∗ 106 heat-killed S. pyogenes strains D471, D471*, UAB152, H3, J17A4 or 
B737 diluted in 50 ml Dulbecco’s saline.  Controls received saline only.  The mice were 
subsequently boosted i.p. at 3 weeks of age with 108 organisms of the corresponding heat-killed 
vaccine in 0.1 ml of Dulbecco’s saline. 
 
Cloning of M protein and its fragments: 
 Cloning, expression, and purification of MP6 have been described (28).  The amino and 
carboxy terminal M protein fragments AB and C were generated by subcloning the Nco1 - 
Bsp1286I (AB region) and Bsp1286I - Xho1 (C region) into pET20b(+) and transformed in
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BL21(DE3):pLysS.  Cells were grown to OD600 of 0.5 and induced with IPTG for one hour, 
harvested by centrifugation and lysed by resuspension in 8 M urea. The his-tagged recombinant 
proteins were purified using Ni-NTA super flow resin (Qiagen).  The purified proteins were 
dialyzed extensively against Dulbecco’s PBS and stored at -20° C. 
 
Preparation of mouse myosin:   
Myosin was prepared from mouse skeletal (gastrocnemius and soleus) and hearts (1 day old 
mice) or heart ventricle tissue (adult mice) essentially as described by Margossian et al. (33).  
Briefly, crude muscle extracts were prepared by mincing tissue in four volumes/wt extraction 
buffer (0.3 KCl, 0.15 M KH2PO4 (pH 6.5), 0.02 M EDTA, and 5 mM MgCl2) and incubated on 
ice for 15 min.  Samples were precipitated with 10 volumes of cold deionized water and placed at 
4˚ C for at least 3 hours or overnight.  Precipitate was collected with centrifugation at 9000 rpm 
for 25 min at 4˚ C, resuspended in a minimal volume of 1.0 M KCl, 25 mM EDTA, 0.06 M, 
KH2PO4 (pH 6.5) buffer, and dialyzed against 30 volumes of 0.6 M KCl, 25 mM KH2PO4 (pH 
6.5), 10 mM EDTA, 1 mM DTT buffer.  The precipitation and dialysis were repeated once more. 
Samples were filter sterilized and protein concentrations were determined by Dc protein 
colormetric assay (Bio-Rad).  The samples were then aliquoted and stored in aliquots at -20°C.   
 
Electrophoresis of myosin:   
Mouse myosin preparations were electrophoresed onto either standard 8% SDS-PAGE gels as 
previously described (34) or 8% acrylamide gels with 30% glycerol using a Mini-PROTEAN II 
electrophoresis system  (Bio-Rad).  Preparation and execution of 8% acrylamide gels with 30% 
glycerol were carried out as previously described (36), however, with the addition of 2-
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mercaptoethanol in the running buffer of the upper reservoir at a final concentration of 10 mM 
(50).  Following electrophoresis gels were stained with either Coomassie G-250 (Bio-Rad) or 
silver stain (Bio-Rad Silver Stain Plus Kit). 
CTL assay:   
CTL assays were carried out as described before (28).  Briefly, P815 cells were pulsed with 
tryptic digests of M protein, AB, CD, the mouse myosins or the control protein cytochrome c at 1 
mg/ 2∗ 105 cells.  Single cell suspensions of effector spleen cells were plated with MHC matched 
P815 cells at an E/T ratios of 200, 100, 50 25, unless otherwise noted, in phenol red-free RPMI 
with 2.5% fetal calf serum and incubated at 37o C for approximately 5 hours.  Controls included 
spontaneous release of effector and target cells, maximum release of targets and media 
background.  Supernatants were harvested and assayed using a non-radioactive colorimetric 
cytotoxicity assay kit (Cytotox96, Promega). Absorbance was read at 490 nm.  Percent lysis was 
calculated as follows:   
 Experimental release- Effector spontaneous release - Target spontaneous release  







Enrichment of myosin heavy chain isoforms from mouse muscle 
 
 The relative distribution of distinct isoforms in various muscles in inbred mice has been 
described (39 - 41).  We isolated myosin from BALB/c mice from two hindlimb muscles of adult 
mice and from hearts of newborn and adult mice (figure 1).  Myosin was enriched from crude 
extracts (fig. 1a), and although the myosin preparations are not completely free of contaminants 
(fig. 1b) we were able to achieve preparations with greater than 90% homogeneity.  To visually
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determine the myosin isoform composition of each enriched myosin sample they were 
electrophoresed under stringent conditions that take advantage of the subtle molecular 
differences between the isoforms and allow adequate separation.  In figure 1b, the enriched 
myosin samples were electrophoresed onto an 8% acrylamide gel containing 30% glycerol for 24 
hours as described in material and methods.  As seen in figure 1b (lane 1) the neonatal heart 
contains both alpha and beta myosin isoforms, while the adult ventricular tissue (lane 2) is 
composed of solely of alpha myosin. The gastrocnemius (lane 3) is composed predominantly of 
the type IIb and type IIx/IId isoforms with a small amount of IIa and almost type I isoform.  On 
the other hand, the soleus (lane 4) contains approximately an equal amount type I than type IIa 
with a negligible amount of the type IIb and IIx/IId isoforms.  Therefore, we could determine 
whether the myosin CTL epitopes are shared by most mouse myosin isoforms or are restricted to 
isoforms expressed in specific muscle tissues. Therefore, the adult heart ventricle will serve as an 
indicator for responses specific for alpha cardiac myosin and can be compared to responses 
observed against the neonatal heart and soleus to determine reactivity against the beta cardiac 
isoform.  Responses that recognize the gastrocnemius and not the soleus can most likely be 
attributed to the IIb isoform, while responses against both the gastrocnemius and soleus would 
suggest that the response is recognizing an isoform shared between them. 
CTL primed by streptococcal M protein recognize the cardiac isoforms of mouse myosin 
  
Mice were immunized within one week of birth with D471 or UAB152 (MP - variant of 
D471) and sacrificed seven days following the booster (material and methods).  Splenocytes were 
harvested and assayed for the presence of CTL as outlined in material and methods.  Previous 
results have shown us that D471 can induce a CTL response against rabbit myosin (28),
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therefore, this experiment would test whether mouse myosin would be recognized by the M 
protein reactive CTL.  As shown in figure 2, immunization with D471 is capable of inducing a 
CTL response against mouse myosin thus confirming that the endogenous mouse myosin can be 
recognized by myosin-reactive CTL primed by S. pyogenes.   The CTL response induced by 
D471 against myosin from the neonatal heart and soleus is comparable to that measured against 
rabbit myosin, and greater in magnitude than that against the gastrocnemius and adult heart 
ventricular myosin.  These results show that the myosin-reactive CTL response is capable of 
recognizing all mouse myosin isoforms to varying degrees, but because the response against the 
neonatal heart and soleus is greater, this would suggest that the myosin-reactive CTL response 
preferentially recognizes the beta (type I) myosin isoform.  Immunizing mice with UAB152 does 
not induce a CTL response against myosin, whether of rabbit or mouse origin, thus indicating 
that the CTL responses against the mouse myosin induced by D471 are specific and mediated by 
M protein.  
 
Myosin-specific CTL may be primed by non-rheumatogenic S. pyogenes serotypes  
 Strain D471 represents the M6 serotype, which is commonly associated with ARF.  The 
association of this strain with CTL response against cardiac myosin suggests a possible 
contribution to the pathology associated with ARF and rheumatic heart disease (RHD).  We 
therefore chose to test whether other serotypes of S. pyogenes, particularly those not associated 
with ARF, were capable of inducing a myosin reactive CTL response against mouse cardiac 
myosin.  We selected strains H3 (serotype M12) and B737 (M49), isolated from the nasopharynx 
and skin of patients presenting with AGN, respectively.  Other strains expressing the M12 or 
M49 protein have not been associated with ARF.  As previously discussed, S. pyogenes serotypes
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 M6 and M12 belong to class I while M49 belongs to class II (42).  In addition, we chose strain 
J17A4, a non-M typable strain from.   
 Newborn mice were immunized as described above and in material and methods and CTL 
assays were performed seven days following boosters at 3 - 4 weeks of age.  As shown in figure 
3, in mice immunized with J17A4 mounted a CTL response to MP6 that is comparable to that 
mounted by D471 (fig. 2), while H3 and B737 mounted a weaker response.  This is not 
surprising since the M proteins are antigentically distinct with small regions of shared homology.  
Both J17A4 and H3 could induce a CTL response against rabbit, however, B737 did not.  Mice 
immunized with J17A4 mounted a CTL response to cardiac myosin isolated from neonatal mice 
comparable in magnitude to that seen in mice immunized with D471.  However, the CTL 
response against myosin from soleus was poor.  In comparison, mice immunized with H3 or 
B737, we failed to detect strong CTL responses against any of the mouse myosins.  Thus, at least 
one non-rheumatogenic strain of S. pyogenes was capable of inducing a CTL response against 
neonatal cardiac myosin. 
 
The conserved region of M protein is responsible for myosin-reactive CTL response in mice 
 To investigate further the role of M protein in the induction of myosin-reactive CTL, we 
generated subclones of the plasmid containing the cloned emm6 gene to express the amino 
terminal half of the MP6 containing the A and B repeats separate from the carboxy terminal half 
containing the C repeat region and the region associated with the cell wall polysaccharide.  The 
resulting recombinant proteins designated AB6 and C6 were purified and used to immunize 
neonatal mice.  In addition, we prepared D471* by treatment with pepsin as described in material 
and methods.  Since pepsin cleaves M6 protein between the B and C repeat regions this removed  
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the A and B repeat regions of the M6 protein from the whole cell preparation. Thus the D471* 
represented a whole cell preparation containing the carboxy terminal conserved region of MP.  
Newborn BALB/c mice were immunized within a week of birth with D471, D471*, purified AB6 
or C6.  Within five to seven days following the second immunization splenocytes were removed 
and assayed for the presence of CTL against M protein and mouse myosin.  None of the 
immunizing antigens induced responses to the irrelevant control antigen cytochrome c (fig 4a), 
while all groups mounted responses of similar magnitude against recombinant M protein (fig 4b).  
As shown in figures 4c and 4d, in mice immunized with D471, equivalent CTL response against 
both AB6 and C6 were detected.  Thus, CTL epitopes are present in both the variable amino 
terminal half and constant carboxy terminal half of MP.  Immunization with D471* induced a 
CTL response against C6 region that is comparable to the response induced by C6 itself (fig. 4d) 
and weak responses against AB6 (fig. 4c).  These results indicate that the pepsin treatment of the 
vaccine (D471) prior to immunization was sufficient in removing most, if not all, of the AB6 
region.  Immunization with AB6 induced a CTL response against itself (fig. 4c) and a weak 
response against C6 (fig. 4d), whereas, immunization with C6 induced a CTL response to itself 
and weak response to AB6.   
 We next assayed the splenocytes for responses against mouse myosin (fig 4 e - h).  Mice 
immunized with D471 elicited a response to neonatal heart (fig. 4e) and soleus (fig. 4h) and a 
weaker response to adult heart ventricle (fig. 4f) and gastrocnemius (fig. 4g).  One the other 
hand, mice immunized with D471* exhibited CTL responses of greater magnitude against 
gastrocnemius (fig. 4g) and soleus (fig. 4h) and a weaker response to the cardiac samples (fig 4e - 
f).  Immunization with C6 induces a response to all mouse myosin samples with the greatest 
response against the adult heart ventricle (fig 4f).  Immunization with AB6 does not induce a 
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CTL response to the mouse myosin.  Although we were able to measure responses against 
myosin in mice immunized with C6 or D471* they did not discriminate between the mouse 
myosin isolated from different muscle as much as the CTL responses induced by D471.  
Likewise, the myosin CTL response generated in the mice immunized with C6 or D471* was of 
lesser magnitude as those measured in D471 primed mice. 
 
Capacity of M protein C region to induce a myosin-reactive CTL response in adult mice 
  
Previous experiments conducted in our laboratory have shown that immunization of adult 
mice with D471 or whole recombinant M protein leads to a CTL response against M protein with 
no measurable response against rabbit myosin (28).  Since the carboxy terminal half of M protein 
can elicit a myosin reactive CTL response in neonatal mice, we then wanted to determine if this 
response was also dependent on age as that seen with D471 immunization.  Adult mice were 
immunized intraperitoneally with 50 µg of recombinant AB6 or C6 and within seven days of the 
last immunization the splenocytes were harvested and assayed for CTL responses against mouse 
myosin.  Both groups of mice developed a CTL response against M protein as measured by target 
cells loaded with recombinant MP6 with no background response to the irrelevant control antigen 
(fig 5a). Mice immunized with AB6 did not develop CTL responses against the mouse myosin 
(fig. 5b). Immunization with the recombinant C fragment induced a CTL response against the 
mouse myosin, however, with no significant discrimination between the cardiac and skeletal 
isoforms (fig 5b). This CTL response against mouse myosin is comparable to that induced in the 
neonatal mice demonstrated in figure 4 (panels e - h), again underscoring the involvement of the 
C region. A possible explanation for these results could be that extracellular degradation of 
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whole recombinant M protein and the C region does not yield the same epitopes.  The results 
obtained from mice immunized as neonate or adults with the C region suggest that an epitope 




 For several years researchers have attempted to determine the mechanisms of post-
streptococcal autoimmune events by both analyzing human tissue and developing animals model 
systems.  While the argument for a role of cross-reactive antibodies received attention first and is 
still being debated (7, 8, 13, 37, 43, 44, 48), it is becoming increasingly clear that the pathology 
of ARF is mediated by T cells (4, 16 – 21, 52, 53).  In both active and chronic cases of ARF, 
these infiltrates are found to be mostly macrophages and T lymphocytes of which the CD4+ 
population out numbers the CD8+ population 4:1 (14, 15).  Analysis into the distribution of 
peripheral blood lymphocytes (PBL) of ARF patients compared to controls indicate that T cells 
from ARF patients are activated and that there is a sustained increase in the number of CD4+ T 
cells and B cells (45).    Extensive studies conducted with the mouse model of experimental 
autoimmune myocarditis indicate that CD4+ T cells are necessary to initiate the response but the 
pathological outcome is mediated by CD8+ T cells (46 - 48).         
 Various groups have tried to ascertain what the antigenic specificity of these lymphocytes 
and if antigen cross-reactivity is involved.  In vitro and in vivo studies have shown that 
streptococcal proteins, especially the M protein, can induce the differentiation of cytotoxic T 
lymphocytes with the capacity to kill myocardial cells and cell lines (16, 17).  Demellawy et al. 
has demonstrated that PBL from ARF patients recognize a 50 kDa and 54 kDa protein of 
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myocardial extracts and that the proliferative response may be intensified by pre-culturing cells 
with GAS extracts (21).    Cloning of lymphocytic infiltrates, however, have yielded conflicting 
results.  Guilherme et al. have been able to isolate clones that cross-react with M protein and 
myosin, however, Yoshinaga et al. could not, even though they demonstrated that the T cell lines 
from ARF patients preferentially react with lysates of streptococcal strains associated with ARF 
but not strains associated nephritis or non-pathogenic streptococci (19, 20).  Cloning of PBL 
from active and chronic cases of ARF has given no clearer answer either.  The T cell lines 
produced by Pruksakorn et al. that cross-reacted between M protein and myosin were isolated 
from healthy individuals (49).  While this study may not confirm the presence of cross-reactive 
lymphocytes, it does indicate that precursor myosin reactive T cells can exist in the periphery.   
 Still the question of how these T cells are recruited remains.  One possible explanation 
that has been put forth by Kotb et al. suggests that T cell responses initiated against microbial 
antigens and superantigens can generate high levels of inflammatory cytokines that ultimately 
lead to localized tissue destruction and subsequent release of self-antigen that allows for the 
expansion of autoreactive T cells (50).  Certain serotypes of M protein that have been associated 
with ARF have been shown to have superantigenic affects on particular subsets of human 
lymphocytes (24 - 26), however, this has not be correlated to Vβ gene usage in ARF patients 
(27).  In support of Kotb’s hypothesis, local cardiac tissue damage initiated by GAS has been 
demonstrated previously in mice by Cromartie et al. (51).  However, while the cardiac lesions 
they observed were a direct result of an inflammatory response due to antigen localization it 
departs from the human condition in several aspects.  First, the lesions were detectable within 
two days, second, streptococcal antigens are not detectable in biopsied valvular tissue from ARF 
patients (14, 15), and lastly, the cellular infiltrates they observed in the mouse cardiac tissue were
 
 125 
predominantly macrophages but not lymphocytes which have been well documented in the 
human disease.         
 Most animal model systems designed to address the questions regarding this disease have 
been unable to yield any information explain the underlying mechanisms.    Immunizing mice 
with streptococcal heat-killed vaccines or streptococcal cell wall or membrane preparations will 
induce anti-streptococcal antibodies that cross-react with mammalian proteins, including myosin 
(7, 8, 37, 43), but no pathology has been linked with such an antibody response.  Furthermore, it 
has been demonstrated in laboratory animals that whole cell GAS preparations can induce cell 
mediated cytotoxicity to cultured heart cells (18, 52).  Evidence may suggest that this auto-
reactive immune response is attributed to M protein (9 – 11, 17, 24 – 26, 49, 53), however, 
immunizing adult mice with M protein and M protein peptides usually yields a protective T cell 
response with no evidence of cross-reaction with myosin (28 - 30).  Nonetheless, we have 
previously demonstrated the capacity of heat-killed D471, serotype M6, to induce lytic T cell 
responses to both M protein and myosin in neonatal but not adult mice, suggesting that the 
myosin-reactive CTL response is age dependent (28).  However, this ability to induce a response 
to myosin is not exclusive to the M6 serotype.  The results of the current study have 
demonstrated the ability of streptococcal strains representing serotypes M49 and M4 to elicit a 
myosin-reactive CTL response in neonatally immunized mice.  Furthermore, our results suggest 
that M protein plays an important role in the induction of a myosin reactive response, in that, 
mice immunized with UAB152 (M- variant of D471) do not mount a lytic response to myosin. 
 In light of these results we decided to have a closer look at the role M protein plays in the 
induction of a myosin-specific lytic response.  This is an important issue since studies are 
currently being conducted with mice to develop a GAS vaccine using peptides from the C region
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of M protein (29 - 31), with the intention of developing a vaccine that will induce a protective 
immune response to most serotypes of S. pyogenes without the deleterious side effect of inducing 
an autoimmune response.  Our results indicate that the conserved C region of M protein contains 
an epitope that can induce a myosin-reactive response in both adult and neonatal mice. The 
location of this punitive epitope has yet to be determined but it draws into question the safety of 
using the C region of M protein as a potential vaccine candidate.  Furthermore, the results of our 
study are in agreement with work conducted by Pruksakorn et al. (49), who showed that human 
peripheral blood lymphocytic lines stimulated with peptides from the C region of M protein 
cross-reacted to heart proteins.   
 While we did not see any overt pathology with these mice, these results indicate that 
streptococcal M protein, especially the conserved C region, can play a central role in the 





























Figure 1.  Electrophoretic separation of mouse myosin.  Myosin was extracted from mouse 
skeletal and cardiac tissue and electrophoresed onto either 8% SDS-PAGE (a) or 8% acrylamide 
SDS-PAGE with 30% glycerol (b) as described in material and methods.  For comparison of the 
protein content, crude muscle extract is shown in 1a (EXT), otherwise, for each gel:  Lane 1; one 
day heart, lane 2; adult heart ventricle, lane 3; adult gastrocnemius and lane 4; adult soleus.  
Electrophoresis of samples onto 8% acrylamide SDS-PAGE with 30% glycerol in figure b was 
conducted to determine relative representative amounts of each myosin heavy chain isoform (see 
text for isoform definitions). 
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Figure 2. Cytolytic activity against myosin primed in neonatal mice requires M protein.  Groups 
of 5 - 6 BALB/c mice were primed within 5 days of birth and boosted at 4 weeks of age as 
described in material and methods with D471 (!) or UAB152 (").  Splenocytes were harvested 
and assayed within seven days of last immunization.  Data are shown as percent antigen-specific 
lysis (y-axis) of P815 cells labeled with tryptic digests of recombinant M6 protein (MP6), rabbit 
myosin (RMY), bovine cytochrome c (CTRL), and purified mouse myosin from neonatal heart 
(NH), adult heart ventricle (AH), adult gastrocnemius (GAST), and adult soleus (SOL) muscles.  
Each symbol represents the calculated antigen specific lysis generated by spleen cells from an 
individual mouse at E:T ratios of 100:1.  Horizontal bars represent geometric mean.  Asterisks 






































Figure 3. Priming of myosin-specific CTL responses in mice with non-rheumatogenic strains of 
S. pyogenes.  BALB/c mice in groups of 4 - 6 immunized within 5 days of birth and boosted at 3 
- 4 weeks of age with J17A4 (!), B737 (") or H3 (!).  Data represent percent antigen-specific 
lysis (y-axis) versus E:T ratio (x-axis) of P815 cells labeled of antigen at an effector to target 
ratio of 100:1. See legend of figure two for definition of antigen abbreviations.  Each symbol 
represents the calculated antigen specific lysis generated by spleen cells from an individual 
mouse.  Horizontal lines of each set represent the geometric means.  Asterisks indicate statistical 







































Figure 4. Priming of myosin-specific CTL response in neonatal mice with the conserved region 
of M protein.  Mice were immunized as neonates with D471 (!), D471* ("), AB6 (!) or C6 
(!) and boosted at 4 -5 weeks of age with the corresponding immunogen as described in 
material and methods.  Data represent percent antigen-specific lysis (y-axis) versus E:T ratio (x-
axis) of P815 cells labeled with bovine cytochrome c (panel a), MP6 (panel b), M protein 
fragments AB6 (panel c) or C6 (panel d), mouse neonatal heart myosin (panel e), adult heart 
ventricle myosin (panel f), adult gastrocnemius myosin (panel g), and adult soleus myosin(panel 





































































































Figure 5 Priming of a myosin-specific CTL response in adult mice with the conserved region of 
M protein.  CTL responses in adult mice immunized and boosted with M protein fragments AB6 
(!) or C6 (") as described in material and methods.  Data represent percent antigen-specific 
lysis (y-axis) of P815 cells labeled with antigens listed and defined in legend of figure two at an 
E:T ratio of 100:1. Panel a includes responses against streptococcal antigens while panel b 
depicts CTL responses against mouse myosin.  Each symbol represents the calculated antigen 
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Induction of the myosin-reactive CTL responses in mice with heat-killed 
Streptococcus pyogenes:  The role of age, haplotype, route of 




INTRODUCTION    
 In previous studies outlined in chapter one we have observed that BALB/c mice 
immunized as neonates with heat-killed Streptococcus pyogenes are capable of eliciting a myosin 
cross-reactive antibody response that is reminiscent of that in acute rheumatic fever patients 
(ARF).  We have also observed a myosin-reactive CTL response following neonatal systemic 
challenge of heat-killed S. pyogenes (chapter 2).  In addition, we observed that the potential M 
protein epitope responsible for eliciting a myosin-reactive CTL response is found within the 
carboxy conserved region (chapter 3), a region under intense investigation as a potential vaccine 
candidate (1-3).  Additionally, we wanted to examine various aspects of the host that may affect 
the development of the myosin-reactive CTL response including the MHC haplotype, the route of 
infection and the necessity of the B lymphocyte compartment. 
 All studies thus far have been conducted with BALB/c mice, hence experiments were 
performed with mice representing other MHC haplotypes to test their ability to develop a 
myosin-reactive CTL responses following exposure to S. pyogenes.  Next, we addressed the 
potential role route of immunization has since all previous studies were conducted with systemic 
immunizations and most post-streptococcal autoimmune complications follow nasopharyngeal 
infection.  Therefore, these studies would include experiments involving priming through the 
intranasal route, an immunization route most comparable to human nasopharnygeal infection.   
 In our neonatal systemically immunized mice we have a concurrent myosin cross-reactive 
antibody  and CTL response.  While it is believed that CD8+ lymphocytes can mediate tissue 
specific cytolytic damage in ARF and other autoimmune processes (4-10), with the exception of 
SLE no role has been found for the cross-reactive antibody response (7, 11, 12).  B lymphocytes 
can function as antigen presenting cells (APC) and present exogenous antigen, such as
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bacterium, by the classical MHC class II pathway, and non-classically via MHC class I pathway 
(13-15).  In addition, Lin et al. (16) has shown that autoreactive B cells can function as APC and 
initiate autoreactive T cell responses.  We conducted a series of experiments to determine what 
effect the presence of the B lymphocyte compartment has on the capacity to elicit the myosin-
reactive CTL response.  A portion of the following experiments were performed with BALB/c 
mice, however, since the immunoglobulin heavy chain knock-out mutation (Igh-/-) is on the 
C57Bl/6 background we also performed repetitive experiments with C57Bl/6 mice to acquire 
control data for Igh -/- experiments. 
MATERIAL and METHODS 
Mice.  BALB/c, C57Bl/6, DBA/2J, and CBA/J mice were purchased from Jackson Laboratory, 
Bar Harbor, ME and bred at WVU animal facility. Mice were immunized with 107 heat-killed S. 
pyogenes per gram of body weight or 200 µg or 5 µg of recombinant M protein and it 
subfragments for adult and neonatal mice, respectively.  The volumes were maintained at 50-100 
µl (neonatal) or 200 µl (adult) per mouse by the intraperitoneal route or in 5 µl (neonatal) or 20 
µl (adult) per mouse divided equally between two nostrils. 
Preparation of antigens.  Streptococcus pyogenes strains D471 (serotype M6) and UAB152 (a 
derivative of D471 containing insertional inactivation of the emm6 gene) were grown from  
single colonies in 2 liters of Todd-Hewitt broth without aeration in the presence of 7.5% CO2 
until growth ceased.  The cultures were pasteurized by incubation in a 56°C waterbath for 1.5 
hours at which point cells were centrifuged, washed 5 times with 500ml of 0.85% saline and 
resuspended in 0.85% saline.  The cells were frozen at -20oC in 5 ml aliquots after adjusting the 
cell density to OD600 of 2.0/ml (2∗ 108 bacteria / ml).  Both strains were a gift from Dr.
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Hollingshead (UAB).   D471* was prepared as previously described (chapter 3).  Plasmid TR06 
containing the M6 gene was gift of Dr. Hollingshead.  This plasmid contains residues 1 to 413 of 
the mature M6 protein cloned into the NcoI and XhoI sites of pET20b+ (Novagen).  The 
recombinant M6 protein with a carboxy-terminal His-6 tag was expressed in BL21:(DE3), pLysS 
by induction with Iptg for 1 hr and was purified from periplasmic extracts by adsorption to Ni-
NTA-sepharose (Qiagen). Cloning, expression, and purification of AB6 and C6 have been 
described (chapter 3). 
Non-radioactive assay for antigen specific CTL activity.   Assay antigens M protein, rabbit 
myosin and bovine cytochrome c were adjusted to a final concentration of 1 mg/ml in sterile 
Dulbecco’s phosphate buffered saline, to which, trypsin (Sigma chemical Co., St. Louis, MO) 
was added at 10 mg/mg protein.  Proteolysis was carried out overnight at 37o C and digested 
samples were stored at -20 o C.  CTL assays were conducted as previously described (chapter 2).  
Briefly, single cell suspensions were processed from spleens in serum-free RPMI1640, washed 
once and resuspended in phenol red-free RPMI with 5% fetal calf serum.  Target cells of the 
corresponding haplotype (P815 (H-2d), EL4 (H-2b), CBA.D1 (H-2k)) were incubated with tryptic 
peptides of antigen for a minimum of 20 minutes in serum-free, phenol red-free RPMI1640 at a 
concentration of 2∗ 105/ml.  Effector cells (splenocytes) were plated with the peptide labeled 
target cells at various ratios in phenol-red free RPMI in 96-well microtiter plates for each antigen 
tested.  The assay plates were incubated at 37º C for approximately 5 hours in the presence of 7.5 
% CO2.  Cytotoxicity was measured using Promega Cytox96 assay substrate as outlined in 





RESULTS and DISCUSSION 
Myosin-reactive CTL response in C57Bl/6 mice following immunization with heat-killed S. 
pyogenes as a factor of age and M protein.  In BALB/c both the age of the animal at the time 
of immunization and the presence of M protein were key factors in the induction of the CTL 
response against myosin.  In order to carry out the next set of experiments designed to study the 
effects of immunization route and the role of B lymphocytes in the induction of a myosin reactive 
CTL response, we needed to ascertain whether C57Bl/6 mice are capable of responding to 
systemic challenge of heat-killed D471 in a similar manner as BALB/c mice.  To this end, groups 
of 4 - 6 C57Bl/6 mice were immunized within 3 days post partum or at 6 weeks of age with heat-
killed D471 (fig 1a and 1d) as described in material and methods.  As shown in figure 1a, 
C57Bl/6 mice immunized as either adult or neonates with D471 elicit comparable CTL responses 
against M protein.  In comparison to the response elicited in BALB/c mice (chapter 2), adult 
C57Bl/6 mice primed with D471 elicits a CTL response against M protein of greater magnitude, 
whereas the M protein specific CTL response in neonatal mice remained relatively comparable.   
In agreement with the BALB/c data previously acquired (chapter 2), C57Bl/6 mice are capable of 
generating a myosin specific CTL response if immunized systemically with D471 as neonates but 
not adults (fig 1d).  No CTL responses were observed against the irrelevant control protein 
cytochrome c in either group of adult or neonatal mice immunized with D471 (data not shown).     
 Next, we wanted to determine whether the myosin-reactive CTL response in C57Bl/6 
mice exhibits a similar requirement for M protein as previously observed in BALB/c mice.  Mice 
were immunized as neonates or adults with UAB152 (fig 1b and 1e).  As previously observed in 
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BALB/c mice, C57Bl/6 mice immunized with UAB152 were incapable of responding against 
either M protein (fig 1b) or myosin (fig 1e) whether immunized as neonates or adults.   To begin 
further analysis into the involvement of M protein with the myosin-reactive CTL response, mice 
were immunized as adults or neonates with D471*, a preparation of D471 treated with pepsin to 
remove the antigenically variable amino terminus leaving the more conserved carboxy terminus 
remaining.  As shown in figure 1, C57Bl/6 mice immunized as neonates with D471* elicit a 
response against both M protein (fig 1c) and myosin (fig 1f), whereas adult mice elicit a response 
only against M protein (fig 1c and 1f).  These results demonstrate that C57Bl/6 mice immunized 
as neonates with heat-killed S. pyogenes are capable of eliciting a myosin-reactive CTL response.  
Further, this response is dependent upon M protein and the potential epitope for such a cross-
reactive response appears to lie within the carboxy terminal region.  Again, all of the results are 
in agreement with results obtained previously with BALB/c mice. 
M protein is required but not exclusively responsible for the myosin-reactive CTL 
response.  As previously established with BALB/c mice and demonstrated in figure 1 with 
C57Bl/6 mice, M protein is required to induce the myosin-reactive CTL response.  We have also 
demonstrated that the potential M protein epitope necessary to induce the myosin-reactive CTL 
response lies within the carboxy terminal region (fig 1f).  To investigate further the role of M 
protein in the induction of myosin-reactive CTL responses used recombinant M protein 
subfragments AB6 and C6 for immunization.      
 Experiments conducted with BALB/c mice suggested that the C region but not the A and 
B of M protein is sufficient for the elicitation of the myosin-reactive response in both neonatal 
and adult mice (chapter 3).  However, as shown in figure 2, immunization of adult C57Bl/6 mice 
with either AB6 (fig 2a) or C6 (fig 2b) results in lytic responses against M protein, as well as
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respective immunizing subfragments (data not shown) without the induction of a lytic response 
against myosin.  Further, immunizing neonatal mice with the recombinant fragments of M 
protein (fig 2c) or C6 (fig 2d) does not elicit a CTL response against myosin above background 
levels despite the measurable levels of M protein specific lytic response.  A potential reason for 
the disparity of the results between these two strains of mice is their differing haplotype 
backgrounds.  Thus it is conceivable that the epitopes processed and presented from the 
recombinant M protein and C6 within the BALB/c mice that allow cross-priming are not being 
presented in C57Bl/6.   
The myosin-reactive CTL response cannot be elicited by the intranasal route.  All 
experiments conducted thus far in both BALB/c and C57Bl/6 mice have followed systemic 
challenge, however, with the exception of AGN, most post-streptococcal autoimmune diseases 
are known to follow nasopharyngeal infection.  In an effort to determine what role the route of 
infection may play in the development of a CTL response against myosin, groups of mice were 
immunized as either as adults (fig 3a and 3b) or neonates (fig 3c and 3d) with D471 by the 
intraperitoneal route (i.p.) (fig 3a and 3c) or the intranasal route (i.n.) (fig 3b and 3d) as outlined 
in material and methods.  Both spleens and cervical lymph nodes were harvested for assay 7 or 
10 days following the last i.p. or i.n. immunization, respectively.  As previously observed, 
immunization of adult mice with D471 by the i.p. route invokes a M protein response but no 
response to either the irrelevant control protein or myosin (fig 3a).  However, immunization of 
adult mice by the intranasal route is unable to elicit the response against M protein (fig 3b).  As 
expected, immunization of neonatal mice with D471 by the i.p. route elicits a CTL response 
against both M protein and myosin (fig 3c).  In contrast, neonatal mice primed with D471 by the 
intranasal route do not mount a CTL response against either M protein or myosin (fig 3d).
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Similar results were obtained with BALB/c mice immunized intranasally with D471 as either 
adults or neonates (data not shown).    
 The lack of measurable CTL responses in intranasally challenged mice could be attributed 
to several factors.  First, the immunization may not allow for either a local or systemic response 
to be primed, perhaps as a result of inadequate antigen processing and presentation.  Preliminary 
observations suggest that no response to either M protein or myosin were detectable with CLN 
lymphocytes either (data not shown).  Second, immunization by the intranasal route may instead 
initiate tolerance, either as a result of the nature of the antigen or the antigenic dose. 
Intranasal immunization with S. pyogenes during the neonatal period primes for a systemic 
myosin-reactive response. We next wanted to test the hypothesis that perhaps as a means for 
priming an autoimmune event, an individual is first exposed to the organism by the 
nasopharyngeal route and an initial, potentially autoreactive immune response is primed which 
may be subsequently boosted by systemic challenge of the organism.  Although in our mice 
immunization by the intranasal route alone did not prime an immune response, it does not negate 
the possibility that an initial intranasal priming event may alter the systemic response following 
subsequent systemic challenge.  To conduct the experiment, mice were immunized within the 
first three days of life by the intranasal route with heat-killed D471, UAB152, or D471* as 
described in material and methods.  After reaching 4 - 6 weeks of age the mice were challenged 
intraperitoneally with the respective streptococcal vaccine or recombinant M protein.  Seven days 
following the last immunization splenocytes were harvested and assayed for lytic activity against 
M protein, myosin and an irrelevant control antigen. 
 As shown in figure 4, mice immunized with D471 (fig 4a) or D471* (fig 4b) intranasally 
as neonates and boosted as adults with D471 i.p. mount a measurable CTL response against M
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protein but the response against myosin is barely above background.  Mice intranasally 
challenged with D471 or D471* and boosted i.p. with M protein (fig 4c and 4d, respectively) 
mount an antigen specific CTL response against M protein, however, in addition to the antigen 
specific response, these mice mounted a CTL response against myosin. This indicates that i.n. 
challenge with heat-killed streptococcal vaccine does not induce systemic tolerance against M 
protein.  Further, since systemic challenge with M protein in adult animals primes only for an 
antigen specific CTL response (chapter 2 and data not shown) the elicitation of a myosin-reactive 
CTL response following the M protein systemic challenge in this set of experiments must be a 
consequence of the neonatal intranasal challenge with S. pyogenes.  Unlike D471 and D471*, 
intranasal immunization with UAB152 does not allow for a myosin-reactive CTL response 
following systemic challenge with M protein (data not shown).   These results suggest that not 
only is M protein required during the initial intranasal exposure but also that epitopes within the 
C-region of M protein are most likely responsible.  Additionally, the need for subsequent 
systemic challenge with M protein to initiate the myosin-reactive response is further established 
by the fact that mice primed intranasally with D471 as neonates and boosted i.n. with M protein 
elicit a weak response to M protein and no response to myosin (fig 4e).   
Role of B lymphocytes in the elicitation of the myosin-reactive CTL response.  B cells are 
known to function as antigen presenting cells and it has been demonstrated that autoreactive B 
cells can function as an APC and initiate autoreactive T cell responses  (16).  Also, B cells have 
been shown to be capable of processing and presenting exogenous antigen via class I MHC (13, 
15).  Such autoantigen presentation by B cells is believe to occur by receptor mediated uptake of 
the antigen via the surface immunoglobulin (13, 15, 16).  In the laboratory, we have observed 
that mice immunized as neonates with D471 i.p. exhibit life-long myosin cross-reactive antibody
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responses, therefore, the next set of experiments were designed as a preliminary study to 
determine if these autoreactive B cell serve a role in the elicitation of the myosin-reactive CTL 
response.  To perform these experiments we obtained C57Bl/6 immunoglobulin heavy chain 
knockout mice (Igh-/-) that are unable to produce antibody or express a functional 
immunoglobulin receptor on their surface.  Experiments were carried out by immunizing groups 
of Igh-/- mice as adults (fig 5a and 5c) or neonates (fig 5b and 5d) with D471 by either the i.p. 
route (fig 5a and 5b) or the i.n. route (fig 5c and 5d).  Igh-/- mice immunized as adults with D471 
by either by the i.p. route (fig 5a) or i.n. route (fig 5c) mounted a response against M protein that 
is comparable in magnitude to that measured in wild-type C57Bl/6 mice (fig 3a, 3b).  Likewise 
for the myosin-reactive CTL response in Igh-/- mice immunized as neonates with D471 i.p. (fig 
5b) or i.n. (fig 5d) when comparing the magnitude of the response in wild-type C57Bl/6 mice (fig 
3c, 3d).  Despite the lack of functional B cells, no obvious deficiencies with the lytic responses 
were observed.  Thus, this preliminary study suggests that the B lymphocyte compartment does 
not play any obvious role in the capacity of mice to elicit a myosin-reactive CTL response 
following neonatal systemic challenge with S. pyogenes. 
Influence of MHC haplotype on the development of myosin-reactive CTL response.  Host 
genetics has long been suspected a factor in the susceptibility to post-streptococcal autoimmune 
complications (17-20).  Preliminary studies were then conducted to determine what affect if any, 
the MHC haplotype may have on the development of a myosin-reactive CTL response following 
neonatal immunization with D471 and UAB152.  To conduct the experiment, mouse strains 
C57Bl/6 and CBA/J were chosen to represent the H-2b and H-2k haplotypes, respectively.  
Experiments with BALB/c mice indicate the ability of mice with the H-2d haplotype to respond 
against myosin, however, mouse strain DBA/2 (H-2d) was also selected to serve as a control for
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the data generated from the BALB/c mice.  Mouse strains, AKR/J, 129/J, representing haplotypes 
H-2b and H-2k respectively, were also chosen for this study as a means to serve as duplicate 
controls for data generated in C57Bl/6 and CBA/J mice.  However, we were unable to acquire 
adequate numbers of neonates with these strains to perform our experiments.   
 First, we immunized groups of at least six C57Bl/6, DBA/2J and CBA/J mice, as adults 
i.p. at least twice with heat-killed D471 or UAB152.  As we have previously documented with 
BALB/c mice, none of these strains demonstrated CTL responses to myosin (data not shown) 
following adult administration with either heat-killed vaccine and therefore served as a controls 
for the experiment.  Next, groups of neonatal mice representing each strain were immunized i.p. 
with either D471 or UAB152 and boosted as adults with the same vaccine.  Within sevens days 
following the adult boosting splenocytes were harvested and assayed for cytolytic activity against 
P815 cells labeled with tryptic digests of recombinant M protein, rabbit skeletal myosin or the 
irrelevant control protein cytochrome c.  Results of the cytolytic assays are summarized in table 
1.  The resultant data, albeit preliminary, suggests that the haplotype may play a role.  CBA/J 
mice (H-2k) are unable to elicit a myosin-reactive CTL response following neonatal 
immunization with D471, while C57Bl/6 (H-2b) respond to both vaccines in the same manner as 
BALB/c mice.  As anticipated, DBA/2J mice elicit a myosin-reactive CTL response following 
neonatal priming with D471.  However, unlike BALB/c, this strain also developed a detectable 
myosin-reactive CTL response following neonatal immunization with UAB152, suggesting that 
streptococcal antigens other than M protein may initiate a myosin-reactive CTL response.  Again, 
these results are preliminary and require further examination.           
Conclusion.  The data presented within the addendum were compiled as a means to better 
understand the induction of a myosin-reactive CTL response in neonatal mice following
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immunization with heat-killed S. pyogenes vaccine.  They represent the efforts undertaken to 
determine what aspects of the host and organism were key in the induction of an autoreactive 
CTL response.  Together these data suggest that on the part of the host, genetic background may 
play a role in the susceptibility of developing autoreactive CTL responses.  We have shown that 
mice of the H-2d (BALB/c and DBA/2J) and H-2b (C57Bl/6) background are capable of eliciting 
a myosin-reactive CTL response following neonatal but not adult immunization with wild-type S. 
pyogenes, while CBA/J mice (H-2k)  were unable regardless of age of immunization.  However, 
because we were unable to obtain enough neonates from AKR/J and 129/J mice, we were unable 
to duplicate the results obtained with C57Bl/6 and CBA/J mice.   
 We have shown that intranasal immunization, a route of immunization most closely 
related to natural infection, in itself cannot induce autoreactive CTL responses but can alter the 
subsequent systemic response following i.p. challenge with M protein from one that is antigen 
specific to a myosin cross-reactive CTL response.   These results suggest that local (intranasal) 
exposure to S. pyogenes may be able to have a lasting effect upon subsequent systemic responses.  
In the last set of experiments we attempted to discern a role for the autoreactive B cells within 
our immunized mice.  We wanted to determine if the B cells could potentially act as antigen 
presenting cells, present host antigen and have a down-stream effect upon the autoreactive T cell 
responses.  However, upon repeating experiments in Igh-/- mice, we were unable to detect any 
differences in the subsequent myosin-reactive CTL responses, which is not unlike what has been 
previously reported (21).     
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These results provide clues into the requirements for the elicitation of a myosin-reactive 
CTL response.  It appears that the genetic background of an individual can have an effect on the 
development of such a response, as well as, the route of immunization.  Interestingly, according 
to our results in appears that in order to develop a CTL response to myosin, the necessary 

































Figure 1.  C57Bl/6 mice are capable of eliciting a myosin-reactive CTL response following 
neonatal i.p. immunization with S. pyogenes.  Groups of 4 to 6 mice were immunized by the i.p. 
route at least twice as adults (#) or within three days of birth (!) with D471 (a, d), UAB152 (b, 
e), or D471* (c, f).  Within seven days following the last immunization splenocytes were harvest 
and assayed for lytic activity against EL4 cells labeled with M protein (a, b, c) or myosin (d, e, f).  
Each animal was assayed individually and each point within the graph represents the combined 

















































































Figure 2.  M protein is required but not exclusively responsible for the myosin-reactive CTL 
response.  C57Bl/6 mice were immunized i.p. at least twice as adults with 200 µg of recombinant 
M protein subfragments AB6 (a) or C6 (b) or within three days of birth with 5 µg of recombinant 
M protein (c) or M protein fragment C6 (d) and boosted as adults.  Within seven days following 
the last immunization splenocytes were harvested and assayed for lytic activity against M protein 
(!), irrelevant control cytochrome c (") or myosin (!).  Each graph represents the combined 









































































Figure 3. The myosin-reactive CTL response cannot be elicited by the intranasal route of 
immunization.  Groups of four C57Bl/6 mice were immunized with D471 as adults (a, b) or 
neonates (c, d) by the i.p. route (a, c) or i.n. route (b, d) as described in material and methods.  
Splenocytes were harvested for cytolytic activity within seven days following the last i.p. 
immunization or ten days of the last i.n. immunization.  Lytic activity was monitored against EL4 









































































Figure 4.  Intranasal immunization with S. pyogenes during the neonatal period primes for a 
systemic myosin-reactive CTL response.  Groups of four to six C57Bl/6 mice were immunized 
by the i.n. route within three days post partum with either 2∗ 107 D471 (a, c, e) or with D471* (b, 
d) and subsequently boosted as adults i.p. with 2∗ 108 D471 (a, b) or 200 µg M protein (c, d) or 
i.n. with M protein (e).  Seven to ten days following the last booster, splenocytes were assayed 
for lytic activity against EL4 cells labeled with M protein (!), cytochrome c (") or myosin (!).  
Each animal was assayed individually and each point within the graph represents the combined 







































































Figure 5.  Role of B lymphocytes in the elicitation of the myosin-reactive CTL response.  Groups 
of three to four C57Bl/6 Igh-/- mice were immunized as outlined in material and methods with 
D471 by either the i.p. (a, b) or i.n. (c, d) route as adults (a, c) or within three days post partum 
(b, d).  Splenocytes were harvested and assayed for lytic activity against M protein (!), myosin 



















































Table1.  Potential role of genetics in the elicitation of a myosin-specific  
 CTL response following neonatal immunization with S. pyogenes 
D471 (M+) UAB152 (M-) Mouse straina 
MPb MYO MP MYO 
BALB/c (H-2d)  +c + - - 
C57Bl6 (H-2b) + + - - 
DBA/2 (H-2d) + + - + 
CBA/J (H-2k) + - - - 
 
aGroups of at least 4 mice were immunized i.p. within three days post partum 
with either heat-killed D471 or UAB152 vaccine and boosted once as adults 
i.p. with the same vaccine.  The representative MHC haplotype is indicated 
within the parentheses. 
bSplenocytes were harvested within seven days of the final adult boosting 
immunization as assayed lytic activity against MHC matched target cells 
labeled with digests of M protein (MP), commercially prepared rabbit 
skeletal myosin (MYO) and the irrelevant control protein cytochrome c (not 
shown).  All lysis against cytochrome c was negligible. 
cResults are represented with plus signs (+) to indicate percent lysis above 
20% or minus signs (-) indicating less than 10% lysis.  All results represent 
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 General Discussion 
 Non-suppurative autoimmune complications such as acute rheumatic fever and 
glomerulonephritis are potential outcomes following infection with Streptococcus pyogenes, 
especially for children.  Research has focused onto two major hypotheses as to the induction of 
host cross-reactive immune responses.  The first hypothesis suggests that hyper-immune 
responsiveness against various streptococcal antigens may trigger or exacerbate an existing 
quiescent autoimmune response (Ayoub 1991; Kotb 1998).  Proponents have argued a role for 
the numerous streptococcal superantigens and drawn attention to the elevated serum antibody 
titers witnessed in post-streptococcal autoimmune patients.  The second major hypothesis argues 
that the autoimmune responses are due to direct antigen cross-reactivity between streptococcal 
and host components (Dale and Beachy 1985b; Cunningham et al. 1989; Yoshinaga et al. 1995).  
Advocates of the latter theory have focused primarily on the major immunodominant antigen, M 
protein, and the group specific carbohydrate, N-acetylglucosamine.   
 The work presented within this dissertation has addressed the requirements of both the 
host and the immunizing organism for the induction of host cross-reactive immune responses in 
mice.   First, we investigated the qualitative differences between the antibody response generated 
in mice as a function of age and M protein.  Next, we performed a series of studies designed to 
investigate the capacity of S. pyogenes to induce host cross-reactive cytotoxic T cell responses in 
mice.  Then, we attempted to determine what factors may play a role in the development of the 
cytotoxic T cell responses, including age and genetic background of the mice, the route of 
infection and the obligate role of M protein. 
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Characterization of myosin cross-reactive monoclonal antibodies. Antibodies recognizing 
mammalian myosin are a hallmark characteristic of childhood post-streptococcal autoimmune 
complications.  Antibody deposits have been described in biopsied tissue from ARF patients 
(Kaplan 1960; Kaplan et al. 1964b; Kemeny et al. 1989) as well as, serum anti-streptococcal 
antibodies that cross-react with myosin (Cunningham and Russell 1983; Cunningham et al. 
1989).  Immunizing laboratory animals with streptococcal cell wall or membrane preparations 
elicit antibody responses against various mammalian proteins, including myosin and keratin 
(Dale and Beachy 1985a; Dale and Beachy 1985b; Cunningham and Swerlick 1986; Kraus et al. 
1990; Cunningham et al. 1992; Vashishtha and Fischetti 1993).  However, despite their presence 
in humans and the ability to be induced in animals, assessing a role for such antibodies has 
proven difficult.  Likewise, the requirements for their elicitation are not well understood. 
 Our results would suggest that both the age of the animal and the presence of M protein 
maintain a pivotal role in the development of a myosin cross-reactive antibody response.  We 
have observed that in BALB/c mice a single neonatal immunization with heat-killed S. pyogenes 
vaccine will induce persistent antibody titers against the group specific determinant N-
acetylglucosamine, a portion of which cross-react with myosin.  Interestingly, while immunizing 
adult BALB/c mice with the vaccine does not elicit a cross-reactive antibody response, giving a 
secondary challenge with recombinant M protein or mouse skeletal myosin will induce the 
development of  myosin cross-reactive antibody responses.  Western blot analysis of 
representative hybridomas indicate that the cross-reactive antibodies produced in mice 
immunized as neonates with S. pyogenes recognize GlcNAc and cross-react predominantly with 
the cardiac isoforms of mouse myosin.  In contrast, antibodies elicited in mice immunized as  
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adults with S. pyogenes and boosted with either myosin or M protein recognize most cardiac and 
skeletal isoforms of mouse myosin. 
The myosin cross-reactive antibodies elicited following a single neonatal exposure to S. 
pyogenes have been shown to persist within the sera up to 60 weeks beyond the immunization.  
Maintaining this serum antibody response is unique to the neonatal animal and is characteristic of 
the exaggerated antibody response in post-streptococcal autoimmunity patients (Appleton et al. 
1985; Ayoub 1991).  Considering that the cross-reactive antibodies predominantly recognize 
GlcNAc, a classical T independent antigen, the sustainment of the response is probably not likely 
due to lymphocytic memory.  Therefore, it is conceivable that the cross-reactive antibody 
response is maintained as the result of cross-recognition to host antigens.  Additionally, it may be 
postulated that the antibody response is chronically stimulated due to exposure to enteric 
commensal organisms in a manner similar to the immune response maintained against blood 
group antigens (Drach et al. 1972, Yang and Boettcher 1992). 
 We have demonstrated that age and M protein are two requirements for a myosin cross-
reactive antibody response, however the role for the autoreactive B cells and their antibody 
remains in question.  Antibody deposition does occur in target tissue and is known to have a role 
in mediating tissue damage in certain autoimmune diseases, including post-streptococcal 
autoimmune glomerulonephritis (Richards 1991) and systemic lupus erythematosus (Maddison 
1999).  Also, these autoreactive B cells producing cross-reactive antibodies may potentially serve 
as a means to induce autoreactive T cell responses (Lin et al. 1991; Chan et al. 1999).  However, 
CTL studies conducted by us and others (Asano and Ahmed 1996) using Igh-/- mice indicate that 




Requirements for the induction of a myosin-reactive cytotoxic T cell response in mice. The 
pathology associated with ARF is believed to be primarily the result of a cellular mediated 
immune response.  While it can be demonstrated that biopsied cardiac tissue from ARF patients 
contain extensive lymphocytic infiltrates (Raizada et al. 1983; Kemeny et al. 1994), it remains to 
be determined if these cells are recruited due to their ability to cross-react with host antigens 
(Manjula and Fischetti 1980; Guilherme et al. 1995; el-Demellawy et al. 1997) or as a by-product 
of an overzealous immune response (Cairns 1988; Alarcon-Riquelme et al. 1990; Bhatnagar et al. 
1999). 
It has been our observation that neonatal immunization with heat-killed S. pyogenes 
elicits a myosin-reactive cytotoxic T cell response.  Producing a T cell response against an 
extracellular antigen in neonatal mice can present some obstacles.  First, it has been traditionally 
viewed that neonatal immunization will not elicit a productive immune response either due to the 
induction of tolerance (Billingham et al. 1953) or immune deviation  (Singh et al. 1996; Adkins 
and Du 1998).  Neonates are capable of eliciting protective CTL responses, whether anti-
allogenic (Pilarski 1977), against viral challenge (Sarzotti et al. 1996; Siegrist et al. 1998) or 
following DNA vaccination (Pertmer and Robinson 1999).  Furthermore, neonatally 
thymectomized mice produce a Th1 response upon challenge with soluble protein later in life 
suggesting that T cells have fully mature capacity as early as day one of life (Adkins and Du 
1998).  Secondly, the ability of an exogenous antigen like GAS to enter the class I processing and 
presentation pathway is not completely understood.  Observations have been made indicating that 
extracellular particulate antigens, whether protein coated beads or extracellular bacteria, can be 
processed and presented via class I by activated macrophages in vitro (Pfeifer et al. 1993; Rock et 
al. 1993; Kovacsovics-Bankowski and Rock 1995; Harding 1996). 
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Based on our observation, the myosin-reactive CTL response induced in neonatal mice is 
primarily the result of antigenic cross-reactivity to streptococcal M protein.   A large body of 
literature exists detailing the importance of M protein in streptococcal infections and subsequent 
autoimmune complications.  M protein is known to share antigenic determinants with myosin 
(Manjula and Fischetti 1980; Manjula et al. 1985; Manjula and Fischetti 1986) and myocarditis 
can be induced in MRL/++ mice with an M protein peptide sharing homology with myosin (Huber 
and Cunningham 1996).  Furthermore, several laboratory studies have shown that M protein has 
the potential to induce cytotoxic T cell responses with the capacity to kill myocardial cells 
(Friedman et al. 1971; Yang et al. 1977; Dale and Beachey 1987; Kotb et al. 1989; el-Demellawy 
et al. 1997).  In addition to underscoring the importance of M protein, we have also demonstrated 
that the potential cross-reactive epitopes lies within the carboxy terminal region or, more 
specifically the C sequence repeat region.  M protein is classified into two major classes based 
upon C region sequence where class I is more associated with autoimmunity (Bessen et al. 1989).  
We also have found that streptococcal strains expressing class I M protein were more capable of 
eliciting myosin-reactive CTL responses.  These observations are important considering the 
efforts underway to develop a streptococcal vaccine designed with M protein conserved region 
(Robinson et al. 1993; Pruskakorn et al. 1994a; Pruskakorn et al. 1994b).     
 Our observations support the hypothesis of autoimmunity as a result of antigenic cross-
reactivity however, we also wanted to address other conditions, apart from age of immunization, 
which may contribute to autoimmune susceptibility.  The potential role genetics may play in the 
development of post-streptococcal autoimmune complications has been the focus of much 
research, not only as a factor that dictates hyperimmunity to streptococcal infections (Greenberg 
et al. 1981; Hafez et al. 1990) but also as a correlation factor for the susceptibility to post-
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streptococcal autoimmune diseases (Greenberg et al. 1975; Gibofsky et al. 1991; Ertug 1993).  In 
a preliminary study we have shown the genetic background, or MHC haplotype, of the animal 
can dictate the ability to develop a CTL response against myosin as a result of neonatal 
immunization with S. pyogenes.  While we were able to elicit a myosin-reactive CTL response in 
three strains of mice representing two distinct haplotypes, further experimentation with other 
backgrounds is desirable. 
 The route of immunization appears to be another important factor pertaining to the 
capability to elicit a myosin-reactive CTL response.  We have observed in BALB/c and C57Bl/6, 
two distinct genetic backgrounds, that systemic immunization of neonatal mice with S. pyogenes 
vaccine will elicit a myosin specific CTL response.  Immunizing these mice intranasally with S. 
pyogenes, as a means to mimic the natural infectious route, does not yield a measurable CTL 
response to either M protein or myosin, unless a systemic booster of vaccine or M protein is 
administered later in life.  These results have potential application to the human situation, in that, 
where streptococcal skin infections may lead to only AGN, streptococcal throat infections may 
lead to one of several autoimmune disorders including ARF, AGN, and psoriasis.  Taken 
together, this would suggest that an initial intranasal or nasopharyngeal exposure to antigen may 
stimulate a potentially cross-reactive systemic immune response that can be restimulated and 
detected following systemic challenge with S. pyogenes or an antigenic component thereof, 
namely M protein. 
Conclusion. Despite the extent to which the cross-reactive antibody and cytolytic response can 
be induced, we did not observe any pathological outcome however it does indicate the capability 
of S. pyogenes to overcome the immunological privilege of host proteins. Further these results do 
not definitively explain the mechanism underlying the elicitation of a myosin-reactive CTL 
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response following neonatal exposure to wild-type S. pyogenes, they do provide clues into the 
requirements to the development such a response.  Accordingly, it appears that the most 
important factors are the age of the animal at the initial immunization and the presence of M 
protein.  Other factors potentially regulating the elicitation of a myosin CTL response include the 
genetic background of the animal and route of immunization.  Taken together our results would 
suggest that in a genetically susceptible individual local exposure to the organism has a lasting, 
potentially deleterious, effect upon a subsequent systemic immune response and if the necessary 
streptococcal antigens, namely M protein, gain access systemically the primed autoreactive 
immune response will be activated and potentially initiate the pathology characteristic of post-
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